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CHAPTER 1.  INTRODUCTION 
Dissertation organization 
There are five chapters in this thesis.  Chapter 1 covers the general introduction of my 
research on the synergistic regulation of PAI-1 by EGF and TGF-β, including the 
significance, questions to be addressed and major results of this study.  Chapter 2 is a 
literature review of PAI-1 function, related diseases and expression regulation, with an 
emphasis on PAI-1 regulation by EGF and TGF-β.  Chapter 3 addresses the mechanism of 
synergistic regulation of PAI-1 by EGF and TGF-β.  The manuscript will be submitted to the 
Journal of Biological Chemistry.  The co-authors are Xiaoling Song (performed the majority 
of studies for the synergistic regulation of PAI-1 at mRNA level and wrote the manuscript), 
Frederic W.  Thalacker (previous lab member, performed the metabolic labeling studies of 
mink PAI-1 protein), Tsung-Hsien Chuang (previous lab member, performed the Northern 
blots and initiated the studies on mRNA stability) and Marit Nilsen-Hamilton (corresponding 
author, mentored Song XL, Chang TH and Thalacker F, initiated the study, oversaw the work 
including data analysis and revised the manuscript).  Chapter 4 is a manuscript that has been 
submitted to Biomed central Biotechnology.  The chapter describes methods for effective 
identification of RNA accessible sites for antisense oligodexoxynucleotides (ODNs) and 
siRNA.  The coauthors are Xiaoling Song (performed the majority of the cell biology studies 
with antisense, participated in the statistical analysis and computer analysis and in preparing 
the figures), Xiangyu Cong (conceived of the idea to use tiled microarrays, carried out most 
of the microarray studies on Lcn2 and contributed to the computer analysis), Ahmed M. 
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Awad (initiated the cell biology studies, performed the Bcl2 microarray analysis and wrote 
the 1st draft of the paper), Long Qu (performed the cluster analyses and the majority of 
statistics analysis of the experimental results), Lijie Zhai (performed the siRNA cell studies) 
and Marit Nilsen-Hamilton (corresponding author, mentored Song XL, Cong XY, Awad AM 
and Zhai LJ, initiated the study, oversaw the work and participated in analysis of the data).  
Contributions to the writing of the manuscript were made by all co-authors with the major 
contributions being by Xiaoling Song and Marit Nilsen-Hamilton.  The general conclusion of 
the thesis is summarized in chapter 5. 
Significance of the study on PAI-1 regulation 
Plasminogen activator inhibitor type 1 (PAI-1), a protein that is found in many 
vertebrates, plays important roles in extracellular matrix remodeling and fibrinolysis.  PAI-1 
is one of the early inflammatory response genes, and its expression level changes 
dramatically in response to the stimulation by growth factors, lipopolysaccharide, cytokines 
or PMA.  PAI-1 is very important for the regulation of plasminogen activation in the 
fibrinolysis system and for cell motility regulation.  The PAI-1 expression level changes in 
many diseases.  Over-expression of PAI-1 is found in cancers, fibrosis and metabolic 
syndromes.  Studying the molecules involved in PAI-1 regulation will help us to understand 
the mechanism of PAI-1 regulation and the role of PAI-1 in many physiological and 
pathological processes.   
Previously, the lab found a synergistic interaction between epidermal growth factor (EGF) 
and transforming growth factor beta (TGF-β), which elevates the PAI-1 expression up to 80-
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fold at the mRNA level.  The purpose of this project was to understand the molecular 
mechanism of the synergism.   
Synergism is the situation when the effect of a combination of factors is greater than the 
sum of effects of each individual factor.    There are many important roles of synergism in 
the normal function of cells.  First, synergism helps to increase the specificity of the response 
because two or more stimuli are required.  Second, synergism increases the range of the 
response because the responses are more enhanced comparing to the additive effects.  Thirdly, 
it also provides the cell with a means of ignoring environmental noises such as changes of 
one of two factors, which will not affect the specific responses.   
EGF and TGF-β have been shown to cooperatively affect many cellular events, including 
transformation, the epithelial-mesenchymal transition (EMT).  These growth factors are also 
involved in many normal physiological processes, such as wound healing, and disease 
processes, such as tumor metastasis and fibrosis.  Elevated PAI-1 plays a critical role in the 
EGF and TGF-β-affected processes such as the EMT most likely by influencing cell motility.  
Studies of the synergistic regulation of PAI-1 will help to understand the synergistic 
interaction between EGF and TGF-β and to develop therapeutic targets to modulate the 
processes where PAI-1 is highly elevated. 
Hypothesis and major results on PAI-1 synergistic regulation by EGF and 
TGF-β 
A series of hypotheses have benn proposed and tested to address the question of how 
EGF and TGF-β synergistically regulate PAI-1 expression.  First, we tested if synergism 
4 
 
 
between EGF and TGF-β is gene or cell type specific.  The mRNA levels of uPA (urokinase 
type plasminogen activator), uPAR (receptor of urokinase type plasminogen activator) and 
Cox2 (cyclooxygenase 2) were determined after stimulation by EGF and TGF-β.  The results 
showed that the PAI-1 mRNA was uniquely induced in a synergistic manner.  Four cell lines 
were used to determine the cell-type specificity.  The results showed that PAI-1 was 
synergistically increased by EGF and TGF-β in epithelial cells types such as mink lung 
epithelial cells (Mv1Lu) and human hepatoma (HepG2) cells, but not in fibroblast cell types.  
The mechanism of synergism was investigated in Mv1Lu cells in this study.  Mv1Lu cells 
express a very low basal level of PAI-1 and the expression of PAI-1 is highly sensitive to 
outside stimuli, especially TGF-β.  Therefore, Mv1Lu cell line is a very good model to study 
PAI-1 gene regulation.   
EGF and TGF-β regulate PAI-1 expression mainly at the transcriptional level (Riccio, 
Lund et al. 1988).  TGF-β activates PAI-1 expression through Smad2/ Smad3 binding to the 
promoter of PAI-1, and EGF functions through Src to activate gene transcription in human 
mensengial cells (Harradine and Akhurst 2006).  It was of interest to know whether the 
synergistic induction of PAI-1 by EGF and TGF-β occurs at the transcriptional or 
posttranscriptional level.  Preliminary results from our lab suggested that the combination of 
EGF and TGF-β stabilizes PAI-1 mRNA. Our first hypothesis of the study was: the 
synergistic effect of EGF and TGF-β on PAI-1 induction occurs at both the transcriptional 
and RNA stability level.  However, our data show that the synergism occurs only at the 
transcriptional level, although EGF stabilizes PAI-1 mRNA.  TGF-β also increases the 
sensitivity of PAI-1 induction by EGF.  It is known that EGF and TGF-β regulate the 
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expression of their target genes through different signaling pathways.  And our data shows 
that de novo protein synthesis is not necessary for the synergistic regulation because 
pretreating cells with cycloheximide did not alter the synergistic effect.  Our second 
hypothesis was that the synergism occurs during the process of the signal transduction.  A 
series of assays were performed to test this hypothesis.  To understand which signaling 
pathway is involved in the synergistic regulation of PAI-1, specific chemical inhibitors of 
protein kinases, including Mek1/2 (mitogen-activated protein kinase kinase), p38 MAPK 
(mitogen-activated protein kinase), PI3K (phosphatidylinositol 3′-kinase), Src (v-src sarcoma 
(Schmidt-Ruppin A-2) viral oncogene homolog (avian)) and Jnk (c-Jun NH2-terminal protein 
kinase), were used to block different signaling pathways.  The synergism was lost only when 
Erk1/2 phosphorylation was blocked.  The Erk1/2 (extracellular signal-regulated kinase) 
mediated MAPK signaling pathway is activated by many growth factors through their 
tyrosine kinase receptors (RTKs).  We were interested to know if other growth factors that 
activate the MAPK pathway could also synergistically regulate PAI-1 with TGF-β.  Our 
results showed that the growth factors IGF-1 (insulin-like growth factor 1), FGF-2 (fibroblast 
growth factor 2) and the cytokine TNFα (tumor necrosis factor alpha) also synergize with 
TGF-β to increase PAI-1 mRNA expression.  However, the synergistic event is not uniquely 
downstream of tyrosine kinases because PMA, a PKC agonist, also acts synergistically with 
TGF-β on PAI-1 expression as demonstrated in both normal and MSV-transformed Mv1Lu 
cells.  This effect was specific for PAI-1 as demonstrated by the lack of synergistic effect of 
TGF-β and PMA on the production of other secreted proteins including a 73 Kd protein, a 
TGF-β inducible protein. 
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The induction of PAI-1 mRNA by EGF and TGF-β requires ongoing protein synthesis 
because the treatment of protein synthesis inhibitor reduces PAI-1 mRNA level by about 
40%.  However, the synergism was not significantly reduced by the inhibition of protein 
synthesis when the protein synthesis inhibitor is added one hour before growth factors 
treatment.  When protein synthesis was stopped at a series of time intervals after adding the 
growth factors the level of PAI-1 induced by EGF and TGF-β in combination, was observed 
to decrease at a constant rate.  This decay rate in the form of a decrease in PAI-1 mRNA 
level probably reflects the stability of a protein required for the growth factor response.  The 
calculated half-lives of the postulated proteins for each treatment were different.  The 
half-life of the EGF and TGF-β-induced protein is about 1 hour and the half life of the 
protein induced by either EGF or TGF-β appeared to be biphasic, possibly including a 
limited contribution from the 1 hour half life and the contribution of a second protein with a 
longer half-life.  These data could be interpreted as the proteins required for PAI-1 synthesis 
in single and double growth factor treatments were differentially regulated.  These biphasic 
decay curves reflect the presence of a small amount of the protein responsible for synergism 
that is augmented by the combination of EGF and TGF-β.  
It has been shown that c-Fos protein has a very short half-life in vivo.   EGF is known to 
activate the transcriptional activity of activator protein 1 (AP-1: a dimer of c-Fos and c-Jun 
family proteins).  Smad and the AP-1 have been shown to act synergistically on gene 
transcription.  Our next hypothesis is that AP-1 is the rapidly turning over protein and is 
required for the synergistic regulation of PAI-1 by EGF and TGF-β.  To address this question, 
we investigated the regulation of several synthetic promoters containing Smad binding 
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element and/or AP-1 binding sites.  The data showed that AP-1 and Smad binding elements 
in p3TP promoter synergistically respond to EGF and TGF-β.  Suppressing the AP-1 
transcriptional activity by a dominant negative construct for c-Fos, or chemical inhibitors 
reduced the synergistic effect on p3TP reporter.  The synergism on PAI-1 mRNA was also 
blocked by inhibition of AP-1 activity.  However, neither Fos nor Jun phosphorylation is 
synergistically activated by the combination of EGF and TGF-.  Thus, although AP-1 is 
necessary for the synergistic effect, it may not be the target for synergism between the two 
growth factors.   
Significance and major results from studies on RNA accessible region  
Antisense oligonucleotide and RNAi technology, especially the latter, has been widely 
used to knock down gene expression.   The efficiency of silencing gene expression has 
attracted great attention due to the possible use of these technologies in gene therapy for 
variety of diseases.    Because mRNA is usually folded in secondary or tertiary structure in 
vivo, only a limited portion of the mRNA is available for targeting.  Different technologies 
have been developed to provide information for optimal RNA accessible sites, including 
software prediction by using computer algorithm and experimental screening.  Software 
utilizes minimum energy calculations to predict RNA secondary structures based on their 
primary sequences, however these computer programs do not predict RNA tertiary structures 
that may affect RNA accessible sites.  Experimentally screening every possible RNA site is 
expensive and time consuming.   
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Here we showed that tiled microarray is an effective way to identify accessible regions in 
mRNAs with high accuracy.  We investigated the accessible regions of two mRNAs (B-cell 
CLL/lymphoma 2 [Bcl2] and mouse lipocalin 2 [Lcn2]) by tiled microarray and 
computational algorithms.  The efficacy of microarray and computational algorithm 
predictions for Lcn2 were tested in cell culture by using antisense oligodeoxynucleotides 
(ODNs) and siRNA.  For Bcl2, the microarray results were compared to the data in literature 
where antisense oligodeooxynucleotides were reported effective in vivo.   Firstly, we found 
that the tiled microarray analysis provides more selective identification of available sites on 
the mRNA than do computational algorithms.  Secondarily, the regions identified by titled 
microarray accurately predicted the most accessible area in RNA as tested by antisense 
ODNs and siRNA in vivo.  With the advantage of high throughput and high accuracy 
information provided for RNA accessible regions, we proposed tiled microarray is an 
efficient way of identifying effective antisense ODNs or siRNAs.  Tiled microarrays also 
provide a high throughput approach for validating and improving the results from 
computational programs.    
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CHAPTER 2.  REVIEW OF LITERATURE 
Plasminogen activator inhibitor type 1 (PAI-1) is one of the early inflammatory response 
genes, and its expression level changes dramatically in response to many stimuli, including 
growth factors and endotoxins.  The half-life of PAI-1 mRNA is very short (less than three 
hours in human cells and only 21 minutes in mink cells).  Because of the short half-life, the 
PAI-1 mRNA steady level drops quickly once transcription stops.  Our previous results 
showed that EGF and TGF-β synergistically induce PAI-1 expression in mink lung epithelial 
cells Mv1Lu (ATCC# CCL64).  The purpose of my major project is to understand the 
synergistic mechanism of PAI-1 regulation by EGF and TGF-β.  Previous research studies 
regarding PAI-1, EGF and TGF-β are reviewed here.   
 1.  Plasminogen activator inhibitor, type 1(PAI-1) and its functions  
PAI-1, a secreted single-chain glycoprotein, regulates plasmin function during 
fibrinolysis and extracellular matrix remodeling.   Plasmin, a broad spectrum serine protease, 
degrades fibrin and extracellular matrix proteins by which it plays a central role in clot 
dissolution and extracellular remodeling.  Plasminogen activators (PA, tissue-type or 
urokinase-type) are required to convert the inactive proenzyme plasminogen to active 
plasmin by cleavage at a single arginine-valine bond (Kruithof, Tran-Thang et al. 1984).  
While tissue-type plasminogen activator (t-PA) mainly regulates intravascular plasmin 
activity though binding to its receptor annexin II on the endothelial  cell surface, urokinase-
type plasminogen activator (uPA) acts by binding to its cell membrane receptor (uPAR) to 
promote plasmin induced pericellular proteolysis and to modulate cell migration (Czekay and 
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Loskutoff 2004; Myohanen and Vaheri 2004; Kwaan and McMahon 2009).  PAI-1, also 
called as SerpinE 1 (serine peptidase inhibitor, clade E, member 1), is the primary of four 
serpin inhibitors of plasminogen activators (Kruithof 1988).  By controlling the plasminogen 
activator-plasmin proteolysis cascade, PAI-1 is crucial to maintain haemostasis and many 
other biological processes that involve the remodeling of the extracellular matrix (ECM, 
Sprengers and Kluft 1987; Loskutoff, Sawdey et al. 1989; Dellas and Loskutoff 2005).  
PAI-1 is evolutionarily conserved and found in many animal species, including human, 
mouse and mink (Ginsburg, Zeheb et al. 1986; Prendergast, Diamond et al. 1990; Chuang, 
Hamilton et al. 1995).   
PAI-1 activity changes via active/latent conversion   
PAI-1 belongs to the serpin super family that contains conserved structures for inhibiting 
proteinases.  Like other serpins, PAI-1 serves as a pseudo substrate of plasminogen activators 
(Sancho, Declerck et al. 1995).  One distinct character of PAI-1 that distinguishes it from 
other serpin family members is that PAI-1 can automatically convert to a stable latent form 
(Kruithof 1988).  During the spontaneous conversion, the N-terminal reactive center loop is 
inserted into the major β-sheet to form the inactive form and the half-life of PAI-1 protein is 
increased from one hour to three hours (Mottonen, Strand et al. 1992; De Taeye, Gils et al. 
2004).  The activity of PAI-1 can be partially restored through denaturation-renaturation with 
sodium dodecyl sulfate, guanidinium chloride and urea (Hekman and Loskutoff 1985). 
PAI-1 appears as three different forms in normal human plasma: the inactive form of free 
PAI-1 with the molecular weight about 50 Kd, the active PAI-1/vitronectin complex with the 
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molecular weight about 450 Kd, and a high molecular weight inactive t-PA/PAI-1 complex 
(about 700 KD,Alessi, Juhan-Vague et al. 1991).  The binding of active PAI-1 to vitronectin 
stabilizes PAI-1 but does not affect the inhibitory effect of PAI-1 on plasminogen activators 
or the activity of vitronectin on cell adhesion (Lindahl, Sigurdardottir et al. 1989).  
Additionally, by interacting with vitronectin, PAI-1 restricts pericellular proteolysis at focal 
contact sites (Salonen, Vaheri et al. 1989).  In many cases, levels of active and inactive PAI-1 
change in the same direction.   For instance, activation of platelets mainly leads to increasing 
the free PAI-1 level and, to a less extent, the active PAI-1/ vitronectin complex increases.  
And in most patients with elevated PAI-1 activity, both the free PAI-1 and the active PAI-1/ 
vitronectin complex are increased (Alessi, Juhan-Vague et al. 1991).   
Fast acting inhibitor 
PAI-1 is a fast PA inhibitor.  Clearance of PA-inhibitory activity from the circulation is 
rapid with measured half lives of 3.5 to 7 min (Colucci, Paramo et al. 1985).  Like other 
serpins, PAI-1 inhibits cognate proteases by mimicking their substrates, which results in the 
formation of an ester bond between the carboxyl group of serpin P1 residue and the hydroxyl 
group of the protease serine residue to produce a stable covalently linked inhibitor/protease 
inactive complex (De Taeye, Gils et al. 2004).  PAI-1 inhibits the activity of plasminogen 
activators (uPA and tPA) by binding to them at a 1:1 ratio.  The binding process is fast and 
results in inactivation of plasminogen activators.  The binding rate for both plasminogen 
activators (urokinase-type plasminogen activator, and tissue type plasminogen activator) is 
about 107 M-1.sec-1 (kcat), which reaches the upper theoretical limit of the rate constant of 
protein-protein interactions (Kruithof, Tran-Thang et al. 1984; Hekman and Loskutoff 1988).  
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After binding, a slow cleavage at the PAI-1 reactive site Arg346-Met347 (P1-P1') occurs 
followed by the release of the C-terminal peptide of PAI-1 from the PAI-1/PA complex 
(Lindahl, Ohlsson et al. 1990).  The PAI-1/PA complex is internalized by forming a complex 
with integrin and the endocytic receptor low-density lipoprotein receptor–related protein 
(LRP), then both PAI-1 and PAs are then degraded in the lysosomes (Chazaud, Bonavaud et 
al. 2000; Cao, Lawrence et al. 2006).  The fast inhibition of the plasminogen activators 
allows the rapid reduction of plasmin-mediated proteolysis.   
Negatively regulates fibrinolysis 
PAI-1 negatively regulates fibrinolysis. Tissue-type plasminogen activator (t-PA) is the 
main plasminogen activator involved in fibrinolysis because the urokinase-type (uPA) does 
not bind fibrin.  Through inhibiting the activity of t-PA, PAI-1 regulates fibrinolysis which is 
very important for removing the clot after injury (Kawasaki, Dewerchin et al. 2000; Gils and 
Declerck 2004).  Shortly after wounding, coagulation occurs to keep the blood within a 
damaged blood vessel.  Fibrin, together with plasminogen, platelets and other blood proteins, 
form a fibrin clot at the place of damage.  After bleeding stops, fibrinolysis occurs to remove 
fibrin clot.  During fibrinolysis, t-PA produced by endothelial cells immediately surrounds 
the clot to convert plasminogen into the active enzyme plasmin.  Plasmin then degrades 
fibrin in the fibrin mesh to resolve the clot (Ranby and Brandstrom 1988).  The release of 
t-PA is very slow, and the fibrinolytic process, which depends on the activation of plasmin, 
takes days to finish (Harvey, Kim et al. 1989).  Fibrinolysis is negatively regulated by 
plasminogen activation inhibitors (mainly by PAI-1) (Zorio, Gilabert-Estelles et al. 2008).   
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Modulate extracellular matrix remodeling 
PAI-1 also modulates extracellular matrix remodeling. During tissue remodeling, 
proteolysis is required to degrade the extracelluar matrix barrier to allow cell movement.  
Plasmin plays an active role in remodeling the airway and vascular systems (Lijnen 2001; 
Kucharewicz, Kowal et al. 2003; Rakic, Maillard et al. 2003).  Plasmin not only directly 
degrades most glycoproteins but also can activate the proenzymes of matrix 
metalloproteinases (MMPs), including MMP1 and MMP3, to degrade gelatin and collagen in 
extracellular matrix (Lijnen 2001).  Plasmin-mediated proteolysis is positively regulated by 
uPA.  uPA activates plasminogen by binding to its receptor  urokinase plasminogen activator 
receptor (uPAR).  uPAR is a glycosyl phosphatidyl inositol (GPI) - anchored protein that 
tethers uPA on the cell surface to regulate pericellular proteolysis (Blasi, Vassalli et al. 1987; 
Vassalli, Sappino et al. 1991; Ossowski and Aguirre-Ghiso 2000).   
PAI-1 helps to maintain the integrity of the extracellular matrix in three ways.  First, 
PAI-1 directly blocks uPA activity to constrain the proteolytic activity of plasmin.  Second, it 
reduces the uPA level on the cell surface by promoting low-density lipoprotein receptor-
related protein (LRP) mediated endocytosis (Degryse, Sier et al. 2001).  Third, elevated 
PAI-1 can cause accumulation of fibrous material, which promotes fibrosis (Loskutoff and 
Quigley 2000; Kucharewicz, Kowal et al. 2003). 
Modulates cell attachment and migration 
Cell migration occurs during normal physiological processes such as embryonic 
morphogenesis, and during pathological processes such as wound healing, inflammation and 
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cancer metastasis.  Cell migration requires a series of dynamic motions including protrusion 
in the front, adhesion to the extracellular matrix or adjacent cells, detachment and retraction 
in the back (Ridley, Schwartz et al. 2003).   
PAI-1 plays a role in regulating cell movements.  This is demonstrated by the following 
observations.  PAI-1 is deposited onto the migration trail of keratinocytes during the healing 
of monolayer wound (Providence, Higgins et al. 2008).  Addition of active PAI-1 promotes 
directional migration of both wild type and PAI-1 deficient (PAI-1, -/-) keratinocytes 
(Providence, Higgins et al. 2008).   Treating cells with PAI-1 neutralizing antibody 
significantly slowed wound repair (Providence, Higgins et al. 2008).  It has also been 
reported that PAI-1 controls uPA-mediated cell migration by balancing cell adhesion and 
detachment activities (Deng, Curriden et al. 1996). 
PAI-1 modulates cell migration in two opposing ways.  On the one hand, PAI-1 inhibits 
smooth muscle cell movement by inhibiting cell adhesion (Stefansson and Lawrence 1996).  
On the other hand, PAI-1 stimulates migration of a variety of cells, including rat smooth 
muscle cells (RSMC), highly invasive human fibrosarcoma HT-1080 cell, and non-invasive 
human melanoma IF6 cells (Degryse, Sier et al. 2001).  PAI-1 recruits interstitial 
macrophages and myofibroblasts, which are key cellular factors in fibrosis (Oda, Jung et al. 
2001).   
PAI-1 modulates cell migration through regulating pericellular proteolysis.  Plasmin-
mediated proteolysis removes the tissue barrier that prevents cell migration (Allan and 
Martin 1995).  Plasmin also promotes cell migration by activating cell signaling pathways 
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such as p38MAPK/Akt2 pathway (Li, Syrovets et al.).  A high level of PAI-1 inhibits cell 
migration by blocking cell surface proteolysis by plasmin (Andreasen, Egelund et al. 2000).  
Meanwhile, a low concentration of PAI-1 is required for blocking excessive plasmin-
mediated degradation of the extracellular matrix to maintain the matrix scaffold required for 
cell migration.  Because both the plasminogen activation system and PAI-1 are involved in 
cell migration, the balance between plasminogen activators (t-PA and u-PA) and PAI-1 plays 
a crucial role in modulating the cell migration (Booth 1999).   
PAI-1 inhibits uPAR-integrin mediated cell adhesion and regulates cell detachment.  
During wound healing, the expression of the vitronectin receptor, integrin and plasminogen 
activators is greatly increased in migrating cells.  uPAR forms a stable complex with 
integrins on the cell surface, which promotes cell binding to vitronectin through uPAR in the 
extracellular matrix (Wei, Lukashev et al. 1996).  With a relatively high affinity to 
vitronectin (0.5 x 10-7 - 2 x 10-7 M), PAI-1 promotes cell migration by competing with uPAR 
and releasing the cell from the vitronectin attachment.  In human fibrosarcoma HT-1080 cells, 
which use uPAR and integrin as anchors to vitronectin, addition of PAI-1 itself did not 
detach these cells from the vitronectin coated surface (Czekay and Loskutoff 2004).  
Sequential addition of uPA and PAI-1 promoted cell detachment, which suggests this PAI-1 
function requires uPA.  Binding of PAI-1 to the uPA-uPAR-integrin complex initiates 
internalization of the complex, which is mediated by low-density lipoprotein receptor–related 
protein (LRP) (Chazaud, Bonavaud et al. 2000).  PAI-1 and uPA are then degraded in the 
lysosomes, but uPAR, integrin and LRP are recycled back to the cell surface.  
Disengagement of the adhesive receptors uPAR and integrin from the ECM promotes cell 
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detachment.  Interfering with the formation of the PAI-1-uPA-uPAR complex or the binding 
of this complex to LRP significantly suppresses cell motility (Chazaud, Bonavaud et al. 
2000).   
 PAI-1 affects the signaling pathway to promote cell migration.  By binding to LRP, 
PAI-1 activates Jak (Janus kinase 2) /Stat (Signal transducer and activator of transcription 
protein) signaling and promotes rat smooth muscle cell (RSMC) migration in chemotaxis and 
monolayer wound-healing assays (Degryse, Neels et al. 2004).  Addition of PAI-1 rapidly 
and transiently changes the cell morphology by reorganizing actin skeleton during cell 
migration (Degryse, Neels et al. 2004).  Cell migration is inhibited by blockage of the 
interaction between PAI-1 and LRP through either mutation of LRP binding site on PAI-1 or 
LRP antagonist (Degryse, Neels et al. 2004). 
Although PAI-1 has important roles in cell migration, it is not sufficient to promote 
migration by itself.  Other factors are required to regulate cell migration.  For example, PAI-1 
and uPA, uPAR, are essential for the invasion of lung cancer cells through Matrigel barrier 
(Liu, Shuman et al. 1995).   
In summary, by influencing fibrinolysis, extracellular matrix remodeling and cell 
migration, PAI-1 is involved in many physiological and pathological processes.   
2.  Aberrant expression of PAI-1 associated diseases 
Both PAI-1 deficiency and PAI-1 overexpression are correlated with many human 
diseases.  Therefore, the expression of PAI-1 must be tightly regulated.  The antigen level 
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and activity of PAI-1 in plasma or serum are parameters for screening PAI-1 deficiency and 
overexpression.  In healthy individuals, the PAI-1 antigen level ranges from undetectable to 
28 ng/ml in plasma (Declerck, Moreau et al. 1993), and the activity of PAI-1 ranges from 0.5 
U/ml to 47 U/ml (t-PA neutralizing units, 1 ng of active PAI-1 corresponds to 0.7 U) (Lijnen 
2005).   
PAI-1 deficiency in disease 
PAI-1 deficiency was found in a hemostatic defect patient (Fay, Parker et al. 1997).  
However, no developmental defect has been found in PAI-1-deficient patients.  PAI-1 
deficiency was documented for a child who carried a homozygous PAI-1 loss of function 
allele due to a frame shift (Fay, Shapiro et al. 1992).  In his family, 7 patients with 
homozygous PAI-1 mutation were identified by using allele-specific oligonucleotide 
hybridization (Fay, Parker et al. 1997).  PAI-1 deficiency causes abnormal bleeding in 
homozygous deficient patients.  However, the abnormal bleeding only occurs after trauma or 
surgery.  A variety of bleeding patterns were documented for these patients including 
intracranial and joint bleeding after less serious trauma, delayed surgical bleeding, severe 
menstrual bleeding and frequent bruising.  Oral fibrinolysis inhibitors, such as tranexmic acid 
or ε-aminocaproic acid can be used to treat this bleeding effectively.  Heterozygous 
individuals have no history of excessive bleeding even after a significant trauma or surgical 
procedure.  Mice with a homozygous PAI-1 null allele also exhibit an accelerated vascular 
fibrinolysis but do not bleed spontaneously (Carmeliet, Stassen et al. 1993). 
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Although there is a defect in hemostasis, genetic PAI-1 deficiency might be beneficial to 
cancer or fibrosis patients due to its attenuation of the fibrogenic response.  Studies in mice 
show that PAI-1 deficiency prevents the invasion and vascularization of transplanted cancers, 
and supplying PAI-1 by way of a transgene restores the cancer cell invasion and angiogenesis 
(Bajou, Noel et al. 1998).  PAI-1 deficient mice have less chance of developing fibrosis after 
lung injury (Hattori, Degen et al. 2000), bile duct ligation (Wang, Zhang et al. 2007) or after 
renal surgery (Oda, Jung et al. 2001).   
PAI-1 over expression in disease 
PAI-1 levels are elevated in variety of diseases including cardiovascular diseases, fibrosis, 
and malignant tumors (Kruithof, Gudinchet et al. 1988; Urano, Wu et al. 1996).  Abnormal 
induction of PAI-1 activity can result in a fibrinolysis defect.  In the nervous system, the 
fibrinolysis defect caused by PAI-1 overexpression is associated with multiple sclerosis 
(Gveric, Herrera et al. 2003).  In the cardiovascular system, PAI-1 elevation leads to 
thrombosis by blocking fibrin degradation and vessel wall remodeling.  PAI-1 levels can be 
used as an independent risk factor of cardiovascular diseases (Kruithof, Gudinchet et al. 1988; 
Landin, Tengborn et al. 1990; Segarra, Chacon et al. 2001).  The increase of PAI-1 in plasma 
is positively correlated with a variety of thrombotic vascular diseases, such as myocardial 
infarction (Scarabin, Aillaud et al. 1998), deep venous thrombosis (Kruithof, Gudinchet et al. 
1988) and Budd-Chiari syndrome (BCS) (Hoekstra, Guimaraes et al.) in the human.  Studies 
of transgenic mice consistently showed that overexpression of PAI-1 results in venous 
thrombosis (Erickson, Fici et al. 1990). 
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 Overexpression of PAI-1 is also positively correlated with tissue fibrosis, and the 
overexpression is found in many experimental fibrosis models (Yang, Hsieh et al. 2003; Liu 
2008).  Fibrosis, a dysregulated tissue repair process, is characterized by excessive 
accumulation of fibrous connective tissue after injury or infection.  PAI-1 is involved in the 
recruitment of myofibroblasts that express excessive amount of fibrous tissue during fibrosis 
(Oda, Jung et al. 2001).  PAI-1 also plays an important role by inhibiting pericellular 
proteolysis and promoting accumulation of fibrous tissue (Yang, Hsieh et al. 2007).  
Treatments that decrease PAI-1 level can lower the chance of developing fibrosis.  For 
instance, inhibition of PAI-1 by decoy peptides attenuated tubulointerstitial (Gonzalez, Klein 
et al. 2009).  Suppression of PAI-1 by siRNA protects affected mice from the development 
and progression of pulmonary fibrosis (Senoo, Hattori et al. 2010).  A positive feedback loop 
between TGF-β and PAI-1 is involved in the development of renal fibrosis in diabetes (Seo, 
Park et al. 2009).  TGF-β induces fibronectin and collagen I expression through PAI-1, at the 
same time PAI-1 activates transcription of TGF-β in mouse mesangial cells (Seo, Park et al. 
2009). 
PAI-1 is also involved in tumorigenesis and metastasis by influencing pericellular 
proteolysis and cell migration during angiogenesis (Liu, Shuman et al. 1995).  PAI-1 levels 
are elevated in many cancers including breast cancer (Meryet-Figuieres, Resina et al. 2007), 
endometrial cancer (Steiner, Pollow et al. 2008) and lung cancer (Annecke, Schmitt et al. 
2008).  PAI-1 promotes tumor growth and invasion in stromal fibroblast and endothelial cells 
(Andreasen 2007).  Overexpression of PAI-1 is associated with poor prognosis for several 
human cancer types, especially for breast cancer (Andreasen 2007).  In breast cancer, PAI-1 
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and uPA are the most powerful prognostic markers (Andreasen 2007; Annecke, Schmitt et al. 
2008).  However, high levels of uPA and PAI-1 in node-negative primary breast cancers 
patients could predict beneficial responses to adjuvant chemotherapy (Annecke, Schmitt et al. 
2008).   
PAI-1 over-activation is also found in many other diseases, such as obesity and some 
metabolic syndromes including insulin-resistance syndrome (Idell 2003; Prabhakaran, Ware 
et al. 2003; Dellas and Loskutoff 2005).  Obese patients, especially those with abdominal fat 
tissue distribution, have a high level of PAI-1 antigen and activity (Valle, Gascon et al. 2000).  
In those patients, PAI-1 is expressed in mature adipocytes, vascular smooth muscle cells and 
occasional endothelial cells in adipose tissue (Samad and Loskutoff 1996).  Many factors in 
these patients can induce PAI-1 expression, including insulin, glucocorticoids, angiotensin II, 
fatty acid and tumor necrosis factor-alpha and transforming growth factor beta (Skurk and 
Hauner 2004).  PAI-1 levels are positively correlated with the serum triglyceride levels and 
hypertension (Scarabin, Aillaud et al. 1998).  However, some changes in life style, such as 
weight reduction and increased physical activity, can decrease plasma PAI-1 activity in 
affected individuals (Hoekstra, Geleijnse et al. 2004). 
 Great therapeutic potential for PAI-1 inhibitors  
Because overexpression of PAI-1 contributes to thrombosis and the complications of 
obesity and cancer, strategies blocking PAI-1 activity could reduce cardiovascular risk and 
tumor metastasis.  A variety of PAI-1 antagonists have shown promising results in treating 
PAI-1 elevation related diseases in experimental models.  Tiplaxtinin (PAI-039), an orally 
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active PAI-1 inhibitor, specifically inhibits the newly activated but not vitronectin-bound 
PAI-1 (Elokdah, Abou-Gharbia et al. 2004; Gorlatova, Cale et al. 2007).  It significantly 
reduces thrombus formation in a variety of animal injury or thrombosis models (Elokdah, 
Abou-Gharbia et al. 2004; Smith, Dixon et al. 2006; Hennan, Morgan et al. 2008).  
Tiplaxtinin blocks angiogenesis in a Matrigel implant (Leik, Su et al. 2006) and protects mice 
from developing diet-induced obesity (Crandall, Quinet et al. 2006).  Another PAI-1 inhibitor 
S35225 directly inhibits PAI-1 activity in vitro and in vivo (Rupin, Gaertner et al. 2008).  
PAI-1 aptamer SM-20 has been shown to be a potential anti-metastatic reagent for breast 
cancer (Blake, Sullenger et al. 2009).  The aptamer blocks PAI-1 promoted cell detachment 
by inhibiting vitronectin binding but not its anti-proteolysis function.   
3.  Regulation of PAI-1 expression 
PAI-1 gene expression is regulated by many factors including cytokines, growth factors, 
hormones, phorbol esters, endotoxins, glucocorticoids, angiotensin II, and fatty acids 
(Sandberg, Eriksson et al. 1997; Loskutoff and Samad 1998; Skurk and Hauner 2004).  Some 
of these effects on PAI-1 expression are cell-type specific.  For example, a main G-actin–
sequestering peptide Thymosin 4 (T 4) enhances PAI-1 only in human endothelial cell 
lines HUVEC and EA.hy926 but not in human fibroblasts, prostate cancer cell line PC3 or 
promonocyte cell line U937 (Al-Nedawi, Czyz et al. 2004).  Most regulation of PAI-1 occurs 
at the transcriptional level.  Examples of factors that regulate PAI-1 at the transcriptional 
level include EGF, TGF-β, glucocorticoids, PMA (Phorbol 12-Myristate-13-acetate), Tβ4 
and P53 (Riccio, Lund et al. 1988).  Factors that influence cellular microfilament 
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organization, such as cytochalasin D (CD), also activate PAI-1 transcription (Higgins, Ryan 
et al. 1994). 
PAI-1 is expressed in many tissues including liver, lung, heart, kidney (Quax, van den 
Hoogen et al. 1990), blood platelets (Kruithof, Tran-Thang et al. 1986) and adipose tissue 
(Samad and Loskutoff 1996).  Cell culture studies show that PAI-1 is expressed in many cell 
types in the vascular system such as platelets (Quax, van den Hoogen et al. 1990), vascular 
endothelial cells (Hekman and Loskutoff 1985) and vascular smooth muscle cells (Reilly and 
McFall 1991).  PAI-1 is also expressed by many nonvascular cells including hepatocytes 
(Hopkins, Westerhausen et al. 1991).  While PAI-1 serves as an important regulator of 
fibrinolysis in the vascular system, it is also deposited in the extracellular matrix where it 
regulates plasmin-mediated extravascular proteolysis in the nonvascular system.  PAI-1 
expression is also regulated by cellular growth state (Ryan and Higgins 1993).  The 
expression is higher in low density, exponentially growing normal rat kidney (NRK) cells 
than in confluent and post-confluent cells (Ryan and Higgins 1993).   
Immediate early expression  
Under normal physiological conditions, PAI-1 expression levels are very low.  Stimuli 
that induce inflammation such as LPS (lipopolysaccharide) increase PAI-1 expression (Quax, 
van den Hoogen et al. 1990; Luyendyk, Mattes et al. 2004).  PAI-1 activity in plasma is 
rapidly elevated with the peak level at 4 h after endotoxin injected into the rat (Quax, van den 
Hoogen et al. 1990).  PAI-1 is markedly increased in lung and liver, and moderately induced 
in heart and kidney (Quax, van den Hoogen et al. 1990).  Some mediators of the acute phase 
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response, such as interleukin-1 (IL-1), IL-6 and dexamethasone, also induce PAI-1 
expression (Healy and Gelehrter 1994).  The induction of PAI-1 in quiescent cells by EGF, 
TGF-β and serum is also in an immediate early pattern (Nilsen-Hamilton and Holley 1983; 
Thalacker and Nilsen-Hamilton 1987; Kutz, Hordines et al. 2001).  After adding serum, 
transcription of PAI-1 occurs within 10 min (Ryan, Kutz et al. 1996).  Insulin injection in 
lean mice increased the PAI-1 mRNA level in the adipose tissue during the first 6 h and then 
it gradually declined to the basal level (Samad and Loskutoff 1996).   
PAI-1 is synthesized in the leading motile cohort of keratinocytes shortly after the 
scraping of monolayer wound (Providence and Higgins 2004).  Blockage of Erk activity, 
either with chemical inhibitors or with dominant-negative Erk, suppressed PAI-1 expression 
and keratinocyte migration (Providence and Higgins 2004).  Suppression of PAI-1 by 
antisense RNA or PAI-1 neutralizing antibodies blocked wound closure over a 24 h period 
(Providence and Higgins 2004).  De novo PAI-1 synthesis is not required for early cell 
movement during wound healing because inhibition of PAI-1 RNA synthesis does not affect 
the response of cell migration.  However PAI-1 synthesis is required to maintain the normal 
rate of wound closure (Providence and Higgins 2004). 
Promoter elements corresponding to transcription activation   
Many cis-elements in the PAI-1 promoter region have been identified as involved in 
PAI-1 transcriptional regulation including a CAGA box, activator protein 1 (AP-1) like site, 
E-box, specificity protein 1 (Sp1) bind site, glucocorticoid regulatory element (GRE), 
hypoxia-response element (HRE) and Nuclear Factor-KappaB (NFκB)-binding sites.  Some 
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cis-elements are involved in the basal expression of human PAI-1, such as one activator 
protein 2 consensus binding sequence in the region of -78 to -69.   It is recognized by 
helicase-like transcription factors (HLTF) that controls PAI-1 basal level (Ding, Benotmane 
et al. 1999).   Most of these cis-elements are involved in positive regulation of PAI-1 upon 
stimulation.  For example, two Sp1 binding sites in the proximal PAI-1 promoter (-85 to -42) 
are required for PAI-1 expression induced by glucose (Chen, Su et al. 1998; Du, Edelstein et 
al. 2000) and PMA (Descheemaeker, Wyns et al. 1992).  Some motifs could be either 
positive or negative regulatory elements depending on the interacting transcription factor.  
For example, an E-box motif (CACGTG) located at -160 to -165 in the PAI-1 promoter 
mediates the transcriptional response to the helix-loop-helix family transcription factors that 
include TFE3 (transcription factor binding to IGHM enhancer 3), USF-1 (upstream 
transcription factor 1), USF-2 & HIF-1 (hypoxia-inducible factor 1) and Max (MYC 
associated factor X) (Hua, Liu et al. 1998; Kietzmann, Roth et al. 1999; Providence, White et 
al. 2002; Grinberg and Kerppola 2003).  While TFE3 cooperates with Smad3/4 to activate 
transcription of TGF-β-responsive genes, Max inhibits Smad-mediated TGF-β-induced PAI-
1 expression (Grinberg and Kerppola 2003).  The same cis-elements can be activated in 
response to different stimuli.  For example, AP-1 (PMA-responsive element: TRE; 5'-
TGAG/CTCA-3') like sites in the PAI-1 promoter are involved in growth factors and PMA-
induced transcriptional activity (Descheemaeker, Wyns et al. 1992).   
PAI-1 RNA stability regulation 
PAI-1 mRNA has a very short half-life.  The half-life of PAI-1 mRNA is 1 to 3 hs in 
human and only 21 min in mink (Hopkins, Westerhausen et al. 1991; Chuang, Hamilton et al. 
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1995).  However, the half-life of human PAI-1 might have been overestimated due to using 
actinomycin D in the experiment.  Actinomycin D has been shown to stabilize PAI-1 mRNA 
in human HepG2 cells (Bosma and Kooistra 1991) and in mink lung epithelial Mv1Lu cells 
(Chuang, Hamilton et al. 1995).  The stability of PAI-1 mRNA can be changed in response to 
different stimuli.  PAI-1 mRNA can be stabilized by oxidized high-density lipoprotein 
(Ox-HDL) in endothelial cells (Norata, Banfi et al. 2004), insulin and insulin-like growth 
factor-1 (IGF-1) in HepG2 cells (Fattal, Schneider et al. 1992) and progesterone in 
endometrial stromal cells (Sandberg, Eriksson et al. 1997).  In some tumors, the observed 
increases in PAI-1 protein level may be due to the stabilization of PAI-1 mRNA.  The 
half-life of PAI-1 is over 20 hs in human glioblastoma A172 cells (Paugh, Paugh et al. 2008).  
Again this study blocked transcription using actinomycin D which probably stabilized PAI-1 
mRNA.  
In human, two isoforms of PAI-1 mRNA are reported.  One is 2.3 kb and the other is 3.2 
kb, which results from alternative splicing at the 3` UTR region.  The AU-rich element in 3’ 
UTR is very important for the PAI-1 mRNA half-life.  The longer transcript of PAI-1, which 
contains an AU-rich region, has a much shorter half-life (73 min) than the short one (215 min) 
(Hopkins, Westerhausen et al. 1991).  Regulatory factors may affect the PAI-1 protein level 
by specifically increasing one transcript.  For example, TGF-β preferentially increases the 2.3 
kb PAI-1 mRNA in retinal endothelial cells (Wileman, Booth et al. 2000), while 
cycloheximide (CHX) preferentially stabilizes the 3.2 kb PAI-1 mRNA in keloid fibroblasts 
(Zhang, Wu et al. 2003).  IL-1 induces 40-fold the 3.2 kb PAI-1 mRNA and 30-fold of the 
2.2 kb PAI-1 mRNA in HepG2 cells (Healy and Gelehrter 1994).  Nuclear run-on 
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experiments showed a 10-fold increase in transcription after 2 h addition of IL-1 (Healy and 
Gelehrter 1994).  However no change in PAI-1 mRNA stability was found 4 h after IL-1 
addition (Healy and Gelehrter 1994).  PMA preferentially firstly increases 3.2 kb PAI-1 
mRNA, and then 2.4 kb mRNA (Bosma and Kooistra 1991).  The differential regulation of 
these two PAI-1 mRNA isoforms results from their differences in transcriptional termination, 
RNA processing and mRNA half-lives (Bosma and Kooistra 1991). 
The mechanism(s) by which PAI-1 mRNAs are stabilized are not fully understood.  
Radha found that a nuclear protein stabilized PAI-1 mRNA by binding to its 3`UTR in an 
iron-dependent manner in adenocarcinoma cells (Radha, Sugiki et al. 2005).  In human lung 
carcinoma cells, a 60-Kd mRNA binding protein destabilizes PAI-1 mRNA by binding to 
another region in the 3`UTR (Shetty and Idell 2000).  The stability of PAI-1 mRNA 
regulated by cyclic nucleotide cAMP was extensively studied in HAT rat heptoma cells.  
Cyclic nucleotide cAMP down-regulates PAI-1 expression in many cell types (Heaton and 
Gelehrter 1990).  The PAI-1 mRNA decay rate is increased by two-fold with 8-bromo-cAMP, 
a cAMP analog (Heaton, Kathju et al. 1992).  An interaction between a distal region 
cis-element of 3`UTR (3`-most 134nt) in PAI-1 mRNA and a PAI-1 mRNA binding protein 
(Serbp1) (Heaton, Tillmann-Bogush et al. 1998) is involved in this regulation (Heaton, 
Dlakic et al. 2003).   However, due to the weak binding of Serbp1 to PAI-1 mRNA, Serbp1 is 
not sufficient to stabilize PAI-1 mRNA (Heaton, Dlakic et al. 2003). Other proteins that are 
involved in this regulation remain to be identified. 
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4.  Regulation of PAI-1 expression by TGF-β 
  TGF-β is a multifunctional growth factor, which controls cell proliferation, 
differentiation, apoptosis and cell migration (Harradine and Akhurst 2006).  It is expressed 
broadly by many cell types and is up-regulated in some human cancers.  TGF-β functions in 
a cell type specific manner.  It inhibits the proliferation of epithelial, endothelial and 
haematopoietic cells (Like and Massague 1986; Jennings, Mohan et al. 1988; Moses, Yang et 
al. 1991); but promotes the growth of many mesenchymal cells (Andrades, Han et al. 1999).  
TGF-β also induces the epithelial-mesenchymal transition (EMT) (Levy and Hill 2005; 
Valcourt, Kowanetz et al. 2005).  For example, TGF-β inhibits the growth of mouse 
mammary epithelial cell EPH4, and promotes EpRas, a v-Ha-Ras-transformed EPH4 derived 
cell line, to undergo EMT (Oft, Peli et al. 1996).  TGF-β treatment inhibits mammary 
epithelial NMuMG cell growth and stimulates cell apoptosis (Gal, Sjoblom et al. 2008).  
However, surviving cells undergo epithelial-mesenchymal transition (EMT) (Gal, Sjoblom et 
al. 2008).  TGF-β can also induce anchorage-independent growth, which requires the 
presence of mitogens including EGF (Uttamsingh, Bao et al. 2008) and hepatocyte growth 
factor (HGF) (Taipale and Keski-Oja 1996).   
Smad-mediated TGF-β signaling  
TGF-β-initiated signaling is mainly mediated by the Smad proteins (Derynck, Zhang et al. 
1998; Miyazono 2000).  TGF-β binds to its specific receptors on the cell surface as a dimer 
(Massague 1998; Massague and Wotton 2000).  There are three types of TGF-β receptors: 
type I and type II serine/ threonine kinase receptors (TβR-I, TβR-II) and type III receptor 
(TβR-III).  TβR-III does not transduce TGF-β signaling.  TβR-I is normally repressed by a 
28 
 
 
negative regulatory protein FKBP12 (the 12-kDa FK506-binding protein).  TβR-II is 
constantly present on the cell surface.  Upon binding to TGF-β, TβR-II recruits and 
phosphorylates TβR-I at the GS rich domain to activate it.  The active TβR-I then 
phosphorylates the Smad proteins to initiate intracellular signaling.   
Three types of Smads have been reported in mammals, including receptor-regulated 
Smads (R-Smads, such as Smad2 or Smad 3), common partner Smads (Co-Smads such as 
Smad4) and inhibitory Smads (I-Smad such as Smad 7).  The Smads contain an N-terminal 
MH1 (MAD homolog 1) DNA binding domain, and a C-terminal transcription activation 
domain (MH2 domain), which are connected by a linker region.  Without TGF-β, Smad2 and 
Smad3 are located on the cell membrane and interact with membrane bound proteins such as 
Smad Anchor for Receptor Activation (SARA).  Upon TGF-β stimulation, Smad2 and 
Smad3 are phosphorylated by TβR-I at the C terminal SSXS motif (pSmadC).  Homodimers 
or heterodimers of phosphorylated Smad2 and Smad3 form complexes with Smad4 (Yingling, 
Datto et al. 1997).  The Smad complexes then move into the nucleus and mediate 
transcriptional activation (Nakao, Imamura et al. 1997).  Both the MH1 domain and the 
linker region of the Smads are required for direct DNA binding.  The Smad Binding Element 
(SBE), the optimal binding sequence for the Smad3/ Smad4 complex, is identified in vitro as 
an 8 bp palindrome, GTCTAGAC (Zawel, Dai et al. 1998).  A CAGA box, which is exactly a 
half of the typical SBE, is also sometimes called the SBE.  This element, which is found in 
the promoters of many TGF-β responsive genes such as PAI-1 (Dennler, Itoh et al. 1998), 
JunB (Jonk, Itoh et al. 1998), and Smad7 (Stopa, Anhuf et al. 2000), is responsible for the 
binding of the TGF-β-induced Smad3/Smad4 complex.  Although there is over 90 % amino 
29 
 
 
acid sequence identity between Smad2 and Smad3, the complex of Smad2/ Smad4 does not 
bind to the SBE.  Two extra amino acids in the DNA-binding β-hairpin of N-terminal MH1 
domain in Smad2 may be responsible for this difference in the binding capability (Dennler, 
Huet et al. 1999).  Although phosphorylated Smad2 does not bind DNA, it forms a complex 
with Smad4 and the forkhead activin signal transducers (FAST) and activates transcription 
via the DNA binding function of FAST and Smad4.  In the FAST-1/Smad2/Smad4 complex, 
Smad4 provides the transactivation domain (TAD) that interacts with the basal transcription 
machinery (Liu, Pouponnot et al. 1997).  This complex has been reported to regulate the 
Xenopus homeobox gene mix2 during early embryogenesis (Yeo, Chen et al. 1999; Attisano, 
Silvestri et al. 2001).    
Interaction of Smad with other transcription factor. Smad mediates transcriptional 
regulation by directly binding to the SBE and by interacting with other transcription factors.  
The affinity of the Smad3 MH1 domain for the SBE is relatively low, with a Kd of about 10-7 
M (Shi, Wang et al. 1998).  By contrast, the DNA binding affinities of different AP-1 
proteins to TRE are very high, with Kds of about 12.5 – 50 nM as tested by EMSA 
(Tateyama, Horisawa et al. 2006).  Although there are usually several copies of SBE sites in 
TGF-β responsive genes, other factors that facilitate Smad binding are required, and are 
usually present in a cell and tissue specific manner.  Smad proteins have been shown to 
physically interact with DNA-specific binding proteins to modify Smad mediated 
transcriptional activation.  Adjacent binding sites of Smad interacting partners are required.  
For example, Smad3 physically interacts with a variety of transcription factors such as AP-1, 
transcription factor microE3 (TFE3) and hepatocyte nuclear factor 4 (HNF-4), each in 
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specific situations (Hua, Liu et al. 1998; Zhang, Feng et al. 1998; Wong, Rougier-Chapman 
et al. 1999).  Cooperative binding of Smad3/4 and AP-1 to their recognition sites 
synergistically activates transcription of TGF-β responsive genes such as collagenase I (Qing, 
Zhang et al. 2000).   
  The Smads interact with co-activators, co-repressors and chromatin 
modeling factors.   
Smad-mediated transcription is modulated by co-activators and co-repressors.  CREB 
binding protein (CBP) and p300 (also known as E1A binding protein) are co-activators of 
Smad2 and Smad3.  They recruit the Smad nuclear complexes to the basal transcription 
machinery via direct interaction (Derynck, Zhang et al. 1998; Feng, Zhang et al. 1998).  
Smad co-repressors include TG-interacting factor (TGIF), c-Ski and SnoN (Pessah, Prunier 
et al. 2001; Pessah, Marais et al. 2002).  The transcription factor c-Jun directly binds to the 
transcription repressors Ski or TGIF and Smad2 to restrict Smad2-mediated transcription.  
TGF-β activates Smad2-mediated transcription by causing the dissociation of c-Jun from Ski.  
Thus, by recruiting coactivators or corepressors to the Smad transcriptional complexes in the 
promoter, the transcriptional activity of Smad is differentially modulated.   
Non Smad-mediated TGF-β signaling     
Besides the Smad-mediated signaling, TGF-β activates other signaling pathways 
including the mitogen-activated protein kinases (MAPK), Rho-like GTPase and 
phosphatidylinositol-3-kinase (PI3K)/ Akt signaling pathways (Runyan, Schnaper et al. 2004; 
Moustakas and Heldin 2005; Zhang 2009). These non-Smad signaling pathways act 
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independently or cooperatively with the Smad-mediated pathway.  Three most extensively 
studied MAPKs subfamilies: Erk/MAPK, p38 kinases and Jnks, can be activated by TGF-β.  
TGF-β can rapidly and directly activate Ras and Erk1 in the untransformed Mv1Lu epithelial 
cells (Mulder and Morris 1992).  Erk activated by TGF-β has two different roles: first, it 
phosphorylates of Smad2/3; second, it works in the Smad3-independent manner such as 
acting through AP-1 (Hayashida, Decaestecker et al. 2003).  The p38 MAPK activated by 
TGF-β can promote apoptosis (Yu, Hebert et al. 2002; Undevia, Dorscheid et al. 2004), cell 
adhesion (Hayes, Huang et al. 2003 ; Walsh, Ampasala et al. 2008), and fibroblastic 
transdifferentiation (Vayalil, Iles et al. 2007).  Meanwhile, TGF-β can activate Mek/Erk and 
PI3K/Akt-mediated signaling to regulate cell proliferation, survival and the EMT (Davies, 
Robinson et al. 2005).   
PAI-1 regulation by TGF-β 
TGF-β stimulates PAI-1 expression in almost all cell types.  PAI-1 induced by TGF-β is 
close related to the increase of T2 renal epithelial cell motility (Kutz, Hordines et al. 2001).  
At low doses (1-2 ng/ml), TGF-β promotes cell migration, while at high doses (≥ 5ng/ml) it 
inhibits migration (Kutz, Hordines et al. 2001).  PAI-1 is stimulated by both  low and high 
doses of TGF-β, and the bi-functional role of PAI-1 on cell migration is consistent with the 
dual function of TGF-β in regulating migration (Kutz, Hordines et al. 2001).   Cells lacking 
PAI-1 do not respond to TGF-β with suppressed basal locomotion. PAI-1 is also required for 
maintaining the TGF-β-induced growth arrest (Kortlever, Nijwening et al. 2008).  
Knockdown of PAI-1 by RNA interference blocks the antiproliferative activity of TGF-β in 
human keratinocytes (HaCaTs) and primary mouse embryo fibroblasts.  Prolonged activation 
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of protein kinase B by PAI-1 repression leads to the escape of cells from TGF-β-induced 
growth inhibition (Kortlever, Nijwening et al. 2008).   
Signaling pathways involved in TGF-β regulates PAI-1 expression.  TGF-β regulates 
PAI-1 mainly through Smad-mediated signaling (Nakao, Imamura et al. 1997).  There are 
also several CAGA boxes in the PAI-1 promoter to which the TGF-β-activated nuclear 
Smad3/Smad4 heterodimer binds (Dennler, Itoh et al. 1998).  Meanwhile, other signaling 
pathways activated by TGF-β, include Erk in the MAPK pathway (Harradine and Akhurst 
2006), Jnk (Matsuzaki, Murata et al. 2007), P38 kinase (Vayalil, Iles et al. 2007) and PI3 
kinase/Akt(Das, Ghosh-Choudhury et al. 2008) also contribute to increases PAI-1 level 
(Figure 2A).   Experiments with pharmacologic inhibitors or dominant negative proteins 
show that maximal PAI-1 induction by TGF-β requires the EGFR, P21 Ras, Mek, Erk1/2 and 
pp60 (c-Src) signaling (Kutz, Hordines et al. 2001; Kutz, Higgins et al. 2006).  In renal 
mesangial cells, TGF-β-induced PI3 Kinase/Akt signaling enhances Smad-mediated PAI-1 
expression by promoting CBP-mediated Smad3 acetylation (Das, Ghosh-Choudhury et al. 
2008).  Matsuzaki reported that Jnk, activated by TGF-β, phosphorylates Smad3 at the linker 
region (pSmad3L), which increases PAI-1 expression in heptocellular carcinoma (HCC) 
(Matsuzaki, Murata et al. 2007).   
Regulators that affect the MAPK pathway also modulate TGF-β-induced PAI-1 
expression.  For example, by inhibiting the Jnk/P38 pathway in 3T3 cells, glutathione (GSH) 
represses TGF-β-induced PAI-1 expression (Vayalil, Iles et al. 2007).  During this process, 
the binding of transcription factors, like AP-1, sp1 and Smad, to the cis-elements in PAI-1 
promoter is blocked (Vayalil, Iles et al. 2007).  In human mesangial cells, actin cytoskeleton 
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reorganization affects TGF-β induced PAI-1 expression by influencing MAPK and Jnk 
activity (Yang, Hsieh et al. 2007).  In these cells, Erk and Jnk are colocalized with α-actinin 
along with F-actin.  Actin disassembly reduces basal and TGF-β-induced PAI-1 expression 
by inhibiting the phosphorylation of Erk and Jnk (Yang, Hsieh et al. 2007).  T2 renal 
epithelial cells grown as monolayer cultures produce more PAI-1 in response to TGF-β than 
cells grown in suspension culture due to different Mek activities in adhesive and suspended 
culture state (Kutz, Hordines et al. 2001).  
Cis-elements required for TGF-β-induced PAI-1 expression. The elements responsible 
for TGF-β induction mainly locate at two regions within the 800 bp region upstream of the 
PAI-1 transcription initiation site.  The distal promoter region (-636 to -740) contains the 
cooperative SBE-like site (-684/-677) and AP-1 like site (-670/-664, GGAGTCA) which 
mediate most of the response to TGF-β stimulation in Hep3B and HepG2 cells (Keeton, 
Curriden et al. 1991; Westerhausen, Hopkins et al. 1991).   Electrophoresis Mobility Shift 
Assays (EMSA) assay using overlapping oligonucleotide in this distal region identified these 
two sites are important for binding of Smad (Stroschein, Wang et al. 1999).  Mutation of 
either site significantly reduced the binding of Smad4 and Smad3, and mutation of both sites 
completely blocked Smad binding and PAI-1 gene activation in response to TGF-β 
(Stroschein, Wang et al. 1999).   A CAGA element (-732 to -721) in the distal region is also 
important for the TGF-β response in Hep3B cells (Song, Siok et al. 1998).  The proximal 
region (-77/-40) containing one AP-1 like site (-61 to -54) and two Sp1 DNA binding sites 
also elevated PAI-1 promoter activity in response to TGF-β (11-fold)  (Keeton, Curriden et al. 
1991; Datta, Blake et al. 2000).    An intact E box motif (5`CACGTG3`) at -566 to -561 of 
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PAI-1 promoter was also reported to be required for maximal PAI-1 induction by TGF-β in 
human epidermal keratinocytes (Allen, Qi et al. 2005).   
Due to the relatively low affinity of Smad to the SBE, other transcription factors are 
essential to enhance the binding of Smad to PAI-1 promoter.  Overexpression of both Smad3 
and c-Jun AP-1 protein synergistically activates transcription of PAI-1 with a 50 fold 
increase in promoter activity, which is most likely through their binding to the SBE-like 
motif and AP-1 like motif in the distal promoter region (Verrecchia, Vindevoghel et al. 2001).  
The cooperative binding of TFE3 to the E-box (-160/-165) and Smad3 to the nearby SBE in 
the promoter region is critical to meditate TGF-β-induced PAI-1 promoter activity from a 56 
bp enhancer (Hua, Liu et al. 1998; Hua, Miller et al. 1999).  Datta et al. showed that two Sp1 
sites in the proximal PAI-1 promoter (-77/-40)  were involved in PAI-1 induction by TGF-β 
in Mv1Lu and HepG2 cells where TGF-β promoted the physical interaction between the 
carboxyl terminus of Sp1 and the activated Smad3 at the Sp1 binding sites (Datta, Blake et al. 
2000).  However, in fibroblasts, Sp1 was dispensable in TGF-β-induced PAI-1 expression 
(Ghosh, Mori et al. 2007).  Thus it is possible that the function of Sp1 on PAI-1 expression is 
cell type specific or indirect.  In summary, the distal region containing the SBE-like and the 
AP-1-like sites and the proximal region containing AP1 sites contribute to the most of the 
induction of PAI-1 by TGF-β.  In the meanwhile activation of other elements, such as E-box 
and Sp1, may also be required for the maximal PAI-1 induction. 
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5.  Regulation of PAI-1 expression by EGF 
 EGF and EGF-mediated signaling 
Epidermal growth factor (EGF) is another important growth factor that regulates cell 
proliferation, differentiation and survival.  EGF is up-regulated in many cancers, and it 
promotes tumor cell motility and invasion (Hofler and Becker 2003).  These mitogenic 
effects are initiated by the binding of EGF to its receptor (EGFR) with high affinity on the 
cell surface (Goi, Shipitsin et al. 2000).  The binding of EGF to EGFR triggers the receptor to 
form dimmers and phosphorylate each other through its tyrosine kinase activities.  The 
phosphorylated receptors can initiate signal transduction, including the MAPK, Akt and Jnk 
pathways and regulate gene expression (Wang, McCullough et al. 2000; Jiang, Zhou et al. 
2006). 
 PAI-1 regulation by EGF 
EGF-induced PAI-1 expression has been reported in a variety of cells types, including 
liver epithelial cells (Seebacher, Manske et al. 1992), microvascular endothelial cells 
(Mawatari, Okamura et al. 1991), endometrial (Miyauchi, Momoeda et al. 1995), astrocytes 
(Tranque, Naftolin et al. 1994), gliomas (Paugh, Paugh et al. 2008), hepatomas (Hopkins, 
Westerhausen et al. 1991) and trophoblasts (Anteby, Greenfield et al. 2004).  EGF-stimulated 
PAI-1 (earlier reported as EGF/TGFα-inducible protein EIP-1) synthesis is closely associated 
with EGF-induced cell migration in both normal and Ha-Ras-transformed liver epithelial 
cells (Bade and Feindler 1988; Manske, Feindler et al. 1990; Seebacher, Manske et al. 1992).  
PAI-1 (reported earlier as inhibitor inducible protein-48 kDa IIP48) protein levels could be 
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detected as early as two hours after EGF stimulation (Nilsen-Hamilton and Holley 1983; 
Thalacker and Nilsen-Hamilton 1987; Bade and Feindler 1988), and these proteins are 
deposited into the ECM migration tracks (Seebacher, Manske et al. 1992).  However, PAI-1 
is not sufficient to stimulate cell migration in these cells (Seebacher, Manske et al. 1992).   
Although EGF activated Erk1/2, Jnk phosphorylation and DNA binding activity of AP-1, 
none of these were involved in PAI-1 stimulation in human glioma cells.  An ordered 
activation of EGFR, Src, PKCδ (protein kinase C delta), SphK1 (sphingosine kinase 1) and 
S1P (sphingosine 1-phosphate) signaling is required for EGF activating PAI-1 transcription 
in a c-Jun dependent manner (Paugh, Paugh et al. 2008).  Experiments using specific 
chemical inhibitors showed that inhibitors of PKC (protein kinase C) and c-Src efficiently 
blocked PAI-1 induction by EGF (Paugh, Paugh et al. 2008).  Knock-down of sphingosine 
kinase 1 by siRNA eliminated the EGF-induced PAI-1 expression in human glioma cells 
(Paugh, Paugh et al. 2008).     
6.  Synergistic regulation of PAI-1 by EGF and TGF-β 
TGF-β cooperates with EGF affecting many biological processes 
Integration of the EGF- and the TGF-β- mediated signaling dramatically influences cell 
function in normal processes and during disease progression including cell transformation 
(Roberts, Frolik et al. 1983), the epithelial-mesenchymal transition (EMT) (Uttamsingh, Bao 
et al. 2008; Hardy, Booth et al.; Taylor, Parvani et al.), migration (Stolz and Michalopoulos 
1997), proliferation (Saltis, Agrotis et al. 1992) and survival (Saha, Datta et al. 1999).  
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Cooperation between EGF and TGF-β also affects wound healing (Lawrence, Norton et al. 
1986). 
 EGF and TGF-β cooperate to promote the transformation of many cells such as normal 
rat kidney (NRK) cells (Roberts, Frolik et al. 1983), rabbit corneal keratocytes (RCKs) (He 
and Bazan 2008) and rat intestinal epithelial cell (RIE) (Uttamsingh, Bao et al. 2008).  
Transformation of eukaryotic cells results in anchorage dependent cells losing contact 
inhibition of growth, gaining the capability of growing in soft agar and becoming anchorage-
independent.  These changes are found during tumorigenesis in vivo.  The transformation 
induced by EGF and TGF-β changes keratinocytes to myofibroblasts with the loss of 
dendritic shape and synergistically increased fibronectin synthesis (He and Bazan 2008).  By 
significantly increasing the levels of extracellular matrix protein expression in myofibroblasts, 
EGF and TGF-β play a crucial role in tissue fibrosis (He and Bazan 2008). 
As well as acting independently, EGF and TGF-β cooperate to promote a variety of 
epithelial cells to undergo the EMT (Uttamsingh, Bao et al. 2008; Hardy, Booth et al.; Taylor, 
Parvani et al.).  An epithelial cell is characterized by apical-basal polarity and tight cell-cell 
contact (Xu, Lamouille et al. 2009).  During the epithelial-mesenchymal transition, epithelial 
cells lose their polarity and epithelial cell markers such as E-cadherin, and transform to a 
spindle like cell shape similar to that of fibroblasts.  They also express mesenchymal markers 
such as vimentin and smooth muscle actin, and their motility is enhanced (Xu, Lamouille et 
al. 2009).  Elevated TGF-β synthesis and amplified EGFR signaling cooperatively promote 
cell migration and the invasive phenotype (Wilkins-Port, Higgins et al. 2007).  TGF-β alone 
inhibits epithelial cell migration and stimulates the synthesis of fibronectin, laminin, 
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proteoglycans and PAI-1 to increase the matrix deposition (Freytag, Wilkins-Port et al. 2009).  
The inhibiting effect of TGF-β on cell growth and migration is reversed by the positive effect 
of EGFR signaling and cell migration is synergistically enhanced by the combination of these 
growth factors (Uttamsingh, Bao et al. 2008).  Both metallomatrix proteinases (MMPs) and 
PAI-1 are synergistically induced by the presence of EGF and TGF-β to enhance focal 
degradation and extracellular matrix remodeling (Freytag, Wilkins-Port et al. 2009).  
Blocking the activities of these metalloproteinase (MMP1 and MMP9) significantly reduces 
EGF and TGF-β-induced cell migration and colony formation (Uttamsingh, Bao et al. 2008).  
The remodeling of extracellular matrix enables acquisition of motility and plasticity of 
epithelial cells (Freytag, Wilkins-Port et al. 2009).   
EMT plays a critical role in morphogenesis during early embryonic development (Shook 
and Keller 2003) and in many pathological processes including wound healing, tissue fibrosis 
and tumor progression (Bates and Mercurio 2005; Radisky, Kenny et al. 2007; Kalluri 2009).  
EMT in cancers signals the change of cancer cells from the benign to malignant forms with 
increased potential of invasion and metastasis (Kalluri 2009).  In the late stages of tumor 
progression, the EGFR mediated signaling is often amplified.  Sustained activation of MAPK, 
which is enhanced in the presence of TGF-β, is required for EGF and TGF-β-induced EMT.   
Cooperation between EGFR and TGF-β explains the tumor-promoting activity of TGF-β, 
which is frequently found elevated in advanced stages of tumors. 
TGF-β also acts synergistically with EGF to stimulate hepatocyte motility during liver 
tissue regeneration (Stolz and Michalopoulos 1997).  The increased motility is observed in 
the non-transformed primary rat heptocytes and hepatoblastoma HepG2 cells (Stolz and 
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Michalopoulos 1997).  It occurs only on a collagen surface and is independent of the effect of 
these growth factors on DNA synthesis (Stolz and Michalopoulos 1997). 
TGF-β also synergizes with other ligands of tyrosine kinase receptors  
Besides EGF, TGF-β also acts synergistically with TGFα (transforming growth factor 
alpha).  TGFα is a member of EGF family and shares the same receptor (EGFR) as EGF 
(Roberts, Frolik et al. 1983).  In many cases, TGFα can replace EGF to synergize with 
TGF-β.  For example TGF-β enhances the TGFα effect on promoting the motility of primary 
rat hepatocytes and HepG2 cells (Stolz and Michalopoulos 1997) and inducing the 
transformation of normal rat kidney (NRK) fibroblast (Roberts, Frolik et al. 1983).  Both 
EGF and TGFα synergize with TGF-β to stimulate inorganic pyrophosphate (PPi) production 
by articular cartilage during the formation of calcium pyrophosphate dehydrate (CPPD) 
crystals in joints (Rosenthal, Cheung et al. 1991).  Thus the mechanism of synergism is likely 
arising from cross talk between the signaling pathways mediated by EGFR and TGF-β. 
Other growth factors have also been found to synergistically interact with TGF-β.  For 
example, hepatocyte growth factor (HGF) cooperatively acts with TGF-β to induce scattering 
phenotype of epithelial cells (Stolz and Michalopoulos 1997).  Insulin like growth factor I 
(IGF-I) synergizes with TGF-β in inducing the EMT of RIE cells (Uttamsingh, Bao et al. 
2008).  Basic fibroblast growth factor (bFGF or FGF-2) and platelet-derived growth factor 
(PDGF), cooperate with TGF-β to enhance the proliferation of vascular smooth muscle cells 
(Saltis, Agrotis et al. 1992).   
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There are four canonical signaling pathways induced by RTKs, including the mitogen-
activated protein kinase cascades (MAPKs), the lipid kinase phosphatidylinositol 3 kinase 
(PI3K), a group of Stat transcription factors, and the phospholipase Cγ (PLCγ) mediated 
pathway (Katz, Amit et al. 2007).  These signaling pathways are shared by all RTKs and are 
potentially involved in the mechanism(s) of synergism with TGF-β. 
PAI-1 is synergistically induced by EGF and TGF-β 
PAI-1 is synergistically induced by EGF and TGF-β in both normal and MSV-
transformed mink lung epithelial (Mv1Lu) cells (Thalacker and Nilsen-Hamilton 1987; 
Thalacker and Nilsen-Hamilton 1992). A synergistic induction of PAI-1 was also found 
during EGF and TGF-β activated EMT (Wilkins-Port, Ye et al. 2009).  The PAI-1 cellular 
protein level is synergistically increased in Ras transformed human HaCaT II-4 keratinocytes 
in the presence of both growth factors (Wilkins-Port, Ye et al. 2009).  Microarray 
experiments also showed that PAI-1 is the most highly expressed early gene during EGF and 
TGF-β induced EMT of transformed human keratinocytes (Freytag, Wilkins-Port et al. 2009).   
MAPK signaling plays an important role in the synergistic induction of PAI-1.  Maximal 
expression of PAI-1 induced by EGF and TGF-β requires the activation of Mek/Erk and p38 
MAPK signaling (Freytag, Wilkins-Port et al. 2010).  Inhibition of the Mek and p38 MAPK-
mediated pathways blocks both PAI-1 expression and EGF and TGF-β induced cell 
locomotion (Freytag, Wilkins-Port et al. 2010).  Transactivation of the EGFR is also involved 
in the synergistic regulation of PAI-1 in human keratinocytes (Freytag, Wilkins-Port et al. 
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2010).  Blocking EGFR signaling with an inhibitor AG1478 attenuated PAI-1 synthesis 
(Wilkins-Port, Ye et al. 2009).     
PAI-1 plays a critical role in the EGF and TGF-β-affected processes such as EMT, which 
is mostly likely through influencing cell motility.  Cotreatment with EGF and TGF-β induces 
the plastic phenotype of several epithelial tumor cells including SCC (Wilkins-Port, Ye et al. 
2009; Freytag, Wilkins-Port et al. 2010).  PAI-1 is critical in the EGF and TGF-β-induced 
invasion in Ras-transformed human (HaCaT II-4) keratinocytes and human cutaneous 
squamous carcinoma cells (Wilkins-Port, Higgins et al. 2007; Freytag, Wilkins-Port et al. 
2010).   Suppression of PAI-1 expression efficiently blocks cell locomotion (Freytag, 
Wilkins-Port et al. 2010) and colony formation induced by EGF and TGF-β (Wilkins-Port, 
Ye et al. 2009).  Addition of exogenous PAI-1 or inhibitor of urokinase-type plasminogen 
activator supressed the dissolution of the collagen matrix (Wilkins-Port, Ye et al. 2009).  
Knockdown of PAI-1 by siRNA also inhibited TGF-β-induced EMT in mouse lung epithelial 
LA-4 cells (Senoo, Hattori et al. 2010).   In summary, the role of PAI-1 in EMT is likely 
related to its ability in modulating remodeling of extracellular matrix and cell migration. 
7.  Molecular mechanism of the interaction between the TGF-β and EGF- 
mediated signaling 
Pathways involved in EGF and TGF-β affected EMT 
The TGF-β-induced EMT requires activity of the MAPK, Smad and AP-1 signaling 
pathways (Davies, Robinson et al. 2005).  Blocking the MAPK signaling supresses progress 
of the EMT (Grande, Franzen et al. 2002).  In cells bearing a normal Ras, EGF cooperates 
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with TGF-β to promote EMT by activating MAPK and AP-1 (Davies, Robinson et al. 2005).  
PMA substitutes for EGF in promoting EMT with TGF-β via AP-1 activation (Davies, 
Robinson et al. 2005).  In rat intestine epithelial (RIE) cells, TGF-β enhances the EGF-
induced MAPK signaling and prolongs the EGF-activated AKT signaling (Uttamsingh, Bao 
et al. 2008).  Both PI3K and MAPK-mediated pathways are involved in EGF and TGF-β-
mediated cell migration and invasion, but only the MAPK pathway is required for EGF and 
TGF-β induced EMT in RIE cells (Uttamsingh, Bao et al. 2008).  The EMT in mouse 
mammary epithelial cells requires synergistic interaction between TGF-β receptor and EGF 
signaling, especially involving the Ras/MAPK signaling (Janda, Lehmann et al. 2002).  
During EGF and TGF-β induced EMT, the EGFR level or its phosphorylation was not 
significantly increased by TGF-β (Uttamsingh, Bao et al. 2008).  The EMT induced by EGF 
and TGF-β can be reversed by removing the growth factors from medium.  However, 
sustained TGF-β receptor activation cooperates with the prolonged Ras/Raf signaling to 
maintain the EMT in EpRas4 cells (Janda, Lehmann et al. 2002).  Autocrine regulation of 
TGF-β production is also involved in the stabilization of the EMT progression (Janda, 
Lehmann et al. 2002).   
MAPK signaling influences Smad-mediated transcriptional activity  
The effect of Mek/Erk on Smad activity may depend on the Erk activity.  A certain 
amount of Erk activity is needed for maximal activation of Smads by TGF-β.  For example, 
in human mesangial cells, Erk activation by TGF-β helps to phosphorylate the carboxyl-
terminal serines (SSPXSP motif) of R-Smad (pSmadC), which greatly promotes TGF-β 
induced transcriptional activity (Hayashida, Decaestecker et al. 2003).  Inhibiting Erk activity 
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decreased TGF-β induced Smad transcription in an AP-1 independent way (Hayashida, 
Decaestecker et al. 2003).  MAPK activated by other factors can also enhance Smad-
mediated transcription.  For example, HGF and EGF phosphorylate Smad2 in the SSMS 
motif in a TβR-I independent manner, which promotes nuclear translocation of Smad2 that 
depends on Mek1 (de Caestecker, Parks et al. 1998)   
However phosphorylation of the linker region of R-Smads (pSmadL) by EGF- or 
oncogenic Ras-induced Mek/Erk inhibits nuclear translocation of Smad2/3 in mammary and 
lung epithelial cells (Kretzschmar, Doody et al. 1999).  The inhibition of nuclear 
translocation of Smad2/3 is much stronger by oncogenic Ras than by EGF (Kretzschmar, 
Doody et al. 1999).  The inhibiting effect of EGF on nuclear translocation of Smad2/3 is 
more effective at a low concentration than at a high concentration of TGF-β.  Thus the 
relative strength of the EGF signal compared to the TGF-β signal affects nuclear 
accumulation of Smad2/3 and TGF-β-mediated transcription.  These effects were confirmed 
to be true in Mv1Lu cells (Kretzschmar, Doody et al. 1999).   
AP-1 and Smad cooperatively activate transcription  
Transcription factor AP-1 is made of either homodimer of Jun family proteins or 
heterodimer of Jun and Fos family proteins (Nakabeppu, Ryder et al. 1988; Angel and Karin 
1991).  There are five known members in Fos family: c-Fos (Curran and Teich 1982), Fos B 
(Zerial, Toschi et al. 1989), ΔFosB, Fra-1 (Cohen and Curran 1988) and Fra-2 (Matsui, 
Tokuhara et al. 1990) and three known members in Jun family: c-Jun (Ball, Bos et al. 1988), 
JunB (Ryder, Lau et al. 1988) and JunD (Hirai, Ryseck et al. 1989).  Although all AP-1 
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complexes bind to the common AP-1 site (TRE), the transcription activity of AP-1 is 
determined by the composition of the dimer and the phosphorylation states of each 
component (Kaminska, Pyrzynska et al. 2000).  c-Jun is the most important Jun family 
member because it recruits Jnk to phosphorylate its binding partner (Kaminska, Pyrzynska et 
al. 2000).   Upon stimulation by UV-irradiation, growth factors and cytokines, c-Jun is 
rapidly phoshorylated by Jnk at serine 63 and 73 within the amino terminal transactivation 
domain (TAD) resulting in increased protein stability and significantly enhanced 
transcriptional activity (Morton, Davis et al. 2003).   Fos is the most important member in 
Fos family, which is activated by Erk1/2 and Frk (Fos regulating kinase) at the Thr-232, 
Thr-325 (Erk2), Thr-331, Ser-374 (Erk1/2) and Ser362 within the carboxy-terminal TAD 
resulting in activation of AP-1 (Chen, Abate et al. 1993; Cavigelli, Dolfi et al. 1995; Murphy, 
Smith et al. 2002; Monje, Marinissen et al. 2003).   Fos is also rapidly phosphorylated in its 
transactivation domain by p38 kinases upon UV-light exposure (Tanos, Marinissen et al. 
2005).   
It has been shown that AP-1 transcription factor cooperates with Smads to activate the 
transcription of some TGF-β responsive genes including Collagenase I (Zhang, Feng et al. 
1998; Qing, Zhang et al. 2000).  The cooperative binding of Smad to the SBE and the AP-1 
complex to its recognition sites (TRE) results in the synergistic activation of TGF-β inducible 
genes.  During this interaction, Smad3/Smad4 forms a complex with AP-1 via the physical 
interaction of the Smad3 MH1-linker binding to c-Jun and the Smad3 MH2 domain to c-Fos 
at AP-1 binding sites (Zhang, Feng et al. 1998; Liberati, Datto et al. 1999).  Cooperative 
interaction between AP-1 and Smad also elevates the transcription of PAI-1 (Verrecchia, 
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Vindevoghel et al. 2001).  Overexpression of Smad3 elevated the transcriptional activity 
from a 800-bp PAI-1 proximal promoter (p800-Lux) by 18-fold, and overexpression of c-Jun 
alone only slightly increased PAI-1 promoter activity (about 2-fold) (Verrecchia, 
Vindevoghel et al. 2001).  However, simultaneous overexpression of both Smad3 and c-Jun 
increased the promoter activity of PAI-1 by about 50-fold over control (Verrecchia, 
Vindevoghel et al. 2001).    Although JunB alone showed the similar stimulation on PAI-1 
transcription as c-Jun, it only had slightly additive effect with Smad3 (Verrecchia, 
Vindevoghel et al. 2001).   
 AP-1 induced by other stimuli also acts synergistically with the Smad proteins to activate 
gene transcription.  For example, AP-1 activated by Gonadotropin-releasing hormone (GnRH) 
and Smad activated by activin synergistically induce transcription of the FSH β subunit (Coss, 
Hand et al. 2007).  AP-1 is involved in the modulation of TGF-β-induced PAI-1 expression 
by promoting cytoskeleton reorganization in human mesangial cells.  Actin stabilization 
prolongs the phosphorylation of Erk and Jnk and enhances the binding of AP-1 to its DNA 
binding sites (Yang, Patel et al. 2007).  Dominant negative mutants for either MAPK or Jnk 
decrease TGF-β- induced PAI-1 promoter activity and the binding of AP-1 to the PAI-1 
promoter (Yang, Patel et al. 2007).   
However, not all AP-1 sites promote TGF-β-induced transcriptional activity.  An 
overlapping Smad binding site is required to produce the cooperative transcriptional 
activation by Smads and AP-1 (Zhang, Feng et al. 1998).  Thus, the impact of AP-1 on 
Smad-mediated transcription depends on the position of its recognition sites in the promoter 
and the availability of active AP-1 transcription factors.  For example, of two AP-1-like sites 
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in PAI-1 distal promoter, only one in the region of -670 to -664 acts cooperatively with the 
adjacent SBE-like site (-684 to -677) and the other one (-659/-653) does not have such effect 
(Stroschein, Wang et al. 1999).   
Mechanisms of synergistic regulation of gene expression by EGF and TGF-β 
The synergistic effects of EGF and TGF-β on different biological processes involve the 
expression of different target genes.  For example during the EMT, matrix metalloproteinases 
(MMPs) are synergistically induced by EGF and TGF-β to break down the extracellular 
matrix components to promote the motility of cells (Uttamsingh, Bao et al. 2008; Wilkins-
Port, Ye et al. 2009).  In addition with synergistically induced PAI-1, these proteins facilitate 
the formation of a proper environment for epithelial cells to acquire the invasive phenotype 
(Wilkins-Port, Ye et al. 2009).   
The synergistic regulation of target gene expression by EGF and TGF-β occurs mainly at 
the transcriptional level.  EGF alone shows very weak activation of Smad3-mediated 
transcription in hepatocytes (Peron, Rahmani et al. 2001).  However, the transcriptional 
activity mediated by either Smad2 or Smad3 is synergistically increased by EGF and TGF-β 
(Peron, Rahmani et al. 2001).  This synergism requires the activity of AP-1 because the 
synergism between EGF and TGF-β is reduced by dominant negative c-Jun, which inhibits 
the AP-1 activity by preventing the endogenous Jun and Fos protein from forming a 
functional heterodimer.  Dominant negative c-Jun or c-Jun RNAi decreases the 
transcriptional activity of Smad3 in the EGF and TGF-β cotreatment but not that in the 
treatment of either growth factor alone.  Co-immunoprecipitation experiments have shown 
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that c-Jun is physically associated with Smad3 (Peron, Rahmani et al. 2001).  PI3K and p38 
MAPK, but not JNK-mediated pathways activate c-Jun by phosphorylation.  EGF and TGF-β 
synergize in the transcriptional activation of the SBE promoter, which can be blocked by 
dominant negative AP-1 (Peron, Rahmani et al. 2001).  In Mv1Lu cells, EGF and TGF-β 
synergistically induce the expression of cyclooxygenase-2 (COX-2) and prostaglandin E2 
(PGE2) to inhibit cell apoptosis and promote cell invasion and angiogenesis (Saha, Datta et 
al. 1999).  TGF-β receptor type I (TβR-I) and the EGF receptor are required in the synergistic 
induction of COX2 and PGE2 (Saha, Datta et al. 1999).   Mek/Erk and p38 MAPK are also 
involved because blocking either activity by specific inhibitors significantly reduces the 
induction of COX-2 (Saha, Datta et al. 1999).    
Post-transcriptional regulation also plays an important role in the synergistic induction of 
some target genes by EGF and TGF-β.  For example, EGF and TGF-β synergistically 
increase the mRNA level of leukemia-inhibitory factor (LIF) by increasing the mRNA 
stability in thymic epithelial cells (Schluns, Cook et al. 1997).  However the mechanism of 
this post transcriptional regulation is unclear. 
8.  Summary 
PAI-1 plays important roles in inhibiting fibrinolysis, regulating extracelluar matrix 
remodeling and modulating cell migration.  Elevated PAI-1 levels are correlated with many 
diseases including thrombosis, cancer, fibrosis and metabolic diseases.  PAI-1 antagonists 
have shown promising results in treating such diseases.  Many stimuli, including growth 
factors, cytokines and LPS, that stimulate the expression of PAI-1 may induce PAI-1 in vivo.  
EGF and TGF-β synergistically induce PAI-1 expression in both normal and transformed 
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mink lung epithelial Mv1Lu cells (Thalacker and Nilsen-Hamilton 1987; Thalacker and 
Nilsen-Hamilton 1992) and transformed human keratinocytes (Freytag, Wilkins-Port et al. 
2009).  PAI-1 plays important roles in EMT induced by EGF and TGF-β in human 
keratinocytes (Freytag, Wilkins-Port et al. 2009).  TGF-β activates PAI-1 expression through 
Smad3/Smad4, while EGF functions through Src activating gene transcription in human 
mensengial cells (Harradine and Akhurst 2006).  However the synergistic regulation of 
PAI-1 is not fully understood.  This thesis will address the mechanism of synergistic 
regulation of PAI-1 by EGF and TGF-β.   
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Figure legends 
Figure 1. The function of PAI-1.   
Plasmin, a broad spectrum serine protease, degrades fibrin and extracellular matrix 
proteins by which it plays a central role in fibrinolysis and extracellular remodeling.  PAI-1 
inhibits the conversion of inactive plasminogen to active plasmin mediated by urokinase type 
or tissue type plasminogen activator (uPA, tPA), by which PAI-1 negatively regulates 
fibrinolysis and modulates remodeling of extracellular matrix.  PAI-1 modulates cell 
migration in different ways: 1) by influencing plasmin-mediated pericellular proteolysis. 
Plasmin-mediated proteolysis removes the tissue barrier to aid cell migration. A certain 
amount of PAI-1 is required for blocking excessive plasmin-mediated degradation to 
maintain the necessary matrix scaffold required for cell migration. 2) PAI-1 inhibits uPAR-
integrin mediated cell adhesion and promotes cell detachment, both of which promoter cell 
migration.  With a high affinity of PAI-1 to matrix protein vitronectin, PAI-1 inhibits the 
adhesion of uPAR-integrin-baring cells to vitronectin.  PAI-1 promotes cell detachment by 
forming a complex with uPA-uPAR-integrin.  Binding of PAI-1 to the complex of uPA-
uPAR-integrin on the cell surface initiates LRP (low indensity lipoprotein receptor-related 
protein) mediated complex internalization. Disengagement of the adhesive receptors uPAR 
and integrin from the extracellular matrix promotes cell detachment and migration. 
Figure 2. Signaling pathways that involved in PAI-1 regulation by TGF-β and EGF.  
Induction of PAI-1 by TGF-β mainly acts through Smad mediated pathway.  Binding of 
TGF-β to its receptors triggers the activation of Smad2/3 by TβRI through phosphorylating 
the C terminal SSXS motif of Smad.  Homodimmers or heterodimmers of activated Smad2 
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and Smad3 form complexes with Smad4 and then move into nucleus to activate transcription.  
The Smad3 transcription complex binds to the Smad Binding Elements (SBEs) at PAI-1 
promoter.  Meanwhile, TGF-β-activated non-Smad signaling pathways also contribute to 
PAI-1 induction in various cases including Mek/Erk, p38, Jnk, PI3K and Src, which all can 
be activated by EGF.  The mechanism of PAI-1 induction by EGF was reported only in 
human glioma cells where an ordered activation of EGFR, Src, PKCδ (protein kinase C 
delta), SphK1 (sphingosine kinase 1) and S1P (sphingosine 1-phosphate) signaling is 
required.  Black line: reported required for PAI-1 induction; grey lines: involved in PAI-1 
regulation, but function varies in cases; dashed lines, not yet reported in PAI-1 regulation. 
Figrue 3. Cis elements involved in PAI-1 regulation by TGF-β.   
The SBE-like motif is the most important cis elements to mediate the transcription of 
Smad.  Other elements also play important role, including AP-1, Sp-1 and E box.  The cis-
elements involved in TGF-β-induced PAI-1 are distributed two regions in PAI-1 promoter: 
The distal region (-636/-740) contributes the most transcriptional activation of PAI-1 by 
TGF-β.  Cooperative binding of Smad3/4 to the SBE-like motif and AP-1 to AP-1 like motif 
in the distal promoter region synergistically activates transcription of PAI-1 with a 50 fold.   
The proximal region (-77/-40) with one AP-1 like site and two Sp1 sites elevates PAI-1 
promoter activity by 10-fold.   The cooperative binding of TFE3 to the E-box (-160/-165) and 
Smad3 to the nearby SBE in the promoter region is critical to meditated TGF-β-induced 
PAI-1 promoter activity from a 56 bp enhancer. 
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Figure 2.  Signaling pathways that involved in PAI-1 regulation by EGF &TGF-β 
 
 
 
69 
 
 
Figure 3.  Cis-elements involved in PAI-1 regulation by TGF-β 
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Abstract:  
As the major physiological inhibitor of plasminogen activator (PA), the type I plasmin-
ogen activator inhibitor (PAI-1) is important for controlling blood clotting and tissue 
remodeling events such as those that involve cell migration.  The changing needs for protease 
activity under various physiological conditions necessitates a tight cellular control of gene 
expression to enable rapid changes in the levels of PAI-1 and PA activity.  Transforming 
growth factor-β (TGF-β) and epidermal growth factor (EGF) interact synergistically to 
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increase PAI-1 mRNA and protein levels in human HepG2 and mink Mv1Lu cells.  Other 
growth factors that activate tyrosine kinase receptors can substitute for EGF.  The mechanism 
by which EGF and TGF synergistically regulate PAI-1 was explored in Mv1Lu cells and 
found to involve synergistic transcriptional activation that is further amplified by a decrease 
in the rate of mRNA degradation, the latter being regulated only by EGF.  The combined 
effect of transcriptional activation and mRNA stabilization results in a rapid two-order of 
magnitude increase in the level of PAI-1 within two h of growth factor addition and a similar 
rapid decline after transcription declines.  TGF-β also increases the sensitivity of the cells to 
EGF, thereby recruiting EGF at suboptimal concentrations to contribute to the synergistic 
activation of PAI-1.  The contribution of EGF to the regulation of PAI-1 involves the MAPK 
pathway and the synergistic interface with the TGFβ pathway is downstream of MEK and 
involves phosphorylation of neither Erk1/2 nor Smad2/3.  Although de novo protein 
synthesis is not required, a rapidly turning over protein is involved in the synergistic 
regulation.  This protein may be the AP-1 protein, which is required for this regulation and 
synergism at transcription requires the presence of both Smad and AP-1 recognition sites.  
This work demonstrates the existence of a multidimensional cellular mechanism by which 
EGF and TGF are able to promote large and rapid changes in PAI-1 expression.   
Introduction   
Plasminogen activator inhibitor type 1 (PAI-1), a secreted glycoprotein, is produced by 
many cell types and is present in plasma and platelets (Haggroth, Mattsson et al. 1986).  It is 
one of three serpin inhibitors of plasminogen activators, which are serine proteases that 
convert the zymogen plasminogen into plasmin.  A broad spectrum serine protease, plasmin 
degrades fibrin and extracellular matrix proteins and plays a central role in clot dissolution.  
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Interaction between PAI-1 and each of the two plasminogen activators (urokinase-type 
plasminogen activator, and tissue type plasminogen activator) is rapid with a second order 
rate constant between 107-108 M-1 s-1 (Hekman and Loskutoff 1988).  By controlling the 
plasminogen activator-plasmin proteolytic cascade, PAI-1 is a crucial to the regulation of 
haemostasis and many biological processes that involve remodeling of the extracellular 
matrix (ECM, Sprengers and Kluft 1987; Loskutoff, Sawdey et al. 1989; Dellas and 
Loskutoff 2005).   
As well as controlling degradation of the ECM, PAI-1 binds with some ECM components, 
particularly vitronectin (Salonen, Vaheri et al. 1989).  The interaction with vitronectin both 
localizes PAI-1 to the ECM and alters its specificity to cell-associated proteases.  
Consequently, vitronectin-associated PAI-1 inhibits the proteolysis that promotes cell 
migration and thereby inhibits angiogenesis and tumor cell migration in vitro (Swiercz, Keck 
et al. 2001).  However, by binding vitronectin, PAI-1 also interferes with the interactions of 
urokinase plasminogen activator receptor and αV-integrins with vitronectin, thereby 
preventing cell-substratum association (Stefansson and Lawrence 1996).  This action could 
promote tumor metastasis and angiogenesis (Loskutoff, Curriden et al. 1999).  Consistent 
with this proposed function, high PAI-1 levels are associated with a negative prognosis for 
tumor metastasis (Pedersen, Brunner et al. 1994; Pedersen, Grondahl-Hansen et al. 1994).  
However, a careful examination of the relative contributions of the PAI-1 effects on plasmin 
activity and cell attachment to tumor angiogenesis in vivo revealed that the ability of PAI-1 
to promote tumorigenesis is primarily due to its inhibiting plasmin activation (Bajou, Masson 
et al. 2001).  By promoting the formation of ECM, PAI-1 is proposed to provide endothelial 
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cells a substratum through which to move, thus promoting angiogenesis and tumor growth 
(Bajou, Masson et al. 2001). 
In addition to its involvement in cancer, altered PAI-1 levels contribute to asthma, 
cirrhosis of the liver and other fibrotic events.  For example, chronically elevated PAI-1 in 
the brain is believed to promote senility by preventing degradation by PA of aggregated α-
amyloid peptides that make up senile plaques (Seki, Imai et al. 1996; Buckova, Izakovicova 
Holla et al. 2002; Higgins 2006).   
Consistent with its role in regulating the activity of potent proteases that participate in 
tissue remodeling and clot resorption, the in vivo levels of PAI-1 can change rapidly.  For 
example, PAI-1 levels in the blood are increased within 1 h of major surgery, severe trauma, 
and myocardial infarction (D'Angelo, Kluft et al. 1985; Kluft, Verheijen et al. 1985; Burzotta, 
Iacoviello et al. 2003; Kruithof, Gudinchet et al. 1988).  A major source of PAI-1 is liver 
because it is an acute phase protein (Kruithof, Gudinchet et al. 1988).  Clearance of PA-
inhibitory activity from circulation is also rapid with measured half lives of 3.5 to 7 min 
(Colucci, Paramo et al. 1985).  Even the PAI-1 that is not cleared from the circulation has a 
limited half life of about 1-2 h due to its spontaneous conversion to an inactive latent 
conformer in which some of the primary recognition residues are incorporated into its largest 
β sheet (Mottonen, Strand et al. 1992). 
PAI-1 expression is regulated by many hormones, cytokines and growth factors including 
insulin, transforming growth factor type beta (TGF-β), epidermal growth factor (EGF), basic 
fibroblast growth factor (FGF-2), insulin-like growth factor I (IGF-I) and tumor necrosis 
factor alpha (TNFα) (Thalacker and Nilsen-Hamilton 1987; Landin, Tengborn et al. 1991; 
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Schneider and Sobel 1991; Thalacker and Nilsen-Hamilton 1992; Peiretti, Alessi et al. 1997; 
Watanabe, Kurabayashi et al. 2001).  TGF-β and EGF cooperatively regulate PAI-1 
expression (Thalacker and Nilsen-Hamilton 1987; Hopkins, Westerhausen et al. 1991).  
Synergism between two or more regulators allows cells to achieve a significantly higher level 
of response than is possible by stimulation with one regulator alone and is likely the means 
by which many critical genes are regulated.  Cooperation in signaling (synergism) is an 
important means of ensuring tight biological control and effecting large increases in gene 
expression, both of which are important for PAI-1.  The requirement of two or more 
regulators for increased gene expression also minimizes the probability of adventitious gene 
activation that could be deleterious to the organism. 
Although transcriptional activity is frequently a point of regulation of gene expression, 
the level of each mRNA available for translation depends on both it transcription and 
degradation.  Here we examine the contributions of transcription and degradation to the 
mechanism by which EGF and TGF-β on PAI-1 act synergistically on gene expression.  We 
demonstrate that the two growth factors interact synergistically at the level of PAI-1 mRNA 
transcription and that EGF alone stabilizes PAI-1 mRNA with the result that the mRNA level 
increases rapidly to two orders of magnitude higher than the basal level.  In addition, TGF-β 
recruits the EGF component of the synergistic mechanism by increasing the cells’ sensitivity 
to EGF.  The mechanism by which synergism is achieved is unique to the combination of the 
two growth factors and the same level of expression cannot be achieved by either growth 
factor alone.  These studies demonstrate a powerful interaction on PAI-1 gene expression 
between two growth factors that are frequently present at elevated levels in diseased tissues 
such as cancer and during an inflammatory response. 
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 Experimental procedures 
 Materials.  Human TGF-β1 and recombinant epidermal growth factor were from R&D 
systems (Minneapolis, MN).  Cordycepin and 4-thiouridine (4SU) were from Sigma (St.  
Louis, MO).  α32 P-dCTP was from New England Nuclear (Boston, MA).  α-32P-UTP was 
from ICN (Irvine, Calif., USA).  The 35S-methionine, 35S-Trans-label (mixture of 35S-
methionine and 35S-cysteine) and Random Primer Labeling Kit were from Amersham 
(Piscataway, NJ) and the Zeta-probe nylon membrane was from Bio-Rad (Hercules, CA).  
Trizol, DNase I and reverse transcriptase were from Invitrogen (Carlsbad, CA).  EZ-Link 
Biotin-HPDP was from Thermo Scientific (Rockford, IL).  Biotin-16-UTP was from 
Epicentre Biotechnologies (Madison, WI).  All reagents were analytical grade or better.  
Rabbit monoclonal antibody against phospho-p44/42 MAP Kinase (Thr202|Tyr204) was 
purchased from Cell Signaling Technology, Inc.  (Danvers, MA, cat# 4370); Rabbit anti-
Smad2 (Phospho-Ser467) polyclonal antibody was purchased from GenSript USA Inc.  
(Piscataway, NJ, Cat#A01037) and β-actin (C4) mouse monoclonal antibody (HRP 
conjugated) was purchased from Santa Cruz Biotechnology, Inc.  (Santa Cruz, CA, Cat# sc-
47778).  Antibodies against phosphorelated Fos at ser32, ser362 & Thr232 (Assay Bio Tech, 
cat# A8212, A0429, A8226) and phosphorylated c-Jun at ser63 and ser73 (Assay Bio Tech, 
cat# A7045, A7046) were bought from Assay Biotechnology Company Inc (Sunnyvale, CA).  
Chemicals including MEK1/2 specific inhibitor U0126 and its negative control U0124, Src 
selective inhibitor PP2 and its negative control PP3, p38 MAPK specific inhibitor SB202190 
and its negative control SB202474, PI3K specific inhibitor LY294002 and its negative 
control LY303511, SP600125, specific inhibitor of JNK and its negative control were 
purchased from Calbiochem (EMD Chemicals Inc., San Diego, CA, USA).  Plasmids p3TP-
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lux (Wrana, Attisano et al. 1992) (plasmid # 11767), CMV-Fast-1 wild-type (Zhou, Zawel et 
al. 1998) ( plasmid # 16521) and SBE4-Luc (Zawel, Dai et al. 1998) (plasmid # 16495) were 
purchased from Addgene, Inc.  (Cambridge, MA).  Vector pRL-SV40 was purchased from 
Promega (Madison, WI).  PAI-1 antiserum (α-Sp46) was a kind gift from JG Rheinwald 
(Rheinwald, Jorgensen et al. 1987).  Curcumin was got from Enzo® Life Science (Plymouth 
Meeting, PA, Cat# ALX-350-028).  The plasmid encoding ΔFosB and the equivalent empty 
vector control were a kind gift of Y Nakabeppu (Nakabeppu and Nathans 1991).  
Cell Culture.  The mink lung epithelial cell line, Mv1Lu (ATCC, CCL64, Manassas, VA), 
was obtained from Dr.  Robert W Holley.  The cells were maintained as monolayer cultures 
in Dulbecco-Vogt's medium (DMEM) containing 0.45 % glucose, 10 % calf serum, 10 
units/ml penicillin and 10 g/ml streptomycin at 37 EC, in a water saturated atmosphere with 
10 % CO2 in air.  MLEC cells clone 32 (Mv1Lu cells stably transfected with a plasmid 
containing the human PAI-1 luciferase reporter (van Zonneveld, Curriden et al. 1988)) were 
a gift from Daniel B Rifkin (New York University, NY).  Human hepatocellular carcinoma 
HepG2 cells (ATCC, HB-8065) were maintained in Eagle’s minimal essential medium 
(MEME, Sigma) supplemented with 10 % fetal calf serum, 1 %  non-essential amino acids 
(Irvine Scientific, Santa Ana, CA), 10 µM sodium pyruvate (Gibco, Carlsbad, CA), 10 
units/ml penicillin and 10 µg/ml streptomycin at 37 ˚C in a water-saturated atmosphere with 
5 % CO2 in air.  All cell lines were confirmed to be mycoplasma negative by regular testing 
by PCR analysis.   
For experiments, cells were seeded and cultured as above until confluent.  The medium 
was then changed to Dulbecco-Vogt's modified Eagle’s medium (DMEM) or minimal 
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essential medium (MEME) with or without 0.2 % calf serum for 24 h prior to addition of 
growth factors and other treatments.  The concentrations of growth factors were 1 ng/ml EGF 
and 5 ng/ml TGF-β unless otherwise stated.  For testing inhibitors, cells were pretreated with 
specific kinase inhibitors or their structural inactive analogs at indicated concentration for 1 h 
and then incubated with EGF and TGF-β, alone or in combination for 2 h   
Measurement of protein production by metabolic labeling.  The rate of PAI-1 protein 
production was measured using metabolic labeling as previously described (Thalacker and 
Nilsen-Hamilton 1987).  Confluent Mv1Lu cells was first treated with EGF and TGF-β for 2 
h respectively, 35S-methionine was added to the conditioned medium to label newly 
synthesized protein.  After 4 h, the medium from mink cells was collected and the amount of 
radiolabeled PAI-1 protein was determined by SDS-PAGE followed with autoradiography.  
After 8 h exposure to growth factors, 35S-Trans-label was added to HepG2 cells to label 
newly synthesized protein.  The amount of human PAI-1 protein was detected after 
immunoprecipitation by using PAI-1 antiserum (α-Sp46), followed by SDS-PAGE and 
autoradiography.   
 Northern blots.  A 1.5 kb mink PAI-1 cDNA fragment corresponding to bases 150-1691 
was generated by digesting mink PAI-1 cDNA with Sma I (Chuang, Hamilton et al. 1995).  
The fragment was resolved by agarose gel electrophoresis and isolated by glass bead affinity 
adsorption (Geneclean, Qbiogene Inc., Carlsbad, CA).  The isolated cDNA fragment was 
radiolabeled with α32P-dCTP to a specific radioactivity of about 1 x 109 cpm/μg using 
random primer extension.  For Northern blots, the cells were washed twice with Tris-
buffered salts (0.14 M NaCl, 5 mM KCl, 0.68 mM CaCl2, 0.49 mM MgCl2, 0.70 mM  
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Na2HPO4, 25 mM Tris⋅HCl, pH 7.1) and lysed with 4 M guanidinium isothiocyanate, 
25 mM sodium acetate, pH 6.  The total RNA was separated from the cell lysate by isopycnic 
centrifugation in 5.7 M cesium chloride, 25 mM sodium acetate (Chirgwin, Przybyla et al. 
1979).  After several rinses with 70 % ethanol to remove the cesium chloride, the RNA was 
resuspended in 0.3 M sodium acetate, pH 6, and preserved at -75 EC.  The RNA was resolved 
by electrophoresis through 1 % agarose-formaldehyde gels using 1 mM EDTA, 5 mM 
sodium acetate, 20 mM MOPS (3-[N-morpholino] propanesulfonic acid), pH 6 as running 
buffer.  The RNA was transferred to nylon membranes in 50 mM sodium hydroxide.  The 
RNA on the blots was hybridized with radiolabeled mink PAI-1 probe for 18 h at 47 EC in 
hybridization buffer (40 % formamide, 7 % SDS, 1 % polyethylene glycol MW=20000, 0.25 % 
non-fat milk, 0.6 M NaCl, 4 mM EDTA, 50 μg/ml salmon sperm DNA, 40 mM NaH2PO4, 
pH 7.5).  The blots were washed in a solution of 30 mM NaCl, 0.2 % SDS, 3 mM sodium 
citrate, pH 7 twice for 15 min at 47 EC then exposed to Kodak XAR film at -75 EC with two 
intensifying screens.  To control for loading of the RNA, the blots were stripped in 0.1 % 
SDS, 10 mM NaCl, 1.5 mM sodium citrate, at 80 EC for 30 min twice and rehybridized with 
radiolabeled 18 S ribosomal RNA probe (Fuke, Dennis et al. 1981).   
Reverse Transcription-Quantitative PCR.  Total RNA was extracted with Trizol.  RNA 
was first treated with 0.1 U/l DNase I for 15 min at 24 EC and transcribed by Superscript II 
reverse transcriptase.  The samples for qPCR were prepared in a 20 l volume containing 
10 mM KCI, 20 mM Tris-HCI, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1 % Triton X-100 (pH 
8.8 at 25°C), 0.2 mM dNTP, 50 U/ml Taq DNA polymerase (New England Biolabs Inc., 
Ipswich, MA), 0.7 x SYBR® Green I (Molecular Probes Inc., Eugene,OR), the appropriate 
primers at 0.1 M each and cDNA templates as defined by the experiment and the RNA 
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sequence to be quantified.  The qPCR was performed in an Opticon real-time PCR detector 
(MJ Research, Inc., Waltham, MA, model CFD-0200) with a  95 ˚C premelt  for 5 min 
followed by 40 cycles of 95 ˚C 15 sec, 60 ˚C 15 sec, 72 ˚C 15 sec and including a final 
determination of melting curves from 65 ˚C to 90 ˚C.  The amount of each mRNA was 
quantified by using a standard curve created in the same qPCR run using a series of known 
dilutions of the amplified fragments.  Values that were outside the range of the standards 
were not included and the affected samples were reanalyzed at dilutions to ensure that the 
values were within the range of the standard curve.  A mixture of samples was also evaluated 
at a series of dilutions and the standard cure thus obtained was found to be parallel with the 
standard curve created by amplified fragments, thus confirming the lack of PCR inhibitors in 
the range of concentrations of the sample preparations used in this study.  The relative PAI-1 
mRNA levels were calculated by normalizing the value for PAI-1 mRNA to the result for the 
amount of reference mRNA, which was either GAPDH or cyclophilin A that had been 
quantified in the same sample.  The primers for mink cDNAs were: PAI-1: TCGCCACCGT-
CAGCAGCA and TGTGGCCAGTTCCGCTGC;  GAPDH: CCCACCCCCAATGTGTC-
TGT  and AATGCCAGCCCCAGCATCGAAG; uPAR: AAGACCAACAGGWCCMTGAG 
and TSCCRGCCCCTCTCACAGC; COX2: ATTAGCTCCCTT GTTCTC and 
AGGTCTTCGTAGTCTGTG.  Primers for human cDNAs were: PAI-1: GAC-
AACAGGAGGAGAAACCC and AGATCCCGCTGGACGAAG; uPA: TGTGAGATCAC-
TGGCTTTG and TTGGAGGGAACAGACGAG; uPAR: GACCCTGAGCTATCGGACT 
and GATGAGCCACAGGAAATG; Cyclophin A: GGCAAAGTGAAAGAAGGC and GA-
TACTGCGAGCAAATGG;  Primers for mouse cDNAs were: PAI-1: 
ACAGTGGCGTCTTCCTCC and ATAACATCTCCAGTTTCGTCC; uPA: TAGACCA-
ACAAGGCTTCC and TTGGGAGTTGAATGAAGC; uPAR: CACAGCAGGTTTCCATA-
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GC  and GGTTTCCCAGCACATCTAA; GAPDH: TCGTCCCGTAGACAAAAT and GCT-
CCTGGAAGATGGTGAT. 
Nuclear run-on assay Nuclear run-on was performed using a biotin-labeled uridyl 
precursor followed by RT-qPCR detection (Patrone, Puppo et al. 2000).  Briefly, after growth 
factor treatment, confluent mink lung Mv1Lu cells were collected by scraping into cold PBS 
(137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 2 mM K2PO4, pH 7.4) and the nuclei were 
isolated by resuspending the cells in NP-40 lysis buffer (10 mM HEPES, pH 7.3, 10 mM 
NaCl, 3 mM MgCl2, 150 mM sucrose 0.5 % Nonidet P40) and disrupting the cells with a 
Dounce homogenizer.  The nuclei were pelleted by centrifugation (4 ˚C, 170 x g for 10 min) 
and washed with lysis buffer lacking NP40.  The supernatant was removed and the nuclear 
pellet was resuspended in 50 µl storage buffer (5 mM MgCl2, 0.1 mM EDTA, 40 % glycerol, 
50 mM Tris HCl, pH 8.3) and stored frozen at -80 ˚C until use.  Nuclear transcription was 
performed by incubating the nuclei in reaction buffer (10 mM Tris-HCl (pH 8.0), 100 mM 
KCl, 2.5 mM MgCl2, 2 mM DTT, 2 mM ATP, 2 mM CTP, 2 mM GTP, 0.67 UTP, 0.33 mM 
Biotin-16-UTP, 100 mM sucrose, 10 % glycerol) at  30 ˚C for 30 min.  Total RNA was 
extracted with Trizol and newly transcribed RNA, labeled with biotin-16-UTP, was isolated 
by incubating the RNA with Dynabeads M-270 in binding buffer (5 mM Tris-HCl (pH 7.5), 
0.5 mM EDTA, 1 M NaCl) at 42 ˚C for 20 min and then room temperature for 30 min.  The 
biotinylated RNA coated streptavidin beads were concentrated by a 3 min exposure to a 
magnet then washed twice with buffer containing 15 % formamide and 2 x SSC (300 mM 
NaCl, 30 mM sodium citrate, pH 7.0) for 15 min and once for 5 min in 1 ml of 2 x SSC.  
Beads containing newly synthesized RNA were suspended in 30 l DEPC-treated water.  
Reverse transcription and qPCR were performed as previously described.   
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mRNA half-life.  Mv1Lu cells were treated with 5 ng/ml EGF and 1 ng/ml TGF-β, either 
alone or in combination for 2 h then 15 g/ml cordecypin was added and the cells incubated 
for the identified time periods before collection and extraction of total RNA for analysis by 
qRT-PCR.  At least five independent experiments were performed for each treatment.   
Transcription rate.  Metabolic labeling of newly transcribed RNA was performed as 
previously described (Dolken, Ruzsics et al. 2008) with modifications.  Fifteen minutes 
before the end of the treatment period, 500 M 4-thiouridine was added to the culture 
medium.  The reaction was stopped 15 min later and total cellular RNA was isolated using 
Trizol reagent.  Newly transcribed RNA was biotinylated by incubation with 0.2 mg/mL 
biotin-HPDP in 10 mM Tris (pH 7.4), 1 mM EDTA for 1.5 h at room temperature.  The RNA 
was extracted with chloroform/isoamylalcohol (24:1), precipitated with isopropanol, washed 
with 75 % ethanol and the biotinylated RNA was isolated using streptavidin coated beads, 
M270.  Specific mRNAs were quantified by RT-qPCR. 
Western blot.  Confluent and quiescent Mv1Lu cells were treated with 1 ng/ml EGF, 5 
ng/ml TGF-β or the combination of both growth factors at the same concentration.  Cells 
were treated with growth factors for 10 minutes to check Erk1/2 phosphorylation and 45 
minutes to check Smad2 phosphorylation.  After wash cells twice in ice-cold PBS, cells were 
lysed in 100 μl RIPA buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 % NP-40, 0.5 % 
sodium deoxycholate, 0.1 % SDS, 2 mM EDTA, 1 mM PMSF, 10 µM leupeptin) and 
centrifuged at 10,000 x g at 4 °C for 10 min.  Ten μl of protein sample in 62.5 mM Tris-HCl 
(pH 6.8), 10 % mercaptoethanol, 2 % SDS, 10 % Glycerol, 0.005 % bromphenol blue was 
heated at 95 °C for 5 min.  Electrophoresis was performed under 100 volts for 1.5 h through 
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a 4 % stacking gel and 10 % resolving polyacrylamide gel in a Tris-glycine buffer system 
(Thalacker and Nilsen-Hamilton 1987).  Protein was transferred to a nitrocellulose membrane 
using a TE 22 mighty small transphor electrophoresis unit (Phamacia) in the presence of 25 
mM Tris base, 0.2 M glycine, 20 % methanol (pH 8.5).  The membrane was blocked for 1 h 
in buffer containing TBS (Tris buffered saline, 2.42 g/L Tris base, 8 g/L NaCl, Ph 7.6), 0.1% 
Tween-20 with 5% w/v nonfat dry milk) and then incubated overnight in TBS, 0.1 % Tween-
20 with 5% w/v nonfat dry milk with primary antibody at the indicated dilutions (1:2000 for 
rabbit phospho-p44/42 monoclonal antibody, 1:1000 for phophore Smad2 polyclonal 
antibody, 1:1000 for monoclonal antibody against acetylated lysine and 1:1000 for β-actin  
monoclonal antibody).  After washing the membrane twice with buffer containing TBS and 
0.1 % Tween-20 for 10 min each time, the membrane was incubated with secondary antibody 
diluted by 2000 fold in TBS and 0.1 % Tween-20 at 24 °C for 2 h.  Following two washes in 
TBS, 0.1 % Tween-20 for 10 min each, the membrane was incubated with 2 mL of 1:1 
Enhanced Luminol Reagent:Oxidizing Reagent (Western lightning chemiluminescence 
reagent plus, PerkinElmer Life Sciences, Waltham, MA) for 1 min and then exposed to 
autoradiography film. 
Transfection.  Mv1Lu cells were seeded one day before transfection.  Cells were 
transfected with 1.6 ng/ml plasmids in DMEG medium in the presence of 0.4 % 
lipofectamine 2000 (Invitrogen).  After 20 h of transfection, the cells were treated with 1 
ng/ml EGF, 5 ng/ml TGF-β or their combination and incubated for the indicated time period.  
Samples were collected and analyzed by the luciferase assay or RT-qPCR. 
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Luciferase assay.  After 6 h stimulation with growth factor, Mv1Lu cells were washed 
twice in cold PBS then lysed in passive lysis buffer (PLB).  The cell lysates were stored at -
20 °C.  Both firefly and renilla luciferase activities were measured in a Glomax 20/20 
Luminometer (Promega) using the Promega Dual-Glo protocol.  The relative reporter activity 
for each treatment was calculated as the ratio of firefly to renilla luciferase activities. 
Statistical analysis.  Data from multiple experiments are summarized and represented as 
the mean ± standard error of the mean.  The data was analyzed by the linear model of 
ANOVA and multiple comparisons were performed according to the least square means 
Student’s t test.  The effects of treatments on the PAI-1 mRNA half-life were assessed by 
linear regression analysis and analysis of covariance (ANCOVA).  All statistical test were 
performed using the software JMP7.0 (SAS Institute Inc, Cary, NC) unless otherwise stated.  
Significant differences between samples are indicated as: * p<0.05, **: p<0.01 and ***: 
p<0.001. 
Results 
Synergism between EGF and TGF-β in regulating PAI-1 mRNA and protein level.  EGF 
and TGF cooperate to stimulate PAI-1 protein production in mink lung Mv1Lu cells and 
human liver HepG2 cells.  Analysis by metabolic labeling, alone for Mv1Lu cells (Thalacker, 
1987 ) or followed by immuno-precipitation in HepG2 cells, showed the increase in PAI-1 
protein level is synergistic (Fig. 1A).  Analysis by northern blot and RT-qPCR showed that 
the synergistic increase in PAI-1 gene expression occurs at the mRNA level (Fig. 1B).  
Synergism is defined as when the increase due to the combination of treatments is more than 
expected from the sum of the increases due to either treatment alone.   
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Synergism in PAI-1 expression was observed in both human and mink cell lines (Fig. 1).  
Unlike the large changes in gene expression observed for PAI-1, much smaller changes in 
mRNA levels were observed for urokinase (uPA) and urokinase plasminogen activator 
receptor (uPAR) in response to EGF and there was no effect of TGF-β (Fig. 1B).  A small, 
but not significant, synergistic increase was observed in urokinase plasminogen activator 
receptor (uPAR) expression (Fig. 1B).  Cyclooxygenase (COX2) mRNA was not altered by 
EGF, TGF-β, or their combination.  Thus, the synergism between EGF and TGF-β is gene 
specific but not species specific.   
Synergism occurs with both growth factors at saturating concentrations.  If EGF and 
TGF-β utilize the same mechanism to increase PAI-1 gene expression they should only 
behave synergistically at concentrations below saturation.  To test this hypothesis, we titrated 
the concentration of each growth factor to reach saturation in the presence of a constant 
saturating concentration of the other (Fig.  2).  The results clearly show that neither growth 
factor can substitute for the other in raising the level of PAI-1 mRNA to the level observed 
with both together, which is about an order of magnitude beyond that achieved with either 
growth factor alone.  Thus, the mechanism by which PAI-1 gene expression is regulated in 
cells treated with a combination of EGF and TGF likely involves cooperation occurring at 
some level of signaling downstream from each growth factor.   
TGF increases the sensitivity of cells to EGF but not vice versa.  Analysis of the EC50s 
of the concentration dependencies of the responses of PAI-1 mRNA levels to EGF and TGF 
also revealed that TGF increases the sensitivity of the cells to EGF by an order of 
magnitude but the presence of EGF did not change the EC50 for TGF responsiveness (Table 
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I).  Thus, TGF helps to recruit low concentrations of EGF that would not alone be high 
enough to have an effect to cooperate in increasing PAI-1 expression.  This result could 
explain synergism at concentrations below saturating levels of the two growth factors, but 
does not explain synergism between saturating levels of EGF and TGF-β. 
The synergism with TGF-β is downstream from tyrosine kinases and PKC.  To test the 
hypothesis that a pathway common to tyrosine kinase receptors is responsible for the EGF 
contribution to the synergism with TGF-β, we examined the effect on PAI-1 expression of 
other ligands of tyrosine kinase receptor (fibroblast growth factor 2, FGF-2, and Insulin-like 
growth factor 1, IGF-1) and that activate soluble tyrosine kinases (tumor necrosis factor 
alpha, TNF-α) in combination with TGF-β.  While the PAI-1 mRNA level was not 
significantly induced after treatment by IGF-1, FGF-2 or TNF-α alone, it was dramatically 
increased when the cells were treated with one of these stimuli and TGF-β (Fig. 3A).  In all 
cases, the combined treatment produced a significantly higher PAI-1 mRNA level than TGF-
β treatment alone.  EGF and TGF-β exhibited the highest synergism, which elevated PAI-1 
mRNA level about 4-fold over the simple additive effects expected from each growth factor 
acting independently.  Although the extent of synergism varied with the growth factor or 
cytokine, TGF-β acted synergistically with all tyrosine kinase activators to induce PAI-1 
mRNA.   
However, the synergistic event is not uniquely downstream of tyrosine kinases because 
PMA, a PKC agonist, also acts synergistically with TGF-β on PAI-1 protein as demonstrated 
in Mv1Lu cells (Fig. 3B) and MSV-transformed Mv1Lu cells (data not shown).  This effect 
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was specific for PAI-1 as demonstrated by the lack of effect of PMA on the production of 
other secreted proteins including a TGF--induced 73kDa protein (Fig 3B, C).  
The MAPK pathway is required for synergism.  The involvement of RTK receptors and 
PKC identified a subset of signal transduction pathways that might be involved in the 
synergistic mechanism.  To identify the likely pathway(s), a series of kinase inhibitors and 
their inactive control analogs were tested (Fig. 4, table II).  Although several inhibitors 
decreased the overall responses to EGF and TGF-β, only inhibition of the p38 MAPK and the 
MEK1/2 reduced synergism, with the largest effect being produced by the MEK1/2 inhibitor, 
U0126 (Fig.  4A).  The phosphorylation of ERK1/2, a major target of MEK, increased within 
10 min after adding EGF but was not altered by the addition of TGF-β (Fig. 4F).  These 
results showed that the synergism is a downstream event of MAPK pathway and further 
downstream than MEK. 
EGF stabilizes PAI-1 mRNA.  We evaluated if enhanced mRNA stability might be the 
post-transcriptional step responsible for the period of persistently elevated PAI-1 mRNA 
level in response to the combination of EGF and TGF-β.  Although the basal level of PAI-1 
mRNA was too low to obtain sufficient quantitative values for a decay curve, we were able 
to determine the mRNA decay rates in cells treated with each growth factor alone and in 
combination (Fig. 5).  The PAI-1 mRNA half-life was determined as 37 min in TGF-β-
treated cells, 52 min in EGF-treated cells and 56 min in cells treated with EGF and TGF-β.  
A statistical analysis of the data verified that the PAI-1 mRNA half-life in cells treated with 
the combination of EGF and TGF-β was significantly different from that in cells treated with 
TGF-β alone (p< 0.05) but not from that in cells treated with EGF.  Thus, by stabilizing PAI-
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1 mRNA, EGF contributes to the magnitude of the increase in expression of PAI-1 mRNA in 
combined treatment with TGF-β and it increases the amount of time during which the 
increased PAI-1 mRNA levels exist.  Transcription of the PAI-1 gene is synergistically 
induced by TGF-β and EGF.  To determine if EGF and TGF-β cooperate to increase the rate 
of initiation of PAI-1 transcription, we performed nuclear run-on experiments and found a 
synergistic effect of about 2-fold for newly transcribed PAI-1 mRNA (Fig. 6A, B).   
A trivial explanation for the observation of synergism is that, rather than increasing the 
maximum level of gene expression, the combination of the two growth factors changes the 
time course of expression to move the peak expression level closer to the monitored time 
point.  To test this question we performed a time course study where it was seen that the PAI-
1 transcription and mRNA level was increased within 1 h of the addition of EGF and TGF-β 
and peaked at 1.5 and  2 h, respectively (Figs.  6C, D).  Synergism was observed throughout 
the induction period.  These results demonstrate that the response of PAI-1 gene expression 
is rapid and that synergism between EGF and TGF does not result from a change in the 
relative time courses of the responses but the response to EGF and TGF was characterized 
by persistently elevated PAI-1 expression compared with cells treated with either growth 
factor alone (Fig. 6D). 
The mechanism of synergism between EGF and TGF-β does not intersect with the Smad 
pathway. Crosstalk has been reported between the MAPK and Smad pathways (Verrecchia, 
2001; Zhang, 1998 ). To determine if this type of interaction is the basis for the cooperation 
between EGF and TGF-, we examined the phosphorylation of Smad 2/3 using an antibody 
that recognizes the phosphorylated c-terminal SS (V/M)S motif and found no synergism in 
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Smad phosphorylation (Fig.  7A).  The  Smads were phosphorylated only in response to 
TGF-β.   
To determine if Smad activity in the nucleus is synergistically increased by mechanisms 
other than phosphorylation, such as increased rate of nuclear entry or decreased rate of 
degradation of activated Smads, we utilized the plasmid pSBE4, which contains four Smad 
binding elements (SBE) that are specifically recognized by activated Smad3/4 (Zawel, Dai et 
al. 1998).  We also tested the possibility that synergism occurs by promoting the interaction 
of Smad2/4 with forkhead activin signal transducer -1 (FAST-1) transcription factor using 
the plasmid p3ARE that contains the activin responsive element, (Labbe, Silvestri et al. 
1998).  TGF- treatment activated Smad3/4 activity (pSBE4) but had little or no effect on 
Smad2/4 activity (p3ARE), whereas EGF inhibited basal Smad3/4 activity by 50 %, TGF--
stimulated Smad3/4 activity by 20% and basal and TGF- β-stimulated Smad2/3 activity by 
65 % (Fig 7B,C).  These results support the conclusion that synergism between EGF and 
TGF-β does not involve increasing the nuclear activities of the Smads. 
Synergism between EGF and TGF-β involves an interaction between AP-1 and Smads.  
Because the Smads have been reported to interact cooperatively with AP-1, we tested the 
hypothesis that the point of synergism between TGF- and EGF is at the interaction between 
AP-1 and Smad.   In these experiments EGF and TGF- were found to synergistically 
increase expression from the plasmid p3TP, which contains three AP-1 recognition sites from 
the enhancer of collagenase and the Smad binding elements from the distal region of the 
PAI-1 promoter (Fig. 8A).  There was a 3-fold synergism on the transcriptional activity 
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observed with p3TP plasmid, which is similar to that observed in endogenous PAI-1 
transcription.   
To confirm the involvement of AP-1 in the synergism between EGF and TGF-β, we 
tested two AP-1 antagonists, curcumin and dominant negative Fos (ΔFosB).  Both 
antagonists significantly reduced PAI-1 synthesis in response to the combination of EGF and 
TGF-β but had little effect on the induction of PAI-1 in response to EGF or TGF-β alone (Fig. 
8B,C).  Consequently the synergism between EGF and TGF-β was significantly reduced in 
the presence of either inhibitor.  By contrast, curcumin had no effect on transcriptional 
activation of the pSBE4 promoter that contains only Smad binding elements (Fig. 8D).  The 
same effect of AP-1 suppression was found for the synergistic induction of PAI-1 mRNA 
demonstrating that the same mechanism as is seen in the reporter constructs is likely to be 
occurring on the endogenous PAI-1 promoter (Fig.  8F).  AP-1 is a heterodimer of Fos and 
Jun family proteins and phosphorylation of these proteins great increased their transcriptional 
activities.  The phosphorylation of Fos and Jun was checked by western blot against 
phosphorylated Fos and Jun protein.  Results showed that both proteins were phosphorylated 
in all cases and there was no synergism at the phosphorylation of these protein (Fig. 8E). 
AP-1 is specifically required for PAI-1 induced by EGF and TGF-β.  So far we know 
MAPK and AP-1 were required for the synergism.  By studies with inhibitors and trans 
negative regulators, we found that EGF-induced PAI-1 expression required the activities of 
MEK, P38 MAPK and JNK (Fig. 4A, C, E).  Suppression of MEK produced significant 
reduction of PAI-1, with a decrease of 75% of induction by EGF.  The antagonists of JNK 
and PI3K also reduced EGF-induced PAI-1 to variable extents.  Blocking the activity of JNK 
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by inhibitor or the dominant negative construct inhibited about 30 - 80 % of PAI-1 mRNA 
production.  Inhibition of PI3K activity reduced 23% of PAI-1 induction by EGF.  The 
weakest modulators are p38 MAPK and Fos which only moderately attenuated about 14% 
PAI-1 induction by EGF as compared to the control.  Src is not involved in PAI-1 regulation 
by EGF because inhibition of Src activity did not altered PAI-1 induction.  These results 
indicated that MEK, JNK and PI3K play important roles in EGF-induced PAI-1 expression.  
In the meanwhile we found out that TGF-β-induced PAI-1 expression requires MEK, p38 
MAPK and src mediated signaling (Fig. 4A, C & D).  TGF-β-induced PAI-1 level was 
significantly decreased when the signaling mediated by MEK, p38 MAPK or src were 
blocked.  Suppression of MEK reduced about 70 % of PAI-1 induction by TGF-β.  The level 
of PAI-1 induced by TGF-β was decreased 50 % after inhibition of p38 MAPK activity and 
37 % after blocking the activity of src.  Blocking JNK activity, either by inhibitor or by the 
trans-negative regulator increased TGF-β-induced PAI-1 level.  Results suggest TGF-β 
induces the expression of PAI-1 through MEK, p38 MAPK and src mediated signaling, and 
JNK activity negatively affects this regulation.  The regulation of PAI-1 by the combination 
of EGF and TGF-β requires the activity of MEK, p38 MAPK and AP-1 (Fig. 4A, 4C, 8F).  
The PAI-1 mRNA level induced by the combination of EGF and TGF-β was significantly 
reduced when the activity of MEK was blocked.  p38 MAPK is also involved in the 
regulation of PAI-1 by the combination because suppression the activity of p38 MAPK by 
small chemical inhibitor significantly reduced PAI-1 mRNA level by 64%.  However, only 
the activity of AP-1 was required for the synergistic induction of PAI-1 by the combination 
of EGF and TGF-β.  Significant reduction in PAI-1 synthesis by the cotreatment and in the 
synergism was observed when AP-1 activity was blocked (p<0.05).  These results indicate 
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that AP-1 might be the rapidly turning-over protein involved in the synergistic regulation of 
PAI-1. 
Synergism is not at the translational level but a rapidly turning over protein is implicated.  
To test if new translation were required for synergism, cells were treated with cycloheximide 
prior to growth factor treatment.  Blocking protein synthesis decreased PAI-1 induction by 
EGF, TGF-β or the combination by about the same extent (~40%) and theresynergism was 
significantly decreased (83% of the control, Fig. 9A, B).   
Protein synthesis was blocked for various time periods with cyclocheximide according to 
the scheme in Fig. 9C, which showed that synergism is completely inhibited after longer 
incubations with cycloheximide.  The apparent delay in the loss of the synergistic response 
compared with the responses to the individual growth factors was further investigated by 
calculating the rate of decay of the PAI-1 response as a function of growth factor treatment.  
The decay curves showed a rapid exponential decay of the response in cells treated with EGF 
and TGF- that can be described by a single half-life.  However, the decay curves in cells 
treated only with EGF or TGF- were not well fit to a single exponential decay (Fig. 9D).   
These latter data sets were fit with the assumption that they could be described by two 
exponential decay constants, the first being the decay constant determined from the cells 
treated with the combination of EGF and TGF- and the second derived by calculation.  
These results suggested that a rapidly turning over protein is involved in PAI-1 regulation 
that is weakly activated by each growth factor separately, but in the presence of both growth 
factors the action of this rapidly turning over protein dominates.   
92 
 
 
Discussion 
Under normal physiological conditions, PAI-1 expression levels are very low.  However 
upon stimulation, PAI-1 levels are rapidly increased as an early expressed gene.  For example, 
the induction of PAI-1 in quiescent cells by EGF and TGF-β is in an immediate early pattern 
(Nilsen-Hamilton and Holley 1983; Thalacker and Nilsen-Hamilton 1987; Ryan, Kutz et al. 
1996; Kutz, Hordines et al. 2001).   
EGF and TGF-β act synergistically to activate several important cellular processes 
including colony formation in soft agar (Roberts, Anzano et al. 1985), the epithelial-to 
mesenchymal transition (EMT) (Okada, Danoff et al. 1997) and cell movement during tissue 
remodeling (Stolz and Michalopoulos 1997).  Specific gene targets have been identified that 
are regulated synergistically including genes encoding the EGF receptor, several matrix 
metalloproteinases, including MMP-10, fibronectin,  β and γ actin (Fernandez-Pol, Hamilton 
et al. 1989; Ranganathan and Getz 1990; Freytag, Wilkins-Port et al. 2009).  As well as at the 
level of transcription, synergism between EGF and TGF-β was reported at the level of RNA 
turnover for Leukemia-inhibitory factor (LIF), a conclusion based on an observed increase in 
LIF mRNA with no regulation of transcription (Schluns, Cook et al. 1997).  The COX2 
protein was found synergistically induced by EGF and TGF-β in Mv1Lu cells (Saha, Datta et 
al. 1999).  But, because we observed no synergism in the regulation of cox2 mRNA, COX2 
expression may be regulated at a post-transcriptional event such as translation.   
Our results, reported here and previously, show that EGF and TGF- synergistically 
increase PAI-1 protein (Thalacker and Nilsen-Hamilton 1987) and mRNA expression by an 
order of magnitude over the effect of either growth factor alone and by almost two orders of 
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magnitude over that of untreated cells.  Here we show that this cooperation in signaling is 
due to a combination of changes in the cell that include 1) a synergistic increase in 
transcription that involves AP-1 and Smad, 2) stabilization of PAI-1 mRNA level by EGF, 3) 
sensitization of EGF signaling by TGF-, and 4) a rapidly turning over protein that is 
uniquely involved in the synergistic response.   
Compared with the expected increase due to the sum of responses due to treatment with 
EGF or TGF-β alone, the combination of the two growth factors resulted in about four times 
the expected level of PAI-1 mRNA.  Nuclear run on assays showed that this increase results 
in part from a synergistic increase in transcriptional activity of the PAI-1 gene giving a two-
fold increase above the expected sum of effects of the two growth factors.  The large increase 
in PAI-1 expression due to transcription is further amplified by stabilization of PAI-1 mRNA 
by EGF.  The PAI-1 mRNA half-life has been estimated in a variety of cells to be 25 min in 
Mv1Lu cells (Chuang, Hamilton et al. 1995), 1-2 h in normal human lung cells (Shetty and 
Idell 2000), 8-12 h in a variety of lung cancer cell lines (Shetty and Idell 2000), and 4 h in rat 
hepatoma cells (Heaton, Tillmann-Bogush et al. 1998).  This variation in reported half-life 
might be a consequence of the fact that PAI-1 mRNA stability is regulated by a number of 
conditions, including growth factors that might regulate PAI-1 mRNA turnover in an 
autocrine fashion (Fattal, Schneider et al. 1992; Sandberg, Eriksson et al. 1997; Heaton, 
Tillmann-Bogush et al. 1998; Nordt, Lutzi et al. 2001; Devaraj, Xu et al. 2003; Norata, Banfi 
et al. 2004).  However, it may also be the result of the means of measuring PAI-1 mRNA 
stability because it is stabilized by the presence of actinomycin D, which was used in many 
of these studies to inhibit transcription (Bosma and Kooistra 1991; Chuang, Hamilton et al. 
1995).   Contrary to the observation with transcription, EGF and TGF do not cooperate to 
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regulate PAI-1 mRNA stability.  This effect is entirely due to EGF, which has been reported 
to stabilize many mRNAs, including those encoding β–tubulin, the EGF receptor, p21/CIP1, 
cyclin D1, TGFα, amphiregulin (AR), IL-1α, IL-1β and IL-6 LIF, TGF-βRII and gastrin 
(Jinno, Merlino et al. 1988; Le, Lazorick et al. 1991; Schluns, Cook et al. 1997; Johannessen, 
Knardal et al. 1999; Stoll and Elder 1999; Dufourny, van Teeffelen et al. 2000; Watanabe, 
Kurabayashi et al. 2001; Song, Song et al. 2006; Lee, Liao et al. 2007).   
Because PAI-1 mRNA is rapidly degraded, the regulation of its half-life can have a large 
impact on PAI-1 expression (Shapiro, Blume et al. 1987).  The combination of a small 
increase in PAI-1 expression in response to EGF alone and the sole effect of EGF on PAI-1 
mRNA turnover results in a significant impact of RNA turnover to the synergistic response to 
the combination of TGF- and EGF.  The observed 2-fold synergism in transcriptional 
activity of the PAI-1 gene combined with the 2-fold increase in stability of PAI-1 mRNA due 
to EGF calculates to about a 4-fold synergism between EGF and TGF-β.  Therefore, we 
conclude that the cooperative regulation by TGF-β and EGF of PAI-1 expression is 
accomplished by a combination of synergism between TGF-β and EGF in activating 
transcription and stabilization of PAI-1 mRNA by EGF.   
Both Mv1Lu and HepG2 cells are epithelial cell types.  By contrast, we have not 
observed synergism between EGF and TGF- in PAI-1 expression in NRK and AKR-2B 
cells, both fibroblast cell types (data not shown).  This observation may be relevant because 
PAI-1 plays an important role in the epithelial to mesenchymal transition (EMT) by 
modulating cell motility and facilitating conversion to an invasive phenotype, perhaps by 
modifying the cells’ environment (Wilkins-Port, Higgins et al. 2007; Freytag, Wilkins-Port et 
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al.).  PAI-1 and MMPs are synergistically induced by EGF and TGF-β during EMT and, as 
for the studies described here, MAPK signaling is required for the response and could be the 
point of interaction of EGF and TGF- (Grande, Franzen et al. 2002; Uttamsingh, Bao et al. 
2008; Wilkins-Port, Ye et al. 2009).   
By activating Mek1 EGF initiates the phosphorylation of Smad2 at its C-terminus to 
activate Smad–mediated transcription (de Caestecker, Parks et al. 1998).  We showed that 
inhibition of Mek1/2 results in loss of the synergistic effect on PAI-1 regulation of EGF and 
TGF-β, which suggests the MAPK pathway contributes to the synergistic regulation.  
Consistent with this conclusion is our observation that other agents that stimulate the MAPK 
pathway, including IGF-I (Schmidmaier, Wildemann et al.  2003), FGF-2 (Stern, Lin-Jones 
et al.1997), TNFα (Schulz and Bauer 2000) and PMA (Hewson, Edbrooke et al. 2004), also 
stimulated PAI-1 expression synergistically with TGF-β.  However, Erk1/2, the major target 
of Mek phosphorylation was not synergistically phosphorylated.  This suggests that Mek is 
required for the synergism to occur, but is not downstream from the synergistic event. 
TGF-β increases the sensitivity to EGF of the PAI-1 response such that a 10-fold lower 
EGF concentration produces half maximal PAI-1 induction in the presence of TGF-β 
compared with in its absence.  By contrast, EGF did not affect the sensitivity of the cells to 
TGF-β.  The increase in sensitivity to EGF may allow cells to utilize the synergistic 
mechanism that produce small quantities of EGF or that are in an environment containing 
low concentrations of EGF.  This effect of TGF-β is most likely not mediated by a change in 
the affinity of the EGF receptor for its ligand, which has been reported not to be influenced 
by TGF-β in Mv1Lu cells (Ranganathan and Getz 1990).  Although the increased sensitivity 
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to EGF does not contribute to the synergism between EGF and TGF-β on PAI-1 expression, 
its outcome is to make it more likely for cells to respond to EGF in their environment.  Thus, 
when TGF-β activates PAI-1 expression in the absence of concurrently added EGF, it might 
still act synergistically with low levels of EGF in the environment, which it recruits to 
promote PAI-1 expression by increasing the cell’s sensitivity to EGF.  This may explain why 
PAI-1 does not appear to be regulated synergistically by EGF and TGF-β in some cells that 
might synthesize enough EGF or other growth factor to prime the synergistic mechanism in 
an autocrine fashion such that only TGF- is required to complete the synergistic signal.  
Modulating the efficiency of signaling of a growth factor with which it acts synergistically is 
a very effective way for a single growth factor to achieve a large change in gene expression.  
By this means, the newly arrived single growth factor sensitizes the cells to pick up a signal 
from a growth factor that is already present in the environment (but at concentrations 
normally too low to signal) that then provides a synergistic boost to the newly arrived growth 
factor’s signal.  Our observation of the effect of TGF- on EGF receptor sensitivity suggests 
that many cases of synergistic interaction between TGF- and EGF may be missed due to the 
presence in the serum or the secretion by cultured cells of low concentrations of growth 
factors that can act in an autocrine manner with a receptor sensitized by the action of TGF-.   
The target of the cooperation between EGF and TGF- seems to be the interaction of AP-
1 and Smad.  Cooperative interactions between AP-1 and Smads have been shown with 
several constructed promoters and for endogenous PAI-1 expression (Zhang, Feng et al. 1998; 
Verrecchia, Vindevoghel et al. 2001).  In these studies we found that the 3TP promoter 
construct that contains both AP-1 and Smad binding elements is synergistically regulated to 
the same extent as PAI-1 transcription.  Curcumin, an inhibitor or AP-1 activity and a 
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dominant negative Fos both independently decrease synergism on the synthetic promoter 
with both AP-1 and also inhibit expression of the endogenous gene.  Neither transcription 
factor is more highly phosphorylated in cells treated with EGF and TGF- compared with 
cells treated with a single growth factor.  In combination with the results of MEK and p38 
inhibition, this suggests that phosphorylation is required for transcription factor activation, 
but synergism involves another mechanism.  These results suggest that the EGF and TGF- 
pathways meet and act synergistically to increase transcriptional activity that involves the 
interaction of Smads and AP-1.  The mechanism does not involve an increased activation of 
either transcription factor by phosphorylation but more likely involves enhanced interaction 
between the transcription factors or increased efficiency of their combined action.   
If the pathways by which EGF and TGF-β stimulate PAI-1 transcription ultimately 
converge on the same event, such as to activate a protein kinase or a transcription factor, 
synergism might occur at concentrations of each that are below saturating for the targeted 
response.  But, once one growth factor is present at saturating concentrations and has thus 
fully activated the target event, the other growth factor might be expected to have no further 
stimulatory effect because all target enzymes/proteins would be activated to their maximum.  
If such were true, the synergism between EGF and TGF-β should be observed only when the 
two growth factors are present at below saturating concentrations and not once either growth 
factor is present at a saturating concentration.  Such is the case for the synergism between 
EGF and insulin in stimulating S6 phosphorylation (Nilsen-Hamilton, Hamilton et al. 1982).  
We examined the possibility that the cooperation between EGF and TGF-β might be 
similarly lost at saturating concentrations of both growth factors.  However, this was not true 
and synergism is observed when either or both growth factors are present at saturating 
98 
 
 
concentrations.  This observation suggests that the combination of the two growth factors 
results in a signal that is different from those initiated by either growth factor alone.   
The involvement of an additional signal that depends on both growth factors is consistent 
with the published observation that, although recombinant the combined expression of 
recombinant Smad and AP-1 results in increased promoter activity, this activity is further 
increased in cells activated by TGF- (Zhang, Feng et al. 1998).  Our study, which shows a 
rapidly turning over protein implicated in synergism, also shows that the decay of PAI-1 
expression in the presence of either growth factor is biphasic with a rapid and a slower phase. 
The results suggest that the cell contains a limiting amount of the rapidly turning over protein 
that promotes PAI-1 expression in the presence of either growth factor, but that the 
combination of both growth factors activates this protein or promotes its movement into the 
nucleus where it can interact with Smad and AP-1 to enhance their combined activity. 
Proteins that might be involved in mediating the synergism are CBP which is a 
coactivator of the Smads and AP-1 (Kamei, Xu et al. 1996; Feng, Zhang et al. 1998; 
Janknecht, Wells et al. 1998) and its associated protein PCAF, an acetyltransferase with a 2 h 
half-life that is regulated by ubiquitination (Jin, Zeng et al. 2004).  CBP or its paralog p300 
and PCAF have been identified as involved in TGF- signaling and the regulation of several 
genes.  For synergism to occur at saturating concentrations of each growth factor, TGF- and 
EGF must regulate different functions that together give more activity than can be achieved 
by a maximum signal from either growth factor.  For example,    in vitro analysis of the 
mechanism by which MyoD is activated by a combination of p300 and PCAF showed that 
p300 acetylates histones H3 and H4 and then recruits PCAF to myoD whereupon PCAF 
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acetylates myoD and activates transcription (Dilworth, Seaver et al. 2004).  We propose a 
related mechanism to explain the synergism between EGF-TGF- in which EGF-initiated 
Erk or p38 phosphorylate CBP, which promotes its recruitment of AP-1 (Janknecht and 
Nordheim 1996; Zanger, Radovick et al. 2001).  The CBP then recruits PCAF, which 
acetylates Smad thus promoting its association with the promoter (Tu and Luo 2007).  In this 
model, the synergism arises from the cooperative interaction on the promoter of two 
transcription factors that are recruited by different mechanisms; AP-1 recruited by CBP 
(activated by Erk1/2) and Smad (activated by TGF-beta RII) recruited by PCAF which in 
turn is recruited by CBP.  All the features in this model have been demonstrated to occur on 
other promoters, but have yet to be demonstrated as the mechanistic basis for synergism 
between EGF and TGF- in regulating PAI-1.  
In summary, we have shown that TGF and EGF synergistically increase PAI-1 
expression at the level of transcription.  EGF adds to the effect by stabilizing the PAI-1 
mRNA and TGF-β increases the sensitivity of the cells to EGF by an order of magnitude.  
The results demonstrate a multidimensional cooperation between growth factors that involves 
a combination of regulations by one or both growth factors at transcription and mRNA 
degradation that enables a rapid response in gene expression of two orders of magnitude over 
the control levels.   Expression is also rapidly cut off due to the short half-life of the mRNA, 
which is regulated by mechanisms different from those that promote transcriptional 
activation of the gene.  In the presence of signals from both growth factors a different 
mechanism for gene regulation is in place than in the presence of either growth factor alone.  
In addition, TGF-β alone can recruit suboptimal concentrations of EGF into the synergistic 
mechanism by increasing the sensitivity of the cells to the EGF signal.  One or more of these 
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regulatory mechanisms are also likely to control the expression of other genes whose 
products act in concert with the plasminogen activator cascade.  Such combined mechanisms 
of regulation may be how the local and systemic concentrations of PAI-1 are so closely 
controlled in vivo so as to appropriately regulate the level of plasminogen activator activity 
and plasmin production.  Increased PAI-1 expression has been identified as one of the events 
responsible for increasing epithelial cell motility during the epithelial mesenchymal transition, 
a process that is linked to cancer progression.   
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Tables 
Table I. TGF increases the sensitivity of Mv1Lu cells to EGF 
Growth factor 
EC50 , ng/ml (R2 from fit) 
TGF EGF Fold change 
TGF  1.0 (0.73)  
  
TGF + EGF  0.89 (0.99)  
 
1  
EGF  
 
2.8 (0.79)  
 
EGF + TGF  
 
0.36 (0.88)  8  
EC50 of each growth factor was calculated by using the online software BioDatafit 1.02 
with four parameter (Hill-slope) model (Chang Bioscience, Inc., Castro Valley, CA; 
http://www.changbioscience.com/stat/ec50.html) .   
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Table II.  Synergistic induction of PAI-1 after blocking kinase pathways   
 
Synergism is calculated as: Synergism = TE net effect / (T net effect + E net effect).  The 
data is represented as mean ± sem. N: the number of experiments.  
  
Blocking target Addition Synergism Alteration P-value N*
MEK1/2
Control (U0124) 2.5 ± 0.3
-60% 0.09 2
Inhibitor (U0126) 1.0 ± 0.1
P38 MAPK
Control SB202474 3.0 ± 0.4
-30% 0.08 3
Inhibitor SB202190 2.1 ± 0.6
JNK
control 10.9 ± 0.9
36% 0.27 3
Inhibitor SP600125 14.8 ± 4.3
control 5.5 ± 3.0
-38% 0.21 3
Dn-JNK 3.4 ± 1.2
SRC
Inhibitor PP2 2.9 ± 0.2
21% 0.07 3
Control pp3 3.5 ± 0.3
PI3K
Inhibitor LY294002 5.2 ± 1.5
23% 0.30 2
Control LY303511 6.4 ± 0.1
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Table III.  Effect of AP-1 suppression on the synergistic effect of EGF and TGF-β 
 
Synergism is calculated as: Synergism = TE net effect / (T net effect + E net effect).  The 
data is represented as mean ± sem. N: the number of experiments.  
Blocking
target Addition Synergism Alteration P-value N*
3TP
Control 2.5 ± 0.4
-44% 0.02 5
Inhibitor (Curcumin) 1.4 ± 0.3
3TP
Control 2.5 ± 0.5
-36% 0.03 5
Dn-Fos 1.6 ± 0.4
PAI-1 
mRNA
Control 3.7 ± 1.0
-36 % 0.06 3
Dn-Fos 2.4 ± 0.7
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Supplementary Table  
 
Supplementary Table I.  Effect of EGF and TGF-β on gene induction in various cell 
lines.  *N: number of independent experiments.  **Observations regarding synergism were 
also made in previously published work for Mv1Lu, BSC-1, AKR-2B, and NRK cells 
(Nilsen-Hamilton and Holley 1983; Thalacker and Nilsen-Hamilton 1992).  # Results 
reported in (Wilkins-Port, Ye et al. 2009).   
Cell line gene Synergism N*
Mv1Lu
(CCL64)
Mink lung epithelial cells
PAI-1 4.5 ± 0.9 11
uPAR 0.4 ± 0.8 4
COX2 0.3 ± 0.3 3
MLEC stably transfected Mv1Lu cells PAI-1 1.7 ± 0.1 3
HepG2 Human heptoblasma
PAI-1 3.4 ± 0.3 2
uPAR 2.1  ± 1.9 2
uPA 2.0  ± 0.1 2
EpH4
mouse mammary gland 
epithelial cells
PAI-1 1.2 ± 0.5 4
uPAR 0.9 ± 0.3 4
uPA 1.4  ± 0.9 4
HaCaT II-4#
transformed human 
keratinocytes
PAI-1 ~ 4
BSC-1** monkey kidney epithelial cells PAI-1 No synergism
AKR-2B 
84A**
mouse embryo fibroblasts PAI-1 No synergism
NRK** normal rat kidney fibroblasts PAI-1 No synergism
112 
 
 
Figures Legends 
Figure 1.  Synergistic regulation of PAI-1 protein and mRNA in mink and human 
cells.  A) top panels: Synergistic regulation of PAI-1 protein production. PAI-1 protein 
production in mink Mv1Lu and human HepG2 cells was established by labeling with a 4 h 
pulse of 35S-methionine or 35S-Trans-label  after incubating Mv1Lu cells for 2 h or HepG2 
for 8 h with growth factors.  The amount of radiolabeled PAI-1 in the medium (Mv1Lu) or 
after immunoprecipitation with PAI-1 antiserum. (HepG2) is shown after resolution by SDS-
PAGE. Bottom panel: The effects of EGF and TGF-β on PAI-1 synthesis in Mv1Lu cells 
were quantified by scanning the identified bands (PAI-1 and 38kDa) in the gel shown in the 
top left panel (Mv1Lu) and normalizing these values to the total 35S-cpm loaded onto the gel 
for each sample.  Duplicate independent samples were tested and the average results with 
standard errors are shown.    B,C) Synergistic regulation of PAI-1 mRNA.  Cells were 
treated for 2 h with 5 ng/ml EGF, 1 ng/ml TGF-β or the combination of EGF and TGF-β at 
the same concentrations.  PAI-1, uPAR, COX2 and uPA mRNAs were quantified by RT-
qPCR for Mv1Lu (upper panels) and HepG2 (lower panels).  The inset in the top left panel 
shows a Northern blot of PAI-1 (open arrow) and 18S RNA (filled arrow) in Mv1Lu cells. 
Each experiment was performed 11 times for PAI-1, four times for uPAR and three times for 
COX-2 in Mv1Lu cells and twice for PAI-1, uPAR and uPA in HepG2 cells.  The northern 
blot experiment was performed twice.  -, vehicle control; E, EGF; T, TGF-β; TE, TGF-β and 
EGF.  *: p<0.05; **: p<0.01; ***: p<0.001.    
Figure 2.  Synergism is observed at saturating concentrations of both growth factors.  
A) PAI-1 mRNA induction by EGF (0.08 to 100 ng/ml) either alone or in combination with 1 
ng/ml TGF-β for two hours in Mv1Lu cells.  B) PAI-1 mRNA induction by TGF-β (0.0016 
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to 25 ng/ml), either alone or in combination with 5 ng/ml EGF for 2 h in Mv1Lu cells.  PAI-1 
mRNA was quantified by RT-qPCR and normalized to the GAPDH values in the same 
samples.  In both panels the lines show the result of a nonlinear fit of each data set. 
Figure 4. MAPK is involved in the synergism.  A-E) Effect of blocking specific 
pathways by kinase inhibitors.  Cells were treated for 1 h with inhibitors (or control 
analogs) prior to two hours growth factors treatment and PAI-1 mRNA was measured with 
RT-qPCR. Empty bars: control analogs; filled bars: inhibitor.  F) No synergism in 
phosphorylation of Erk1/2. Cells were treated for 1 h with 20 µM MEK inhibitor U0126 or 
its inactive analog U0124 then for10 min with 1 ng/ml TGFβ, 5 ng/ml EGF or their 
combination.  The phosphorylation of Erk1/2 was determined by western blot. -: vehicle 
control, T: TGF-β, TE: EGF and TGF-β. * : p<0.05; **: p<0.01; ***: p<0.001  
Figure 5.   EGF, but not TGF-β, increases the half life of PAI-1 mRNA.  Mv1Lu cells 
cultured in DME medium with 0.2% calf serum were incubated for 2 h with 1 ng/ml TGFβ 
and 5 ng/ml EGF or their combination.  Coredycepin (15 g/ml) was then added (set as zero 
time) to block transcription.  Total RNA was isolated at the indicated times and PAI-1 
mRNA was quantified by RT-qPCR and normalized to the GAPDH values in the same 
samples.  The results are from at least five independent experiments.  The half life of PAI-1 
mRNA in TGF-β-treated cells was calculated to be 36 min (regression coefficient from a 
least squares analysis = 0.90) and that in EGF-treated cells as 53 min (regression coefficient 
= 0.90).  The half life of PAI-1 mRNA in TGF-β plus EGF treated cells is 58 min (regression 
coefficient = 0.80).  When tested by using analysis of covariance (JMP 7.0) the difference 
between treatment with TGF-β alone and treatment with the combination of EGF and TGF-β 
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was significant to the level of p < 0.05.  Figure 6.  A, C) EGF and TGF- cooperate to 
increase PAI-1 transcription.  Cells were treated for 2 h with 5 ng/ml EGF, 1 ng/ml TGF-β 
or their combination.  Newly transcribed PAI-1 mRNA (A) and total mRNA (B) were 
quantified by the nuclear run-on assay.  Shown are the average results with the SEM from 
two independent experiments.  C,D) The synergistic mechanism is activated soon after 
growth factor addition Cells were treated with EGF and TGF-β or their combination for 
various time periods then 4SU was added for the last 15 min of each incubation. Newly 
synthesized (C) and total (D) RNAs were isolated and quantified for PAI-1 and GAPDH by 
RT-qPCR. -, vehicle control; E, EGF; T, TGF-β; TE, TGF-β and EGF. *: p<0.05; **: p<0.01; 
p<0.001.  
Figure 7. The phosphorylation and activities of Smads are not synergistically 
regulated by EGF and TGF-.  A No synergism on Smad2/3 phosphorylation. Cells 
were treated with growth factors for 45 min.  Western blots showing the phosphorylation of 
Smad 2/3 compared with -actin in the same samples. B,C): Transcriptional activities 
mediated by Smad (pSBE4) or Smad plus FAST-1 (p3ARE) in cells stimulated with 
growth factors.  Cells were transiently transfected with luciferase reporters for 17 h then 
incubated for 6 h with growth factors   -: vehicle control, E: EGF, T: TGF-β, TE: EGF and 
TGFβ. * : p<0.05; **: p<0.01; ***: p<0.001.   
Figure 8. AP-1 is involved in the synergism between EGF and TGF-β.  A: 
Transcriptional activities mediated by Smad2/3 and AP-1 respond synergistically to 
EGF and TGF-β. Cells were transiently transfected with the 3TP luciferase reporter for 17 h 
then for 6 h with growth factors B, C: Synergism is inhibited by curcumin and FosB.  
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Cells were transiently transfected with 3TP with and without FosB for 17 h then for 6 h 
with growth factors with or without 20µM curcumin added 1 h prior  D: Curcumin has no 
effect on Smad activity.  Cells were transfected with pSBE4 and treated with curcumin and 
growth factors.  Promoter activities were measured with luciferase asay.  E: No synergism 
on phosphorylation of Fos and Jun.   Cells were treated with growth factors for 40 min.  
Antibodies against phosphorylated Fos at ser32, ser362 & Thr232 were used to detect Fos 
phosphorylation and antibodies against phosphorylated c-Jun at ser 63 and ser73 was used to 
detect c-Jun phosphorylation.  Western blots showing the phosphorylation of Fos and Jun in 
the same samples.  F: Synergistic induction of PAI-1 mRNA is inhibited by FosB:  Cells 
were transiently transfected with FosB for 17 h then for 2 h with growth factors.   -: vehicle 
control, E: EGF, T: TGF-β, TE: EGF and TGFβ.  * : p<0.05; **: p<0.01; ***: p<0.001.  
Empty bars: control; Filled bars: inhibitors.   
Figure 9.  A,B: Synergism does not require de novo protein synthesis.  Cells were first 
treated with 50 μg/ml cycloheximide for 1 h and then with 1 ng/ml TGF-β, 5 ng/ml EGF, or 
their combination for 2 h.  PAI-1 mRNA was measured with RT- qPCR.  About 3 fold of 
synergism was observed in both cycloheximide treated (filled bar) and control cells (Empty 
bar).  B-D: Synergism requires a rapidly turning over protein.  Cells were treated with 
10 μg/ml cycloheximide before, during or after the addition of growth factors as shown in B.  
PAI-1 mRNA was quantified after 2 h treatment with 1 ng/ml TGF-β, 5 ng/ml EGF, or their 
combination as shown in C. And the response of PAI-1 mRNA as the fraction of no 
cycloheximide control for each treatment with growth factors was plotted to determine the 
decay constants (D) -: vehicle control, E: EGF, T: TGF-β, TE: EGF and TGFβ. *: p<0.05; **: 
p<0.01; ***: p<0.001  
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Figure 10.  Proposed model for the regulation of PAI-1 by EGF and TGF-.  TGF-  
regulates PAI-1 expression through Smad mediated signaling.  EGF synergizes with TGF-β 
in PAI-1 gene expression at the mRNA level.  Other stimuli that activate MAPK signaling 
pathway including FGF-2, IGF-I, TNFα and PMA substitute EGF in synergism with TGF-. 
EGF regulates PAI-1 expression through MAPK signaling pathway.  AP-1 and Smad are 
involved in the synergistically increased transcription.  A synergistic recruitment of AP-1 and 
Smad was proposed. 
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Abstract  
Identification of regions on mRNAs that are accessible for hybridization in the living cell 
is required for antisense and RNAi technologies and for accurate prediction of authentic 
targets of microRNAs.  Although the sequence of an mRNA holds some useful information, 
the secondary and tertiary RNA structure determines access for hybridization.  Because in 
vivo assays are very time consuming and expensive, computational and cell culture analysis 
have been utilized with varying success for identifying effective oligonucleotide inhibitors.  
With the advent of microarray spotters and readers as standard equipment in many research 
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facilities, this approach to analyze RNA for accessible regions is worthy of investigation for 
its application to identify antisense and RNAi targets.   We have utilized a tiled microarray 
format to investigate the accessible regions in two mRNAs (Bcl2 and Lcn2) and compared 
this with cell culture and computational approaches for predicting accessible targets for 
antisense oligodeoxynucleotides (ODNs) and siRNAs.  Our results suggest that a tiled 
microarray is an effective means of identifying the mRNA regions that are accessible to 
antisense ODNs and RNAi. 
Introduction 
The sequence-specific silencing of gene expression by antisense oligonucleotides (ODNs) 
and siRNAs has attracted great interest in the development of effective gene therapies for a 
wide variety of diseases (Opalinska and Gewirtz 2002; Biroccio, Leonetti et al. 2003; 
Hokaiwado, Takeshita et al. 2008).  Requirements for successful ODN- and RNAi-mediated 
decreases in mRNA levels and inhibition of protein biosynthesis include high affinity and 
faithful base-pairing specificity of the antisense-mRNA pair, intracellular delivery capability 
and stability of the antisense ODN or siRNA to nucleases in the biological environment 
(Fiset and Soussi-Gounni 2001).  A fundamental requirement for both technologies is that the 
target site of the mRNA must be accessible for hybridization with the antisense or siRNA 
oligonucleotide.  Because mRNAs are normally folded in secondary and tertiary structures, 
only a relatively small portion of the RNA sequence is available for efficient hybridization 
(Uhlenbeck, Pardi et al. 1997; Rivas and Eddy 1999; Vickers, Wyatt et al. 2000).  
Many approaches, experimental and computational, have been developed to identify 
optimal antisense-accessible sites in mRNAs.  In the direct test of in vivo efficacy, ODNs 
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complementary to various regions of an mRNA are synthesized individually and their 
antisense activities are measured using cells in culture (Ziegler, Luedke et al. 1997; Wang, 
Cheung et al. 2001).  However, this approach of empirically testing multiple ODNs in vivo is 
very expensive and time consuming.  The demands of time and expense also limit coverage 
of the mRNA primary sequence investigated by in vivo analyses and therefore a complete 
picture of the accessibility of all possible sites on a target mRNA is usually not obtained by 
these approaches.  
Computer algorithms that utilize minimum free energy calculations can predict secondary 
structures of RNA molecules and have been used to identify target accessibility and as a 
basis of rational design of antisense and nucleic acid probes (Mathews, Burkard et al. 1999; 
Ding and Lawrence 2001; Ding, Chan et al. 2004; Ding, Chan et al. 2005).  However, these 
computer programs do not predict tertiary structures that may influence target accessibility.  
Moreover, RNAs can fold in many different secondary structures with similar free energies 
that could each further fold into one or more tertiary structures.  The uncertainty of the in 
vivo balance of alternate secondary and tertiary RNA structures makes it very challenging to 
identify sequences for effective antisense ODNs from the primary structure of the mRNA 
using computational approaches. 
Several in vitro approaches have been developed to identifying optimal target sequences 
in mRNAs for antisense technology.  One approach is to map the antisense-accessible sites 
on mRNAs by hybridization with random ODN libraries followed by either RNase H 
cleavage or extension with reverse transcriptase (Ho, Bao et al. 1998; Allawi, Dong et al. 
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2001; Lloyd, Giles et al. 2001).  Hybridization of antisense ODNs has also been analyzed by 
MALDI-TOF to identify the accessible regions on an mRNA (Bleczinski and Richert 1998).   
ODN arrays provide a simple tool for quantitative measurement of the binding of a set of 
complementary ODNs to a target RNA.  In this method, an array of ODNs covalently linked 
to a glass surface is used to measure heteroduplex formation with the corresponding target 
mRNA, which is radioactively or fluorescently labeled.  The results obtained with this 
approach show a good correlation between binding strengths and antisense activity in vivo 
(Milner, Mir et al. 1997; Sohail, Hochegger et al. 2001).  However, since these cited studies 
were published, computational methods for folding nucleic acids and identifying 
hybridization targets have greatly improved. 
Here we compared several commonly used computer programs with tiled microarrays 
carried out under physiological conditions for selecting accessible target sites for effective 
antisense ODNs in vivo.  Two mRNA targets were used; mouse lipocalin 2 (aka SIP24, 24p3, 
uterocalin, siderocalin, Ryon, Bendickson et al. 2002) and B-cell CLL/lymphoma 2 (Bcl2).  
The efficacies of ODNs identified by each method were tested as antisense ODNs in vivo for 
Lcn2 and compared with literature reports of effective in vivo antisense for both gene 
products.  We found that the experimental microarray analysis shows better specificity by 
identifying a small number of regions highly accessible for hybridization, compared to 
computational algorithms.  Those regions identified by the tiled microarray were accurate 
predictions of sites for effective antisense action in vivo.  They also predicted an effective 
siRNA site.  Because of their ease of performance and their successful identification of in 
vivo RNA hybridization targets, we propose that tiled microarrays are an efficient means of 
131 
 
 
identifying potential antisense ODNs or siRNAs.  Tiled microarrays could also be effectively 
used as an experimental approach to provide data for validation and improvement of 
computational approaches for identifying RNA hybridization targets.  
Results 
Determination of sites accessible by oligonucleotide arrays 
To identify the regions in the mouse Lcn2 and human Bcl2 mRNAs that are accessible to 
antisense hybridization, fluorescently-labeled transcripts corresponding to each mRNA were 
synthesized and incubated with tiled arrays of complementary ODNs at 37 C for 16 h.  
Hybridization was performed under nondenaturing conditions and at salt concentrations 
reported for inside the cell.  The full-length Lcn2 transcript and a truncated Bcl2 (32-751 nt) 
transcript were used for hybridization.  The tiled arrays consisted of 20mer complementary 
ODNs in 10 nt overlapping intervals.  The Lcn2 arrays included overlapping oligonucleotides 
complementary to the full-length of the Lcn2 mRNA (GenBank: NM_008491, 853 nt).  The 
Bcl2 arrays started at the AUG translation initiation site and included only the coding 
sequence (GenBank: M14745.1, region 32 to 751, 720 nt).   
The quality of the printed arrays were examined using a set of arrays that were not used 
for hybridization but that were printed at the same time as the arrays used for hybridization.  
These slides were stained with SYBR green II then scanned using Pro Scan Array HT 
scanner to detect the nucleic acid.  With some exceptions, the intensities of the printed ODNs 
were similar, which indicated that the printing was consistent from most pins.  There were no 
detectable signals from the three negative controls (no ODN).  The intensities from these 
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arrays were taken as background and used to normalize the intensities from the hybridized 
arrays. 
Analysis of the data for hybridization of Lcn2 mRNA with the microarray resulted in the 
ODNs targeting the mouse Lcn2 mRNA being separated into four clusters through K-means 
clustering with the highest binding associated with ODN 741-760 in the first cluster (Fig. 
1A).  The first and second clusters identified three potentially accessible regions of 30 nt or 
more, which were: 491-530, 561-590 and 741-770.  Interestingly, none of these sequences 
are near the translational start site of the mRNA.  The majority of tested antisense ODNs lay 
in the third and fourth tier clusters in which regions the accessibility of Lcn2 mRNA is 
indicated to be much lower than for the regions identified in the first and second tier clusters.  
We also tested the Bcl2 coding region using the tiled microarray assay.  As well as the 
tiled 20-mer ODNs covering the coding sequence of Bcl2, two previously identified effective 
antisense ODNs were included in the microarray.  One of these ODNs contained the 
sequence known as G3139 or Oblimersen that is complementary to the first six codons of the 
open reading frame of the human Bcl2 mRNA (Tolcher 2005).  The second antisense ODN 
(atg-1 in Fig. 1B) contained a sequence that also targets the translation initiation site but 
includes an additional six nucleotides (CCTTCC) at the 3'-end (denoted 2292 in reference 
Ziegler, Luedke et al. 1997).  Statistical analysis and K-means clustering of the results from 
the Bcl2 microarray resolved the previously identified antisense ODNs (Oblimerisen and atg-
1) in the first tier cluster (red bar in Fig. 1B).   The ODNs 1-20 and 8-27 that overlap in 
sequence with oblimersen and 2292 were found in the second tier cluster (green bars in Fig. 
1B).  These two ODNs contain the sequences that surround the translational start site and 
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have previously been identified as effective antisense sequences (Kitada, Takayama et al. 
1994; Gleave, Miayake et al. 1999).  Clusters 3-6 included the three ODNs with scrambled 
sequences. So, it is likely that the first and second tiers contain the only ODNs that 
specifically hybridize with the Bcl2 coding sequence under native conditions.  
Prediction of accessible regions by computational analyses 
Computational analysis was used to predict available sequences for hybridization with 
the same Lcn2 and Bcl2 RNAs that had been tested against their respective microarrays.  We 
tested three widely used computer programs (Oligowalk, sFold and Block-iT) to predict 
accessible regions in Lcn2 and Bcl2 RNAs.  These programs predicted overlapping but 
different sets of sequences as optimal for effective antisense as seen in Fig. 2.  Although 
some of the mRNA sequences identified by the microarray were also predicted by 
computational analysis, many differences are evident between the experimental and 
computational methods.  A comparison of the predictions of the three computational methods 
also showed considerable disagreement. 
Efficiency of selected antisense oligonucleotides on Lcn2 protein levels 
Based on the results from the microarray and the computational analysis, eight ODNs 
were chosen to test as antisense agents for Lcn2 in vivo. Four ODNs were identified from the 
computational analyses, three from the microarray results and one from a previous literature 
report that is complementary to a region covering the translational start site (positions 11 
through 27).  The effects of these ODNs on Lcn2 protein and mRNA levels were tested in 
mouse HC11 cells, a mammary cell line that expresses this gene at a high level (Ryon, 
Bendickson et al. 2002).  The Lcn2 protein secreted by these cells was determined by 
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western blot analysis and the mRNA by RT-qPCR.  All results were normalized to those 
from cells transfected by an ODN with a scrambled sequence.  In some experiments, the 
transfection efficiency was also determined using a fluorescent AS-ODN.  The measured 
average transfection efficiency was 70% of the cells transfected.   
The amount of the Lcn2 released by the transfected cells (Fig. 3B, upper panel) was 
normalized to the corresponding amount of total protein captured from the medium as 
determined from Ponceau S staining of the nitrocellulose membrane (Fig. 3B, lower panel).  
The amount of the most abundant protein in the medium (albumin) was used as the 
normalizing factor for loading variation.  The results of all experiments were compiled and 
evaluated for statistical significance of the observed differences (Fig. 4).  The average value 
for the scrambled ODN was 128% of the control (no ODN) value although this ratio varied 
between experiments.  Statistical analysis identified AS-ODNs 561 (p<0.0001), 501 
(p<0.0001) and 741 (p<0.001) as causing a highly significant decrease in Lcn2 production.  
with an average transfection efficiency of 70%, the 50 to 60% decrease in amount of Lcn2 
protein is consistent with the majority of transfected cells realizing a very large decrease in 
Lcn2 expression.  The 741 ODN was chosen based on the agreement between the microarray 
analysis and all three tested computational programs. The 501 and 561 ODNs were among 
the first tier cluster in microarray analysis and were also predicted by Oligowalk and 
BLOCK-iT, but not by sFold.  Three other AS-ODNs showed an effect with weaker 
significance (p<0.05 or p<0.01) and all other ODNs showed no effect on Lcn2 production 
(Fig. 4).  Thus, the three sequences that most successfully decreased cellular Lcn2 production 
were identified by the tiled microarray analysis and by at least two of the three computational 
analyses. 
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Efficiency of selected antisense oligonucleotides and siRNA on Lcn2 mRNA  
We also examined the effects of the antisense ODNs on the Lcn2 mRNA and intracellular 
Lcn2 protein levels of the mouse HC11 cells.  Total RNA and cellular protein were extracted 
from the cells 48 h after the second transfection and quantitative measurements of Lcn2 
mRNA were performed by RT-qPCR.  Compared with the control ODN (scrambled 
sequence), the 561 and 741 AS-ODNs selectively reduced the Lcn2 mRNA and intracellular 
Lcn2 protein levels (Fig.  5A).  
It has frequently been demonstrated that sequences around the translational start site are 
good AS-ODN targets (Gleave, Miayake et al. 1999; Marcucci, Byrd et al. 2003; Tolcher 
2005).  Moreover, an effective AS-ODN for Lcn2 has been reported that is complementary to 
the region 11-27 of the mRNA that covers the translational start site (Devireddy, Teodoro et 
al. 2001).  None of the methods employed to identify optimal AS-ODNs predicted that an 
ODN with a sequence complementary to a region near the translational start site of Lcn2 
would be an effective AS-ODN.  Therefore we tested an AS-ODN complementary to 
position 11-27 (AS-ODN11) to determine if it effectively inhibits Lcn2 production by HC11 
cells.  Although the AS-ODN had little effect on protein or RNA levels when used at 0.2 μM, 
it was very effective in inhibiting protein production when used at a 10-times higher 
concentration as was used in the previous study (2 μM, Fig. 5B).  However, by contrast to the 
effects of AS-ODNs 561 and 741, AS-ODN11 did not decrease the Lcn2 mRNA level even 
at the concentration of 2 μM.   
We also tested the effectiveness of siRNAs targeted to the same regions in the Lcn2 
mRNA in two different cell lines (Fig. 5C,D)  In both instances a similar profile of decrease  
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in Lcn2 mRNA was observed as for the AS-ODN series (Fig. 5A).   
Discussion 
Experimental approaches for identifying regions in the RNA susceptible to antisense 
suppression involve testing a series of potential AS-ODNs for their abilities to specifically 
inhibit translation of the target mRNAs.  Many AS-ODNs have been directed against regions 
of the mRNA near the translational start site with the objective of interfering with 
translational initiation.  Thus, RNA walking between the cap site and the translational start is 
one approach to identifying effective AS-ODNs (Bacon and Wickstrom 1991). However, it is 
now recognized that other mechanisms of effective antisense prevail, such as the mechanism 
that involves RNAse H-dependent RNA degradation.  RNA structure is also recognized as an 
important consideration for identifying sequences that can be used to design effective 
AS-ODNs.  Thus, computational approaches have been developed to evaluate RNA structure 
for the purpose of rational design of effective AS-ODNs.  Four factors have been proposed as 
the basis for rationally designing AS-ODNs using computational approaches (Chan, Lim et al. 
2006).  These are 1) predicting RNA secondary structure, 2) identifying the appropriate local 
RNA secondary structures, 3) calculating GC content and motif search, and 4) predicting the 
binding energy (ΔG at 37 EC).  However, there is good evidence that the GC content and 
binding energies of short segments of the RNA are subservient to the secondary and tertiary 
structure of the mRNA. 
In vitro experimental approaches have also been developed for identifying accessible 
sequences in mRNA molecules.  In the MAST approach a combinatorial ODN library is 
hybridized with the full-length RNA under nondenaturing conditions.  The RNA and 
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hybridized ODNs are captured and the ODNs cloned and sequenced.  This procedure was 
successful in identifying accessible regions on the mRNAs encoding β-globin, RhoA and 
luciferase (Zhang, Mao et al. 2003).  Microarrays were developed to examine the structure of 
an mRNA over a range of about 100 nt (Milner, Mir et al. 1997; Sohail, Akhtar et al. 1999; 
Sohail and Southern 2000).  These arrays are produced using an innovative approach to 
synthesizing an array of ODNs of varying lengths that are complementary to regions in the 
target mRNA.  Studies using scanning microarrays provided evidence that microarrays can 
be a powerful tool for identifying accessible regions on an mRNA measured under 
physiological conditions.  By contrast, we have used a tiled microarray of equal length ODNs 
to analyze the structures of about 800 nt segments of the Lcn2 and Bcl2 mRNAs.  The 
microarrays comprised ODNs with overlapping sequences that covered the entire Lcn2 
mRNA sequence and the entire Bcl2 coding region.  Although previously not readily 
available, microarray spotting and reading equipment is becoming increasingly common 
place.  A tiled microarray such as used in this work could be used to analyze the accessible 
sites on any mRNA that can be synthesized in vitro.  
We analyzed the accessible sequences on Lcn2 mRNA by both tiled microarray and 
computational methods to identify optimal AS-ODNs.  Notably, the tiled microarray method 
identified a much smaller cohort of potential antisense sequences than any of the 
computational methods, indicating improved specificity.  ODNs predicted as optimal for 
antisense by experimental and computational procedures were then tested with HC11 cells 
that synthesize large amounts of Lcn2.  The results from the western blot analysis and the 
RT-qPCR studies are in agreement and suggest that the tiled microarray method can be used 
to accurately identify antisense sequences for effective AS-ODNs.  The results of the tiled 
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microarray also successfully predicted siRNA targets in this example.  However, effective 
siRNA sequences must also have characteristics compatible with binding Argonaute such 
that the appropriate strand is chosen as the guide strand for mRNA cleavage (Parker, Roe et 
al. 2006).  Therefore, although the tiled microarray will identify potential siRNA sequences, 
other considerations need to be applied to identify those that are biologically effective. 
Neither microarray nor computational algorithms predicted any sequences around the 
translational start site as potential effective targets for AS-ODNs for Lcn2.   However, a 
17mer ODN (AS-ODN11) has previously been reported to decrease Lcn2 expression 
(Devireddy, Teodoro et al. 2001).  We tested this AS-ODN at 200 nM and 2 μM and found 
that it suppressed Lcn2 protein production only at the higher concentration but did not 
decrease the level of Lcn2 mRNA.  These results support observations made by others that 
AS-ODNs targeted to the region of the translational start site are likely to be effective in 
suppressing translational initiation (Higgins, Perez et al. 1993; Reed 1997; Dias and Stein 
2002).  However, a BLAST search of the AS-ODN11 sequence revealed that, as well as 
being complementary to position 11-27 of Lcn2, it is also complementary to position 
702-719 of the mRNA that encodes Nradd (Neurotrophin receptor associated death domain, 
GeneID: #67169, NM_026012), a death domain protein (Wang, Shao et al. 2003; 
Gowrishankar, Zeidler et al. 2004).  Thus, the effect of AS-ODN11 on Lcn2 expression could 
be an indirect consequence of the inhibition of Nradd production due to a primary antisense 
effect on the level of Nradd mRNA. 
In a retrospective analysis, we also evaluated the Bcl2 mRNA, for which effective 
antisense ODNs have been previously identified, to determine if the tiled microarray would 
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again accurately predict the most effective AS-ODNs.  Because the Bcl2 mRNA is extremely 
large (6,030 nt), we selected the coding region (720 nt) for analysis in this study.  Using 
Mfold, this region was predicted to fold into the same basic structure independently or in the 
context of the full-length mRNA.  Studies of RNA structure have revealed very few 
long-distance base-pair interactions beyond 800 nt.  For example, in the 16S and 23S rRNA 
structures solved by X-ray crystallography, 99.9% of the pairings are of bases within 600 nt 
of each other in the primary sequence (Harms, Schluenzen et al. 2001; Schuwirth, 
Borovinskaya et al. 2005).  Thus, the results from analysis of the accessibility of the Bcl2 
coding region should reflect its accessibility in the full length Bcl2 mRNA given that the 
same structure is predicted of the coding region whether alone or in context of the 5’ and 3’ 
UTRs.  Another consideration for selecting the coding region instead of full length is that the 
accuracy of computational prediction decreases with increasing length of the analyzed 
sequence because the complexity of analysis increases dramatically with the length of 
analyzed sequence.   
When the Bcl2 coding region was analyzed by tiled microarray, three ODNs were 
identified as the most available for hybridization.  All three ODN complementary sequences 
clustered around the translational start site.  This is precisely the region of the Bcl2 mRNA 
that has previously been identified as a prime target for AS-ODNs for reducing Bcl2 
expression (Kitada, Takayama et al. 1994; Gleave, Miayake et al. 1999; Tolcher 2005).  
However, these sequences were not predicted as effective AS-ODNs by computational 
analysis either of the full-length mRNA or the truncated RNA containing only the coding 
region, although a region very close to the start site was predicted by BLOCK-IT (Figure 2). 
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Our results suggest that a tiled microarray analysis of an mRNA is an efficient means of 
identifying effective AS-ODNs and potential siRNAs.  The two mRNAs analyzed by this 
means were found to have a small number of highly accessible regions.  The accessible 
regions identified by tiled microarray were confirmed by cell studies, in this study (Lcn2) 
and in others (Bcl2), to be effective regions for AS-ODN targeting.  It is of interest to note 
that the optimal AS-ODN targets were found to be at opposite ends of the mRNAs for Lcn2 
and Bcl2.  While the most effective AS-ODN for Bcl2 is near the translational start site, 
which is the most frequently targeted region for AS-ODN design, the most effective targets 
for Lcn2 were found near the 3' end of the mRNA.  It would be time consuming and 
expensive to find these latter target sequences by RNA walking and screening AS-ODNs 
with cultured cells. 
Conclusions 
 In this study effective AS-ODN sequences for both Lcn2 and Bcl2 were identified by in 
vitro tiled microarray studies.  Our results suggest that hybridization of ODN arrays to a 
target mRNA under physiological conditions might be used as a rapid and reliable in vitro 
method to accurately identify targets on mRNA molecules for effective antisense and 
potential siRNA activity in vivo. 
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Methods 
Oligonucleotides 
All ODNs used in this study were purchased from Integrated DNA Technologies 
(Coralville, IA).  The ODNs used for the tiled microarrays were 20mer 
deoxyribophosphodiesters and were obtained in a 96-well plate format at a total amount of 15 
nmoles each.  DEPC-water was added to each well for a final ODN concentration of 100 μM.  
The plate was stored at -20°C until used.  The antisense ODNs (AS-ODNs) used in cell 
culture studies were phosphorothioate oligodeoxynucleotides.  One AS-ODN (AS-735) was 
fluorescein-labeled, with 6-FAM, at its 5'-end to visualize cellular uptake. 
Preparation of fluorescently labeled transcripts 
Fluorescently labeled RNA transcripts for hybridization to the ODN arrays were 
synthesized by in vitro transcription.  The Bcl2 encoding DNA was amplified from a 
template plasmid using PCR (94°C, 30 sec; 55°C, 30 sec; 72°C, 1 min; 25 cycles).  A T7 
promoter sequence was included in the 5' primer to produce a template for transcription of 
the sense-strand of the amplified region.  The sequences of the 5'- and 3'-end primers were 
TAATACGACTCACTATAGGATGGCGCACGCTGG and TCACTTGTGGCCCAGAT-
AGGCACCCAG, respectively.  The PCR-amplified product was used as a template for in 
vitro transcription.  The Lcn2 mRNA was prepared from the template plasmid that contained 
a T7 promoter sequence.  The plasmid was linearized with EcoRI.  Transcription reactions to 
produce the Bcl2 and Lcn2 RNAs were carried out in 20 μL volumes at 37°C for 1 h in the 
presence of 2.5 mM each ATP, CTP, and GTP, 2.1 mM UTP and 0.4 mM ChromaTide Alexa 
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Fluor 546-14-UTP (Molecular Probes, Carlsbad, CA) using an AmpliScribe T7-Flash 
Transcription Kit (Epicentre, Madison, WI).  After DNase I treatment, the RNA products 
were purified by ammonium acetate precipitation as described in the transcription kit 
protocol.  The absorbances of RNA (A260) and Alexa Fluor (A555) were measured and the 
base-to-dye ratio for the fluorophore-labeled RNA was determined. 
 Preparation of the tiled oligonucleotide arrays 
Antisense ODNs were designed as 20mers that are complementary to the mRNA target 
from 5' to 3' in 10 nt overlapping intervals.  The ODN solutions were transferred to a Corning 
96-well microplate, dried by vacuum centrifugation and redissolved to a concentration of 150 
μM in epoxide spotting solution (Corning Life Sciences, Acton, MA).  ODNs were then 
printed onto Corning Epoxide Coated Slides according to the manufacturer’s protocol (55% 
relative humidity during printing, followed by incubation at 70% relative humidity for 12-17 
h).  Some spots on the slides were printed with spotting solutions containing either ODNs 
with scrambled sequences or with no ODNs as a negative controls.  After printing, a 
prehybridization step was performed to block the unused surfaces on the slides.  The ODN 
printing quality was examined by staining one or two slides with Sybr green II that were 
scanned using a Pro Scan Array HT scanner. 
Hybridization of mRNAs with arrays and image analysis 
Arrays were hybridized under physiological conditions using the hybridization buffer 
(13.5 mM NaCl, 150 mM KCl, 0.22 mM Na2HPO4, 0.44 mM KH2PO4, 100 µM MgSO4, 120 
nM CaCl2, 120 µM MgCl2, 1 U/mL ribonuclease inhibitor, 6 mM glutathione, 20 mM 
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HEPES, pH 7.25).  The array was covered with a cover glass and a solution of 25 nM 
fluorescently labeled RNA in 100 μL physiological buffer was pipetted onto the arrayed 
surface.  The slide was transferred to a hybridization chamber and left for hybridization at 
37°C for 16 h.  After washing in 150 mM NaCl, 15 mM NaCitrate, 0.01% SDS, the slide was 
dried by centrifugation at 1,600xg for 2 min and scanned using Pro Scan Array HT scanner.   
RNA folding predictions 
The minimum free energy secondary structures of Bcl2 and Lcn2 RNAs were estimated 
using the MFold and SFold web servers for nucleic acid folding and hybridization prediction 
(Zuker 2003; Ding, Chan et al. 2004).  These algorithms were also used to predict the 
antisense sequences and their binding affinity to the RNA target.  The data were analyzed by 
the Soligo program in the sFOLD package (Ding, Chan et al. 2004), OligoWalk (Mathews, 
Burkard et al. 1999), and Block-iT  programs. 
Cell culture and transfection 
HC11 epithelial cells were cultured in medium consisting of RPMI 1640 medium 
supplemented with L-glutamine (Gibco BRL), 10% fetal calf serum (FCS) and 10 U/mL 
penicillin/streptomycin in a humidified atmosphere with 10% CO2 at 37°C.  Cells were 
maintained in the exponential phase of growth by subculturing every 3 days. 
Transfection of the HC11 cells with AS-ODNs was performed in 6-well plates.  Cells 
were seeded at a concentration of 2 x 105 cells/well in 2 mL culture medium (containing 10% 
FCS).  After 18-20 h the cells were washed with 1 mL PBS (137 mM NaCl, 2.7 mM KCl, 10 
mM Na2PO4, 2 mM K2PO4, pH 7.4) followed by 1 mL culture medium, then 800 μL fresh 
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RPMI was added to each well.  A transfection mixture containing either AS-ODN or no oligo 
control (final concentration of 0.2 μM unless otherwise stated) and 3 μL Oligofectamine 
reagent (Invitrogen Inc., Carlsbad, CA) in 200 μL RPMI medium was added to each well to a 
final volume of 1 mL.  After 4 h incubation at 37°C, 500 μL fresh RPMI medium containing 
30 % FCS was added and the cells were incubated at 37°C, 10% CO2 for a further 20 h.  At 
this time, the media were removed from the wells, the cells were washed with PBS and a 
second transfection was performed using the same protocol.  Four hours after transfection, 
cells were incubated in RPMI with 0.3 % fetal bovine serum for another 44 h prior 
termination.  The transfection efficiency was determined by using fluorophore-labeled 
AS-735 as a representative AS-ODN.  The medium was collected from each well of cells 
treated with AS-ODNs, spun at 10,000xg for 10 min and the supernatants were stored at 
-20°C for determination of secreted Lcn2 protein level.  Cells were scraped into TRIZOL 
reagent (Invitrogen Inc., CA) to isolate total RNA and cellular protein according to the 
manufacturer’s instructions.  The control condition for all experiments was transfection with 
an ODN containing a scrambled sequence of AS-591 (Sc; TGTGTGCGTGGGAGCAAG-
AG).  This sequence was blasted against the mouse genome and transcriptome.  From this 
analysis no sequence in the mouse genome was found to be 100% complementary to Sc.  The 
best matches were in the UTRs of three RNAs for which, in each case, 80% of the bases were 
perfect matches.  Transfection with siRNA was done as for AS-ODNs except the second 
transfection was omitted. The control siRNA was non-targeting scrambled siRNA (Ambion, 
cat#4611G).   
145 
 
 
Western blotting 
Protein was concentrated from the conditioned media by precipitation in 10% 
trichloroacetic acid (TCA), incubated for 1-2 h at 4°C to allow total protein precipitation and 
then spun at 3,000xg for 15 min.  The protein pellets were washed once with 10% TCA and 
twice with cold acetone (-20°C acetone) and left for air drying at 4°C.  To determine the 
Lcn2 protein expression level, total protein was resuspended in 30 μL loading buffer and 
resolved by 12 % SDS-PAGE.  Proteins were transferred to a nitrocellulose membrane 
(Amersham Biosciences, Piscataway, NJ) by electroblotting at 400 mA for 1 h, followed by 
Ponceau S staining of the membrane for quantitative determination of the transferred protein.  
The non-specific binding sites of the membrane were blocked with 5 % non-fat dried milk in 
Tween 20 wash buffer (TWB).  The membrane was then incubated with rabbit 
anti-SIP24/Lcn2 primary antibody (1:500 dilution, Davis, Tabatabai et al. 1991) followed by 
peroxide-labeled anti-mouse secondary antibody (1:25,000 dilution).  The blot was washed 
with TWB and the immunoreaction was detected using enhanced chemiluminescence ECL 
reagents (Amersham Biosciences) followed by exposure to x-ray film (Kodak, Rochester, 
NY).  The film was analyzed by densitometric scanning of the Lcn2 bands and the intensity 
of each band was normalized to the corresponding total protein band from the Ponceau S 
staining.  The relative protein levels of the treatment groups were calculated with respect to 
the control values in the absence of ODN.  All experiments were performed at least seven 
times.  
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RNA isolation, reverse transcription and quantitative PCR 
Total RNA was isolated from the transfected cells using Trizol reagent (Gibco BRL) 
according to the manufacturer’s instructions.  At the final step, RNA pellets were dissolved 
in 20 μL DEPC-water and stored at -80°C.  Reverse transcription was performed using 
SuperScript II RT (Invitrogen Inc., CA) and the resulting cDNA was used as a template for 
Lcn2 mRNA reverse transcription and amplification by quantitative PCR (RT-qPCR).  The 
qPCR reaction was conducted using Taq DNA polymerase (Promega, Madison, WI), and 
SYBR green I.  A plasmid containing the Lcn2 coding sequence was used as template to 
establish the standard curve.  The forward and reverse primers for Lcn2 were CAGGCCCA-
GGACTCAACTCAGAA and TCTGGACCGCATTGCCTGC respectively.  The amount of 
Lcn2 mRNA was determined and normalized to the amount of GAPDH (mouse 
Glyceraldehyde-3-phosphate dehydrogenase, GenBank: M32599) or cyclophilin (mouse 
CypA, GenBank: NM_008907) mRNAs (as internal controls) that were measured in the 
same samples.  The forward and reverse primers for GAPDH were TGACATCAAGAAGG-
TGGTGAAGCA and GGTCCACCACCCTGTTGCTGT respectively.  The forward and 
reverse primers for cyclophilin were CTTTTCGCCGCTTGCTGCA and ACCACCCTGGC-
ACATGAATCCT respectively.  Standard curves for GAPDH and cyclophilin were based on 
templates created by PCR amplifying cDNAs containing these sequences with the primers 
previously identified. 
Statistical analysis 
To obtain the microarray data, the scanned digital images of both hybridized microarrays 
and the SYBR green II stained microarrays without hybridization were analyzed using 
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GridGrinder (Corning, Inc.). For each spot on each array, the median pixel intensity was 
multiplied by the number of pixels in the spot area to provide the total spot intensity. Each of 
the total spot intensities on the hybridization array was then divided by its corresponding 
total spot intensity on the staining array to normalize the potential spot-to-spot variations 
brought about by variations such as printing pin efficiencies. The normalized intensities 
corresponding to the same oligonucleotide were then averaged as the final signal for the 
oligonucleotide. K-means clustering (MacQueen 1967; Everitt, Landau et al. 2001; 
Tibshirani, Walther et al. 2001) was applied to the final signals from all oligonucleotides to 
identify intrinsic groups of oligonucleotides with K chosen under the assistance of the gap 
statistic (Tibshirani, Walther et al. 2001). 
For the Western blot and RT-qPCR data in figures 4 and 5(A,B), mixed linear models 
were used for analysis on the natural logarithms of fractions of controls. Fixed factors 
included the oligonucleotide, target molecule (extracellular protein, intracellular protein and 
mRNA) and their interaction. Random factors included independent experiments to account 
for block effects, gels and qPCR reactions within experiments to account for shared 
measurement errors and oligonucleotide within experiments to account for cell culture effects. 
Variance parameters were estimated using the residual maximum likelihood method and 
fixed effect parameters were estimated by generalized least squares. Heterogeneity of error 
variances were observed and accounted for by using sandwich-type empirical standard errors 
for fixed effect parameters and their contrasts.  The analysis was performed in the Mixed 
Procedure of SAS (9.2.3) and code is available upon request. Labels for the level of 
significance relative to “none” (to which no ODN was added) are: *** for p<0.001, ** for 
p<0.01 , and * for p<0.05. 
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Figure Legends 
Figure 1. Selecting effective antisense nucleic acids targeting Lcn2 mRNA by microarray.  
Tiled microarrays were performed and analyzed as described in Materials and Methods.  The 
average normalized intensities determined for each oligonucleotide from scanning 9 slide 
printings were analyzed by K-means clustering with K=4 for Lcn2 and 6 for Bcl2.  A) For 
Lcn2, the horizontal lines separate the 4 clusters defined for Lcn2, which are differentiated 
by the colors of the respective bars [1 (red), 2 (green), 3 (yellow) and 4 (brown)]. The control 
sequences (black) were, in order of presentation: buffer, and 9 different random sequences B) 
For Bcl2, the horizontal lines separate the first two clusters and the last 4 clusters are below 
the 2nd line. Clusters are differentiated by the colors of the respective bars [1 (red), 2 (green), 
3 (yellow) and 4-6 (shades of brown of increasing intensity)]. The controls were three 
separate wells containing a scrambled version of AS-ODN 422. 
Figure 2. Computational predictions.   
The predictions of Oligowalk (blue), S-fold (hatched area) and Block-IT (red lines) are 
compared with the results from the experimental microarray (green lines) for Lcn2 (A) and 
Bcl2 (B).  For Oligowalk and S-fold the lowest G (kcal/moL) indicate the sites predicted to 
be the most effective antisense targets.  For Block-IT, the length of the red line is the given 
rank based on the probability of successful knock down.  The arrowheads identify the 
oligonucleotides tested for their antisense activity in cultured cells.  The white arrowheads 
show oligonucleotides that had no significant effect on Lcn2 production (this study) or on 
Bcl2 (op.cit.) and the filled arrow heads show the sequences that were successful in cells as 
antisense ODNs. 
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Figure 3. Transfection efficiency and Western blot analysis to quantify secreted Lcn2 
protein levels.  
HC11 cells were transfected with 200 nM AS-ODNs and then the medium was collected and 
evaluated by Western blot as described in Materials and Methods. A) Images of cells 
transfected with FAM-labeled AS-ODN.  Left panel, fluorescent image and right panel, 
phase contrast image of the same field.  B) Western blot results showing the Western blot 
image and the Ponceau S stained membrane from the same gel.  The numbers below each 
stained protein band in the Western blot image is the intensity of that band normalized to the 
Ponceau S stained band of the same sample, which is directly below the number. 
Figure 4. Antisense oligonucleotides identified by the microarray decrease secreted Lcn2 
expression.  
Phosphorothioate AS-ODNs (200 nM) were tested for their ability to inhibit Lcn2 production 
by HC11 cells as measured by western blot.  Shown are the results from 12 independent 
experiments.  The yellow dots show the raw data points. In each experiment all values were 
normalized to the average value for the Lcn2 production by cells transfected with an ODN 
consisting of a scrambled sequence of AS-591 (Sc; TGTGTGCGTGGGAGCAAGAG). A 
statistical model was developed, the results of which are shown as brown bars behind each 
data set. 
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Figure 5.  Intracellular and secreted Lcn2 protein and mRNA levels are decreased by 
microarray-identified antisense ODNs and siRNA.   
A. Antisense ODNs: HC11 cells were transfected with 200 nM AS-ODNs with a scrambled 
ODN (Sc) as control. Forty eight hours after the start of the second transfection, the culture 
medium was collected and the cells fractionated to obtain cellular protein and RNA. The 
samples of cells and culture medium were analyzed by Western blot to quantify Lcn2.  Lcn2 
mRNA was quantified by RT-qPCR. C. siRNA: Cells were transfected with siRNA 561 and 
the cells collected 24 h later for analysis of Lcn2 mRNA by RT-qPCR.  
B. Targeting the translational start site decreases Lcn2 protein production but not the 
mRNA level.  HC11 cells were transfected with AS-ODNs and the amount of Lcn2 in the 
medium, collected 48 h after the beginning of the second transfection, was determined by 
Western blot. The level of Lcn2 mRNA was determined by real time RT-qPCR.   
For panels A and B The data are expressed as fractions of the values obtained in the same 
experiment when the cells were treated with a scrambled ODN.  The same statistical model 
was used as for figure 4, the results of which are shown as red and brown bars behind each 
data set.  Original data points are shown as markers: brown triangles, mRNA; yellow circles, 
extracellular Lcn2; inverted green triangles, intracellular Lcn2.   
C,D. The microarray also identified effective siRNAs: Cells were transfected with siRNA 
561 and the cells collected 24 h later for analysis of Lcn2 mRNA by RT-qPCR.  Examples of 
two experiments are shown, one with HC11 cells and the other with Mv1Lu cells. Mv1Lu 
cells were cotransfected with a plasmid expression vector for Lcn2, which was transcribed 
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from a -actin promoter with a CMV enhancer.  siRNA targets were within Lcn2 (numbered 
as for AS-ODNs) or a scrambled sequence (Scr).  Shown are individual values (triangles) and 
the simple means (green bars).   
For all panels: The data are expressed as fractions of the values obtained in the same 
experiment when the cells were treated with a scrambled ODN (Sc).  All AS-ODN 
concentrations were 0.2 M except for ODN11, which was tested at 0.2 and 2 M.  
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Figures 
Figure 1. Selecting effective antisense nucleic acids targeting Lcn2 mRNA by 
microarray.  
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Figure 2. Computational predictions.   
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Figure 3. Transfection efficiency and Western blot analysis to quantify secreted Lcn2 
protein levels.  
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Figure 4. Antisense oligonucleotides identified by the microarray decrease secreted 
Lcn2 expression.  
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Figure 5.  Intracellular and secreted Lcn2 protein and mRNA levels are decreased by 
microarray-identified antisense ODNs and siRNA.   
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CHAPTER 5.  GENERAL CONCLUSION AND DISCUSSION 
Goal of this study 
As the major physiological inhibitor of plasminogen activator (PA), the type I 
plasminogen activator inhibitor (PAI-1) is important for controlling blood clotting and tissue 
remodeling events such as those involving cell migration.  The changing needs for protease 
activities under various physiological conditions necessitates a tight cellular control of gene 
expression to enable rapid changes in the levels of PAI-1 and PA activity.  Previous studies 
have shown that transforming growth factor-β (TGF-β) and epidermal growth factor (EGF) 
interact synergistically to increase the PAI-1 protein level (Nilsen-Hamilton and Holley 1983; 
Thalacker and Nilsen-Hamilton 1992).  The goal of this study is to understand the 
mechanism of this synergistic regulation of PAI-1 by EGF and TGF-β.  
Significance of this study 
     Plasminogen activator inhibitor 1 (PAI-1) has important roles in regulating 
fibrinolysis (Kawasaki, Dewerchin et al. 2000; Gils and Declerck 2004), maintaining the 
integrity of the extracellular matrix (Degryse, Sier et al. 2001) and modulating the motility of 
cells (Deng, Curriden et al. 1996; Providence, Higgins et al. 2008).  PAI-1 levels are elevated 
in a variety of diseases including cardiovascular diseases (Scarabin, Aillaud et al. 1998), 
fibrosis (Yang, Hsieh et al. 2003; Liu 2008), some malignant tumors (Kruithof, Gudinchet et 
al. 1988; Urano, Wu et al. 1996).  EGF and TGF-β dramatically elevates PAI-1 levels in 
several epithelial cell lines including cancer cells (Thalacker and Nilsen-Hamilton 1987; 
Thalacker and Nilsen-Hamilton 1992; Wilkins-Port, Ye et al. 2009).   Cooperation between 
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EGF and TGF-β has been shown to affect many cell activities including cell transformation 
(Roberts, Frolik et al. 1983), the epithelial-mesenchymal transition (Uttamsingh, Bao et al. 
2008; Hardy, Booth et al.; Taylor, Parvani et al.), migration (Stolz and Michalopoulos 1997), 
proliferation (Saltis, Agrotis et al. 1992) and survival (Saha, Datta et al. 1999).  EGF and 
TGF-β- mediated signaling is frequently found over-activated in advanced stages of tumors.  
PAI-1 over-expression has been shown as an early event during the epithelial mesenchymal 
transition (EMT) (Wilkins-Port, Ye et al. 2009).  Understanding the synergistic regulation 
mechanism of PAI-1 will help us understand the fundamental mechanism behind this 
regulation and the function of PAI-1 in a broad range of processes.  Furthermore, strategies 
of blocking PAI-1 level have been shown to reduce thrombosis (Elokdah, Abou-Gharbia et al. 
2004; Smith, Dixon et al. 2006; Hennan, Morgan et al. 2008) and angiogenesis (Leik, Su et al. 
2006).  Understanding the mechanism underlying the synergistic regulation of PAI-1 
expression by EGF and TGF-β will help to identify potential targets that can be used to 
modulate PAI-1 levels in cardiovascular diseases and cancers. 
Major findings and conclusion 
Synergistic regulation of PAI-1 by EGF and TGF-β was observed at both the protein and 
mRNA levels (Figure 1, Chapter 3).  TGF-β and EGF interact synergistically to increase the 
PAI-1 mRNA level about two orders of magnitude over the basal level in human HepG2 and 
mink Mv1Lu cells.  PAI-1 protein levels are also dramatically induced by the combination of 
these two growth factors.  Synergism in PAI-1 expression was observed in both human and 
mink cell lines, demonstrating that this phenomenon is not confined to a particular species.    
A previous study showed that the synergistic regulation of PAI-1 protein by EGF and  
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TGF-β was observed in the mink lung epithelial cells but not in fibroblasts (Thalacker and 
Nilsen-Hamilton 1992).  In this study the synergism on PAI-1 mRNA was tested in several 
epithelial cells including Mv1Lu mink lung epithelial cell, human hepatoblasma cell HepG2, 
and mouse mammary gland epithelial EpH4 cells (Supplementary Table I, Chapter 3).   
Although the range of cells tested was not sufficiently broad to identify cell specificity, the 
data suggests that the synergism between EGF and TGF in regulating PAI-1 is not observed 
in all cells, is only observed in epithelial cell types and is a characteristic that can be lost 
(compare MLEC and Mv1Lu cells).  Consistent with the correlation between epithelial 
characteristic loss and synergism between EGF and TGF, we observed that the MLEC cells 
display a fibroblast-morphology rather than the epithelial morphology of the parent Mv1Lu 
cell line.  
Synergism occurs even when both growth factors are present at saturating concentrations 
(Fig 2, Chapter 3).  The results clearly showed that neither growth factor can substitute for 
the other in raising the level of PAI-1 mRNA to the that observed with both together, which 
is about an order of magnitude above that achieved with either growth factor alone.   Thus, 
the mechanism by which PAI-1 gene expression is regulated by a combination of EGF and 
TGF is different from those initiated by either growth factor alone.   
TGF-β also increases the sensitivity of cells to EGF, enabling synergism at  suboptimal 
EGF concentrations.  TGF-β increases the sensitivity of cells to EGF but not vice versa.  
Analysis of the EC50s of the concentration dependencies of the responses of PAI-1 mRNA 
levels to EGF and TGF-β revealed that TGF-β increases the sensitivity of the cells to EGF by 
an order of magnitude, but the presence of EGF did not change the EC50 for TGF-β 
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responsiveness (Table I, Chapter 3).  This feature of the effect of TGF-β again suggests a 
difference in the mechanism by which EGF regulates PAI-1 expression in the presence or 
absence of TGF-β.  These results also suggest that TGF-β can cooperate with low 
concentrations of EGF to increase PAI-1 expression that would not alone be high enough to 
have an effect.   
The synergism with TGF-β is downstream from tyrosine kinases and PKC.  TGF-β acts 
synergistically with tyrosine kinase activators to induce PAI-1 mRNA even though the extent 
of synergism varied with the growth factor or cytokine (Fig. 3A, Chapter 3).    The fact that 
TGF-β synergizes with PMA, a PKC agonist, in PAI-1 mRNA expression indicated the 
synergism is not a unique event downstream of tyrosine kinases (Fig. 3B,C, Chapter 3).   
Synergism between EGF and TGF-β occurs downstream of Mek.  Experiments using 
specific chemical inhibitors of protein kinases including Mek1/2, p38 MAPK, PI3K, Src and 
Jnk showed that, although the synergism between EGF and TGF-β was decreased when both 
p38 MAPK and Mek activity were blocked, it was only completely lost when Mek was 
blocked (Fig. 4A,C, Chapter 3).  There was no synergism on the phosphorylation of Erk1/2 
or Smad2/3 (Fig. 4F, Capter 3), which indicates that synergism occurs further downstream of 
Erk1/2 in the Mek signaling pathway. 
The mechanism(s) of the cooperative action of EGF and TGF-β involve synergistic 
transcriptional activation (Fig. 6, Chapter 3) and an increase in mRNA stability, which is 
regulated only by EGF (Fig. 5, Chapter 3).  The combined effect of transcription and mRNA 
stabilization results in a rapid two-order of magnitude increase of PAI-1 within two hours of 
growth factor addition and a rapid decline after transcription peaks.   
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The phosphorylation and activities of Smads are not synergistically regulated by EGF and 
TGF-β (Fig. 7, Chapter 3).  EGF decreased TGF-β-induced Smad 3-mediated promoter 
activity if only the Smad binding element (SBE) was present (pSBE4, Fig. 7B, Chapter  3).   
Transcription factors Smads and AP-1 regulated by EGF and TGF-β are required for the 
synergistic effect on PAI-1 induction.  This was demonstrated because the synergism occurs 
only when both the Smad binding element and the AP-1 recognition site are present in the 
promoter region (p3TP, Fig. 8A, Chapter 3).  There was about 3-fold synergism of EGF and 
TGFβ on p3TP-luciferase reporter activity, which was about the same increase as for PAI-1 
transcription induced by EGF and TGF-β.  Consistently, we found the AP-1 transcriptional 
factor is required for the synergistic effect on p3TP reporter (Fig. 8B, C, Chapter 3).    
Suppression of AP-1 activity by a dominant negative regulator ΔFosB blocked 40% of the 
synergism of both luciferase activities in the p3TP reporter system and the endogenous 
mRNA levels of PAI-1.  Similar results were found when AP-1 activity was blocked by the 
chemical inhibitor curcumin.  AP-1 transcriptional factor is also required for the synergistic 
effect on PAI-1 mRNA (Fig. 8F, Chapter 3).   
We found de novo protein synthesis is not necessary for the synergism and a rapidly 
turning-over protein is required for the synergism of EGF and TGF-β.  This conclusion is 
supported by the following data: pretreating cells with protein synthesis inhibitor 
cycloheximide decreased the level of PAI-1 induced by growth factor treatments but did not 
alter the synergistic effect of EGF and TGFβ (Fig. 9A, B, chapter 3).  We also found that the 
PAI-1 mRNA level was negatively correlated with the incubation time with cycloheximide 
and PAI-1 mRNA level decreased at a constant rate, which suggests a rapidly turning-over 
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protein is involved in the synergistic regulation of PAI-1 mRNA by EGF and TGF-β (Fig. 
9D, Chapter 3).  However, the decay curves in cells treated only with EGF or TGF- were 
not well fit to a single exponential decay (Fig. 9D).  The biphasic decay curves reflect the 
presence of a small amount of the protein responsible for synergism that is augmented by the 
combination of EGF and TGF-β.   
In summary, the synergism with TGF-β is downstream from tyrosine kinases and PKC.  
The MAPK pathway is required for the synergism. The interaction between Smad and AP-1 
is hypothesized to play an essential role in the synergistic regulation.   
Impacts of this study 
This work demonstrates the existence of a multidimensional cellular mechanism by 
which EGF and TGF-β promote dramatic and rapid changes in PAI-1 expression that may 
contribute to some important physiological and pathological events.   
In this study, we found that TGF-β increases the sensitivity of the PAI-1 response to EGF 
but not vice versa.  This effect, not previously reported, allows a 10-fold lower EGF 
concentration to produce half maximal PAI-1 induction in the presence of TGF-β compared 
with in the absence.  The increase in sensitivity to EGF would allow cells to utilize the 
synergistic mechanism when a low concentration of EGF is in the environment.   This is a 
very effective way for a single growth factor to achieve a large change in gene expression by 
picking up a new signal from a growth factor that is already present and providing a 
synergistic boost to the newly arrived growth factor. 
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We found that the synergistic effect of EGF and TGF-β on transcription requires both 
transcription factor AP-1 and Smad.  It is reported that in heptocytes EGF increases Smad-
mediated transcriptional activation, and synergizes with TGF-β in the transcriptional 
activation of the SBE promoter, which can be blocked by dominant negative AP-1 (Peron, 
Rahmani et al. 2001).  However, our study showed that signaling by Smad alone is not 
sufficient to produce the synergism of EGF and TGF-β.  We also found no synergism in 
phosphorylation of Smad.  Instead, EGF reduced the basal and TGF-β-induced Smad3/4 
mediated-transcriptional activation in the SBE4 promoter.  Similar results were observed for 
Smad2/4 mediated transcriptional activity from the 3ARE promoter.  Our results are 
consistent with a previous study, which showed that EGF treatment results in rapid 
phosphorylation of the linker region but not the c-terminal domain of Smad 2/3 in MV1Lu 
cells.  Phosphorylation of the linker region blocks Smad nuclear translocation and Smad-
mediated transcriptional activity (Kretzschmar, Doody et al. 1999).  EGF also inhibits 
TGF-β-induced nuclear accumulation of activated Smad in Mv1Lu cells in a concentration 
dependent manner (Kretzschmar, Doody et al. 1999).  So it is unlikely that the synergism 
occurs through Smad-mediated signaling.  However with the presence of adjacent AP-1, 
Smad mediated transcription was greatly potentiated.  The synergism occurs only when both 
AP-1 and Smad binding site are present.  Our results are consistent with the notion that the 
synergistic regulation of gene expression by EGF and TGF-β requires adjacent Smad and 
AP1 binding sites on the promoter and therefore is not observed in all genes.    
Limitations of this study 
A limitation of this study is that most of the studies were performed in mink lung 
epithelia cells (Mv1Lu).  There is limited information on the mink genome and transcriptome 
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data and this meant that only two other genes, uPAR and COX2, could be tested for the 
synergistic regulation by the EGF and TGF-β in Mv1Lu cells.  Because the antibodies 
resources against mink proteins are also relatively limited, we were able to successfully 
detect the phosphorylation of some proteins but not all. 
A second limitation is that these results were observed from studies of in vitro cell 
cultures.  The question of synergism has not been addressed in animal systems or tested in 
vivo.  During the establishment of cell lines, some of the original gene expression profiles 
may be changed.  For example, cultured cells usually are grown in normal air condition with 
about 20% of oxygen, while in vivo most of cells lives in lower (<5%) oxygen concentrations.  
Some genes may behave differently with the change of oxygen concentration.  Although 
elevated levels of EGF, TGF-β as well as PAI-1 have been found in many diseases state in 
vivo, it is difficult to determine if the elevated PAI-1 results from the synergistic interaction 
between these two growth factors due to the presence of too many variables and difficulty of 
the experimental systems.  
The third limitation is that only two types of cells, epithelial and fibroblast, were tested 
for the synergistic regulation of PAI-1 by EGF and TGF-β.  The number of cells tested in this 
study is also limited.  To make a general conclusion that the synergism is epithelial cell 
specific, it is necessary to test in more cell types to see whether the synergistic effect is 
present in other cell types, such as endothelial cells or smooth muscle cells. 
Questions remain to be answered 
1. Whether the synergistic induction of PAI-1 is related to the epithelial mesenchymal 
transition (EMT).   The synergistic induction of PAI-1 by EGF and TGF-β has been tested in 
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several epithelial origin and fibroblast cells in this study and by others (Nilsen-Hamilton and 
Holley 1983; Thalacker and Nilsen-Hamilton 1992; Wilkins-Port, Ye et al. 2009).  Although 
the range of cells tested is not sufficiently broad to identify a cell specificity, the data is 
consistent with the notion that synergism between EGF and TGF in regulating PAI-1 is cell 
type specific.  For example this synergistic effect was not observed in five other cell lines 
including monkey kidney epithelial BSC-1 cells, mouse embryo fibroblast (AKR-2B 84A) 
cells, normal rat kidney fibroblasts (NRK) (Thalacker and Nilsen-Hamilton 1992) and mouse 
mammary gland epithelial EpH4 cells.  Synergism is observed in cells of epithelial origin, 
such as mink lung epithelial Mv1Lu cells (Nilsen-Hamilton and Holley 1983; Thalacker and 
Nilsen-Hamilton 1992), human keratinocytes HaCaT II-4 cells (Wilkins-Port, Ye et al. 2009) 
and human liver hepatoma HepG2 cells (this study).  The fact that synergistic induction of 
PAI-1 is only observed in cells of epithelial origin indicates the synergistic increase of PAI-1 
might be one of the early events during the process of EMT induced by EGF and TGF-β.  
Although the synergistic regulation of PAI-1 in HaCaT II4 cells was reported to be related to 
EGF and TGF--induced EMT, there is no study on other cell lines.  Our data showed that 
the synergism is lost when the epithelial characteristics are lost (compare MLEC and Mv1Lu 
cells), which is one of the milestone of EMT.  Consistent with the correlation between 
epithelial characteristics and synergism of EGF and TGF-, we observed that the MLEC 
cells displayed fibroblast morphology.  It will be of interest to test the hypothesis that the 
synergistic induction by EGF and TGF- relates PAI-1 regulation to regulation of the EMT.  
We can test this by using broad range of cells and by examining the necessity of PAI-1 in 
EGF and TGF- induced EMT. 
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2. How the MAPK pathways contributed to the synergistic regulation?  Our data 
suggested the synergism is downstream of MAPK, however the mechanism of how these 
MAPKs contribute to the synergism is not clear.  Our results showed that AP-1, one MAPK 
downstream target, is specifically required in PAI-1 synergistic regulation by EGF and 
TGF-β.   Ablation of AP-1 activity reduced the reporter activity of 3TP and PAI-1 mRNA 
level stimulated by the combination of growth factors.  Activation of AP-1 is the result of 
interaction of phosphorylated Fos and Jun family proteins.  It is speculated that AP-1 is 
specifically activated in the dual growth factor treatment.    However, our preliminary results 
from western blot by using antibodies against phosphorylated Fos or Jun family protein 
showed neither Jun nor Fos is synergistically activated.  Further studies are needed to address 
this question, including test the involvement of more targets downstream of MAPK signaling.  
For example, one MAPK target p300 interacts with both Smad and AP-1 to enhance the 
Smad-mediated transcriptional activity (Verrecchia, Pessah et al. 2000).  CREB binding 
protein (CBP) and p300 (also known as E1A binding protein) are co-activators of Smad2 and 
Smad3.  They recruit the Smad nuclear complexes to the basal transcription machinery via 
direct interaction (Derynck, Zhang et al. 1998; Feng, Zhang et al. 1998).   TGF-β-induced 
Smad-mediated PAI-1 expression is enhanced by promoting CBP-mediated Smad3 
acetylation (Das, Ghosh-Choudhury et al. 2008).  It will be interest to test whether CBP/P300 
has a role in this synergistic regulation.  One way of doing this is to check the acetalyation of 
Smad by western blot.  
3. What is the rapidly turning-over protein in the synergism?  Our data suggested a 
rapidly turning-over is involved in the synergism of EGF and TGF-β.  Transcription factor 
AP-1 proteins are very unstable and bind of c-Jun accelerates the degradation of c-Fos 
(Tsurumi, Ishida et al. 1995).  However there is no proof that AP-1 is the rapidly turning-
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over protein.  For example, P300/CBP-associated factor (PCAF) has a half-life of 2h (Jin, 
Zeng et al. 2004).  The question can be addressed by the following experiments to determine: 
1) is the rapidly turning-over protein regulated by MEK?  Suppression of MEK eliminated 
the synergism; 2) whether AP-1 or CBP are the rapidly turning over proteins.  This can be 
determined by examining protein turning-over rates after knocking down the expression of 
Fos or Jun family proteins;  3) studies using chromatin immuno-precipitation (Chip) and 
proteomics techniques may be useful to identify the unique proteins that occupy the promoter  
in cells activated by the combination of EGF and TGF-β. 
4. What is the mechanism of PAI-1 transcriptional regulation by EGF.  Our study 
showed PAI-1 stimulation by EGF requires the MAPK pathway and the maximal induction 
of PAI-1 also requires the activity of Jnk, PI3K, p38 MAPK and AP-1.  However, PAI-1 
regulation by EGF does not act through Smad-mediated signaling, because EGF does not 
activate Smad.  Others have shown that EGF inhibits Smad’s nuclear accumulation.  AP-1 is 
not sufficient for the regulation by EGF because although there was 2-fold increase in the 
transcriptional activation of PAI-1 mRNA, EGF barely activated the 3TP.  Suppression of 
AP-1 activity also did not significantly reduce the effect of EGF on the 3TP promoter activity.  
There was only slight decrease (14 %) in the level of PAI-1 induced by EGF after AP-1 
activity was blocked.  A previous study in human glioma cells showed that the orderly 
activation of EGFR, Src, PKCδ, SPHK1 and S1P signaling is required for EGF activation of 
PAI-1 transcription in a c-Jun dependent manner (Paugh, Paugh et al. 2008).  Although EGF 
activates Erk1/2, Jnk phosphorylation and DNA binding activity of AP-1, none of them were 
involved in PAI-1 stimulation in these cells (Paugh, Paugh et al. 2008).  In our study, we 
found that Src activity is not required for regulation by EGF because inhibition of Src 
activity didn’t significantly block PAI-1 induction by EGF in Mv1Lu cells.  Thus the 
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requirement of Src in the regulation of PAI-1 by EGF may be cell type dependent.  To 
address this question, other transcription factors that are activated by MAPK should be 
investigated for their involvement in PAI-1 regulation by EGF because blockade of MEK 
activity removed most of the PAI-1 induction.  Analysis of the cis-elements in PAI-1 
promoter region will help to screen for potential transcription factors.  Previous studies on 
genes that are regulated by EGF will facilitate progress as well. 
5.    What is the mechanism of stabilization of PAI-1 mRNA by EGF.  We have shown 
that PAI-1 mRNA has a very short half-life.  The stability of PAI-1 mRNA can be changed in 
response to different stimuli (Fattal, Schneider et al. 1992; Sandberg, Eriksson et al. 1997; 
Norata, Banfi et al. 2004).  EGF also regulates PAI-1 through stabilizing the mRNA.  
However, the mechanism by which EGF regulates PAI-1 mRNA stability remains unknown.  
A similar effect of EGF has also been found on mRNA of other genes, including Cox2 (Slice, 
Hodikian et al. 2003), TβRII (Song, Krebs et al. 2006), EGFR (Jinno, Merlino et al. 1988), 
IL-1alpha, IL-1beta and IL-6 (Le, Lazorick et al. 1991), p21/CIP1 (Johannessen, Knardal et 
al. 1999).  TGFα, which also binds to EGFR, substitute for EGF in mRNA stabilization (Le, 
Lazorick et al. 1991; McCulloch, Walker et al. 1998).   Our results showed that blocking the 
activation of Erk1/2 did not alter the half-life of PAI-1 mRNA in TGF-β treatment, either 
alone or in combination with EGF.  Thus, it is unlikely that the stabilization of PAI-1 mRNA 
is regulated by the Erk MAPK pathway. 
Many reports indicate the important contribution of cis-elements in 3`UTR for mRNA 
stabilization of mRNA in response to EGF (Kesavan, Das et al. 1990; Balmer, Beveridge et 
al. 2001).  The 3`UTR of PAI-1 is also an important region for the regulation of PAI-1 
mRNA stability.  There are many C-rich regions that can be recognized by poly(C) binding 
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protein 1 (PCBP1).  An AGCCCU motif that mediated stabilization of Gastrin mRNA by 
EGF (Lee, Liao et al. 2007) also exists in the 3`UTR of PAI-1 mRNA.  It will be of interest 
to determine how PAI-1 mRNA stability is achieved through these elements.  One way we 
can test this is by mutating these regions or elements. 
Conclusions of using tiled microarray to identify RNA accessible region 
The efficiency of silencing gene expression by antisense oligonucleotide and RNAi 
technology has great potential to be used in gene therapy for variety of diseases, where 
successful know down of genes relies on information of optimal RNA accessible region.  
Different technologies have been developed to provide information for optimal RNA 
accessible sites, including software prediction by using computer algorithm and experimental 
screening.  However these computer programs do not predict RNA tertiary structures that 
may affect RNA accessible sites.  Experimentally screening every possible RNA site is 
expensive and time consuming.   
In this study we showed that tiled microarray is an effective way to identify accessible 
regions in mRNAs with high accuracy.   Here We investigated the accessible regions of two 
mRNAs (B-cell CLL/lymphoma 2 [Bcl2] and mouse lipocalin 2 [Lcn2]) by tiled microarray 
and computational algorithms.  The efficacy of microarray and computational algorithm 
predictions for Lcn2 were tested in cell culture by using antisense oligodeoxynucleotides 
(ODNs) and siRNA.  For Bcl2, the microarray results were compared to the data in literature 
where antisense oligodeooxynucleotides were reported effective in vivo.   Effective AS-ODN 
sequences for both Lcn2 and Bcl2 were identified by in vitro tiled microarray studies.  . 
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Firstly, we found that the tiled microarray analysis provides more selective identification 
of available sites on the mRNA than do computational algorithms.  Using the tiled 
microarray assay identified a small number of optimal accessible regions for both Lcn2 
mRNA and Bcl2 coding region (Fig. 1, Chapter 4).  In contrast, computer programs 
(Oligowalk, sFold and Block-iT) predicted overlapping but different sets of sequences as 
optimal for effective antisense as seen in (Fig. 2, Chapter 4).  Although some of the mRNA 
sequences identified by the microarray were also predicted by computational analysis, many 
differences are evident between the experimental and computational methods.   
Three ODNs were identified by tiled microarray as the most available for hybridization in 
Bcl2 coding region, which all clustered around the translational start site (Fig.1, Chapter 4).  
This is precisely the region of the Bcl2 mRNA that has previously been identified as a prime 
target for AS-ODNs for reducing Bcl2 expression (Kitada, Takayama et al. 1994; Gleave, 
Miayake et al. 1999; Tolcher 2005).   
Secondarily, the regions identified by titled microarray accurately predicted the most 
accessible area in RNA as tested by antisense ODNs and siRNA in vivo.  Based on the results 
from the microarray and the computational analysis, eight ODNs were chosen to test as 
antisense agents for Lcn2 in vivo.  Four ODNs were identified from the computational 
analyses, three from the microarray results (501, 561 and 741 AS-ODN).   The three 
sequences that most successfully decreased secreted Lcn2 production were identified by the 
tiled microarray analysis and by at least two of the three computational analyses (Fig.4, 
Chapter 4).    
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The effects of the antisense ODNs on the Lcn2 mRNA and intracellular Lcn2 protein 
levels of the mouse HC11 cells were also examined.  The 561 and 741 AS-ODNs selectively 
reduced the Lcn2 mRNA and intracellular Lcn2 protein levels (Fig.  5A, Chapter 4).   One 
AS-ODN complementary to a region covering the translational start site (positions 11 
through 27) from a previous literature report was also tested in our study.  By contrast to the 
effects of AS-ODNs 561 and 741, AS-ODN11 did not decrease the Lcn2 mRNA level (Fig. 
5B, Chapter 4).  Although the AS-ODN was very effective in inhibiting protein production 
when used at a 10-times higher concentration as was used in the previous study, it had little 
effect on protein or RNA levels when used at 0.2 μM. 
We also tested the effectiveness of siRNAs targeted to the same regions in the Lcn2 
mRNA in two different cell lines (Fig. 5C,D, Chapter 4)  In both instances a similar profile of 
decrease in Lcn2 mRNA was observed as for the AS-ODN series (Fig. 5A, Chapter 4).   
With the advantage of high throughput and high accuracy information provided for RNA 
accessible regions, we proposed tiled microarray is an efficient way of identifying effective 
antisense ODNs or siRNAs.  Tiled microarrays also provide a high throughput approach for 
validating and improving the results from computational programs.   Our results suggest that 
hybridization of ODN arrays to a target mRNA under physiological conditions might be used 
as a rapid and reliable in vitro method to accurately identify targets on mRNA molecules for 
effective antisense and potential siRNA activity in vivo. 
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APPENDIX I.  ABBREVIATIONS 
(According to alphabetic order) 
3`UTR 3` Untranslated region 
ANOCVA Analysis of covariance 
AIG Anchorage-independent growth 
AKT2 v-akt murine thymoma viral oncogene homolog 2 
ANOVA Analysis of variance 
AP-1 Activator protein 1 
AP-2 Activator protein 2 
ARE AU-rich element 
BCS Budd-Chiari syndrome  
AS-ODN Antisense oligodeoxynucleotides 
CBP CREB binding protein 
CD Cytochalasin D 
CHX Cycloheximide 
CHX Cycloheiximide 
Co-Smad Common partner Smad 
Cox2 Cyclooxygenase 2 
CPPD Calcium pyrophosphate dehydrate  
E1A The protein product from the early 1A region of adenoviruses 
ECM Extracellular matrix 
EGF Epidermal growth factor 
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EGFR Epidermal growth factor receptor 
EIP-1 EGF/TGFα-inducible protein, ailas of PAI-1 
EMT Epithelial-to-mesenchymal transition 
ERK Extracellular signal-regulated kinase 
FAST Forkhead activin signal transducers  
FGF-2 Fibroblast growth factor 2 
GnRH Gonadotropin-releasing hormone  
GPI Glycosyl phosphatidyl inositol  
GRE Glucocorticoid regulatory element  
HDAC Histone deacetylase  
HGF Heptocyte growth factor 
HIF-1 Hypoxia-inducible factor 1 
HLTF Helicase-like transcription factor  
HNF-4 Hepatocyte nuclear factor 4  
HRE Hhypoxia-response element 
IGF-1 Insulin-like growth factor 1 
IL-1 Interleukin-1 
IL-6 Interleukin-6 
I-Smad Inhibitory Smad 
JAK Janus kinase 2 
JNK c-Jun NH2-terminal protein kinase 
LIF Leukemia-inhibitory factor  
LPS Lipopolysaccharide 
LRP low-density lipoprotein receptor-related protein  
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MAP Mitogen-activated protein 
MAPK Mitogen-activated protein kinase 
MAX MYC associated factor X 
MEK Mitogen-activated protein kinase/ERK kinase 
MEK1/2 Mitogen-activated protein kinase kinase 
MH1 MAD homolog 1 
MH2 MAD homolog 2 
MMP Metalloproteinase 
MMP Matrix metalloproteinase 
NFκB Nuclear Factor-KappaB 
ODN Oligodeoxynucleotides 
Ox-HDL Oxidized high-density lipoprotein  
p300 E1A binding protein 
PAI-039 Tiplaxtinin 
PAI-1 Plasminogen activator inhibitor type-1 (also called SERPINE1) 
PAI-CRS PAI-1 cAMP responsive sequence 
PCAF P300/CBP-associated factor  
PDGF Platelet-derived growth factor  
PGE2 Prostaglandin E2  
PI3K Phosphatidylinositol 3′-kinase 
PKC Protein kinase C 
PKCδ Protein kinase C 
PLB Passive lysis buffer 
PLCγ phospholipase Cγ  
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PMA Phorbol 12-Myristate-13-Acetate 
Src v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 
PPi Inorganic pyrophosphate  
pSmadC Phosphorylation of Smad at the carboxyl terminus 
pSmadL Phosphorylation of Smad at the linker region 
R-Smad Receptor-regulated Smad 
RTK Tyrosine kinase receptors 
S1P Sphingosine 1-phosphate 
SARA Smad Anchor for Receptor Activation  
SBE Smad-binding element 
SCC Squamous cell carcinoma 
SERBP1 PAI-1 mRNA binding protein 1 
SERPINE1 Serine protease inhibitor, clade E, member 1 
siRNA Small interference RNA 
SMAD Sma/Mad homologues 
Smad2 Smad family protein member 2 
Sp-1 Specificity protein 1 
SphK1 Sphingosine kinase 1 
STAT Signal transducer and activator of transcription 
TAD Transactivation domain 
TFE3 Transcription factor microE3  
TGFα Transforming growth factor alpha 
TGF-β1 Transforming growth factor-β1 
TGF-βR TGF-β receptor 
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TGIF TG-interacting factor 
TNFα Tumor necrosis factor-alpha (TNF-alpha) 
t-PA Tissue-type plasminogen activator 
TRE PMA-responsive element 
TSA Trichostatin A  
Tβ4 Thymosin beta 4 
uPA Urokinase-type plasminogen activator 
uPAR Urokinase-type plasminogen activator receptor 
USF Upstream transcription factor 
USF1 Upstream transcription factor 1 
USF2 Upstream transcription factor 2, c-fos interacting  
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